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“After a still winter night I awoke with the impression that some question had been put to 
me, which I had been endeavoring in vain to answer in my sleep, as to what—how—
when—where? But there was dawning Nature, in whom all creatures live, looking in at 
my broad windows with serene and satisfied face, and no question on her lips. I awoke to 
an answered question, to Nature and daylight. The snow lying deep on the earth dotted 
with young pines, and the very slope of the hill on which my house is placed, seemed to 
say, Forward! Nature puts no question and answers none which we mortals ask. She has 
long ago taken her resolution.” 
       -Henry David Thoreau, Walden 
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ABSTRACT  
Mitochondrial dynamics includes the processes of fusion, fission, and motility. These 
processes form interdependent adaptive mechanisms that, together with autophagy, 
maintain mitochondrial function to meet cellular needs. Mitochondrial dynamics control 
function directly by inducing bioenergetic remodeling or indirectly by promoting 
turnover of mitochondria via autophagy. Importantly, mitochondrial dysfunction has been 
implicated in beta-cell failure during type 2 diabetes. This thesis will investigate the role 
of dynamics and autophagy in regulating mitochondrial and pancreatic beta-cell function 
during chronic exposure to excess glucose and fatty acids, termed glucolipotoxicity 
(GLT).  
It remains ill-defined what role fusion and motility play in determining mitochondrial 
turnover, as current methodologies to assess turnover lack subcellular resolution. To 
address this need we developed the use of MitoTimer, a mitochondrial fluorescent probe 
that undergoes a time-dependent green-to-red transition. Turnover was revealed by the 
integrated proportions of young (green) and old (red) MitoTimer protein. The results 
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demonstrate that mitochondrial fusion and motility regulate turnover by promoting the 
distribution of newer protein to subsets of mitochondria in the network. 
GLT inhibits mitochondrial fusion and networking in pancreatic beta-cells. Since fusion 
is dependent on motility we tested the hypothesis that GLT impairs fusion by affecting 
motility. We determined that GLT arrests motility, which may contribute to 
mitochondrial and beta-cell dysfunction. We show that excess nutrients increase O-linked 
β-N-acetyl glucosamine (O-GlcNAc) modification of mitochondrial motor adaptor 
Milton1, which decreases its activity and results in arrest of motility and increased 
fission. Thus Milton1 O-GlcNAc modification acts as a nutrient-sensor linking fusion, 
fission, and motility to nutrient supply in the beta-cell. 
Finally, GLT inhibits autophagic flux with concurrent lysosomal pH increase in beta-
cells. To address the hypothesis that impaired lysosomal acidification is a causative event 
inhibiting autophagic flux and beta-cell function, we developed lysosome-localizing 
nanoparticles that expand and acidify upon UV photo-activation. Increasing lysosomal 
acidity with the nanoparticles increased autophagic flux and restored beta-cell function 
under GLT, establishing lysosomal pH as a key mediator of nutrient-induced beta-cell 
dysfunction. 
In summary the work elucidates the interdependence and specific roles of mitochondrial 
fusion, fission, motility, and autophagy in dictating beta-cell responses to excess nutrient 
environment. 
  
  viii 
PREFACE 
 “Our terminal decline into old age and death stems from the fine print of the 
contract that we signed with our mitochondria two billion years ago.” 
- Nick Lane 
  
  ix 
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CHAPTER ONE: General Introduction 
 
Mitochondrial adaptive mechanisms in context 
 
Almost 50 years ago Dr. Lynn Margulis postulated the endosymbiotic theory of 
mitochondrial origin in eukaryotes 1, leading to the idea that mitochondria were an 
evolutionarily beneficial acquisition for the early eukaryotic cell. As interest in 
mitochondrial biology has advanced since then, mitochondria are now appreciated as not 
just an important acquisition but likely the necessary and determining factor that defines 
the eukaryotic kingdom. Evolution of multicellular organisms, especially large 
biologically-complex animals, would require a significant bioenergetic advantage which 
could only arise due to the increase in “energy per gene expressed” provided by 
mitochondria 2. More simply stated, mitochondria were the acquisition of an “engine” for 
the early cell, enabling tremendous advancement in energetic output and a new level of 
complexity for eukaryotic cells that was not possible before. Therefore mitochondrial 
function is especially critical for almost all eukaryotic cells, especially in long-lived post-
mitotic cells and tissues.  
Mitochondria exist within the cell as a highly dynamic network3, 4. Accordingly, the life 
cycle of a mitochondrion within the network is defined by the processes of biogenesis, 
fusion and fission, motility, and autophagy-mediated degradation. This thesis will focus 
specifically on mitochondrial dynamics (fusion, fission, and motility) and autophagy. 
Fusion involves the merging of two mitochondria and fission is the division of one into 
two; together fusion and fission are referred to as mitochondrial dynamics. Motility 
encompasses all aspects of mitochondrial trafficking in the cell, mainly along 
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microtubules via aid of the motor proteins kinesin and dynein. Finally, autophagy is a 
cellular degradation pathway that removes long-lived proteins and organelles, including 
mitochondria. Collectively these three processes can be called mitochondrial adaptive 
mechanisms, meaning they ultimately determine mitochondrial function. All three 
adaptive mechanisms can regulate mitochondrial function indirectly by promoting quality 
control of the population. Mitochondrial networking involves the coordinated interaction 
of motility, fusion, and fission to promote the segregation and autophagy-mediated 
removal of damaged mitochondria. Thus these adaptive mechanisms are key 
determinants of mitochondrial quality control 5, 6 (Fig. 1.1). In addition, dynamics and 
motility may regulate mitochondrial function by promoting bioenergetic remodeling of 
mitochondria, a concept that will be explored in detail later. Overall the adaptive 
mechanisms work together to maintain a functional network of mitochondria.  
Recent research has uncovered that these adaptive mechanisms regulating mitochondrial 
function are altered in various human diseases, especially age-related diseases such as 
neurodegenerative diseases, diabetes, cardiovascular disease, and cancer. Specifically we 
have discovered that changes occur to mitochondrial adaptive mechanisms in several 
pathological states, including pancreatic beta-cell dysfunction in obesity/diabetes, cardiac 
amyloidosis 7 (Appendix One), and diabetic retinopathy 8-11. Furthermore we and others 
have also uncovered how changes to these adaptive processes can dictate physiological 
cellular outcomes, including energy expenditure 12, cellular differentiation status 13 
(Appendix One), apoptosis 14, and others. Therefore when changes to mitochondrial 
adaptive mechanisms are altered in disease it is critical to understand whether the 
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changes are beneficially adaptive or maladaptive. Further understanding of these intricate 
regulatory mechanisms, and whether specific pathologies involve beneficially adaptive or 
maladaptive alterations to these mechanisms, will be necessary for discovering effective 
strategies to improve mitochondrial function in disease.  
Pancreatic beta-cells dysfunction in type 2 diabetes 
The main focus of this thesis work will be investigating mitochondrial adaptive 
mechanisms in the context of the pancreatic beta-cell and how these processes are altered 
in obesity and diabetes. The prevalence of diabetes is greatly increasing in the United 
States and the world, putting a large burden on health care systems15-17. Most patients 
affected develop type 2 diabetes, in which obesity and insulin resistance promote 
development of the disease18, 19.  Pancreatic beta-cells are the specialized glucose-sensing 
cells of the body which monitor and appropriately respond to changes in glucose levels 
with changes in insulin secretion20, 21. Insulin then acts as the key hormone to regulate 
glucose uptake for target tissues, such as skeletal muscle, liver, and adipose tissue22. A 
high nutrient diet has been shown to deregulate insulin secretion and evoke beta-cell 
death, which is implicated in the development of insulin resistance and eventual 
diabetes23, 24. Development of a therapeutic intervention that would restore beta-cell 
health and function would help delay or prevent the onset of diabetes, and could even 
reverse the course of the disease. Any decrease in onset or prevalence of diabetes would 
significantly save health care costs and prevent the onset of diabetes-associated 
complications.  
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Deterioration of beta-cell function is documented early during the onset of type 2 
diabetes25-27, possibly even preceding the onset of insulin resistance 28. Metabolic 
dysfunction of the beta-cell is thought to be exacerbated at least in part from chronic 
exposure to high glucose (glucotoxicity), fatty acids (lipotoxicity), or a combination of 
both (GLT)29, 30. The further deterioration of beta-cell function due to GLT greatly 
aggravates disease progression, since inadequate insulin secretion detrimentally affects 
nutrient uptake of target tissues. In vitro, exposure to monounsaturated fatty acids such as 
oleate induce high basal insulin secretion but reduced glucose-stimulated insulin 
secretion31, 32, and saturated fatty acids such as palmitate can induce beta cell death in 
addition to defective secretion31-33. Importantly, high glucose exposure synergizes with 
fatty acids to induce beta-cell dysfunction, hence the term GLT34. In vitro and in vivo, 
GLT has been shown to induce dramatic changes in beta-cell metabolism, insulin 
secretion, and cell viability. The nature of these changes can vary greatly, mostly due to 
the type and duration of exposure35. Early changes in beta-cell function are likely due to 
compensatory effects of whole body insulin resistance associated with obesity, which can 
include hyper-secretion of insulin and increased beta-cell mass36-38. However chronic 
exposure to GLT ultimately compromises glucose-stimulated insulin secretion and can 
lead to beta-cell death and decreased mass34. Several possible mechanisms have been 
proposed to explain the GLT-induced effects on beta-cell function, including 
accumulation of lipid-derived intermediates39, 40, activation of PKCε41, 42, and impairment 
of insulin gene expression43-45, among others35. Yet further study is needed to identify the 
key contributing mechanisms determining GLT-induced beta-cell dysfunction. 
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Mitochondrial adaptive mechanisms in the beta-cell 
Importantly, GLT-induced mitochondrial dysfunction has been implicated as a precursor 
to beta-cell dysfunction in type 2 diabetes46. In the beta-cell, mitochondrial metabolism 
plays a pivotal role in glucose-stimulated insulin secretion (GSIS). Response to increased 
glucose levels stimulates mitochondrial adenosine triphosphate (ATP) production. 
Increase in cytosolic ATP then closes ATP-sensitive potassium channels in the plasma 
membrane which in turn opens voltage-gated calcium channels allowing for exocytosis of 
insulin granules. Moreover metabolic coupling factors other than ATP, such as reactive 
oxygen species (ROS), malonyl coenzyme A, NADH, and others, are generated by 
mitochondria and support GSIS 47. Thus, deleterious effects of GLT on beta-cell 
mitochondria would significantly contribute to the decline of beta-cell function and 
viability in diabetic patients. 
The concomitant by-product of electron transport for ATP production is ROS in the 
mitochondria, which has the potential to damage surrounding cellular components48. At 
low physiologic levels, ROS toxicity can be adequately controlled by anti-oxidant 
systems, and low ROS levels even play a signaling role in GSIS49, 50, along with other 
important cell processes. However, pathological ROS levels have been shown to damage 
proteins, lipids, and DNA, which can lead to defective mitochondrial metabolism and 
inefficient insulin secretion in beta-cells46, 51. Beta-cells are uniquely susceptible to ROS 
damage since they harbor low levels of key anti-oxidant machinery52, 53. Mitochondria, as 
important intracellular metabolic regulators for the beta-cell, are uniquely positioned to 
be a vital yet susceptible mediator of beta-cell function and viability. Effectively coping 
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with ROS-induced mitochondrial damage is key to maintaining beta-cell function and 
viability under GLT. Thus, understanding the mechanisms that contribute to 
mitochondrial quality control under GLT will allow effective targeting of therapeutic 
interventions, with the hopes of preventing beta-cell dysfunction that occurs during the 
onset of diabetes.   
The key objective of mitochondrial quality control is to specifically segregate, sequester, 
and eliminate damaged mitochondria from the network. Mitochondrial dynamics was 
shown to directly influence removal of impaired mitochondria by generating a 
depolarized mitochondrion after paired fusion-fission events4. Other studies have 
demonstrated that depolarized mitochondria will be targeted for autophagy by 
recruitment of Parkin, an E3-ubiquitin ligase mutated in some forms of Parkinson’s 
disease, and subsequent autophagy-related proteins54, 55. Importantly, inhibition of 
autophagy or mitochondrial fission promote the accumulation of mitochondrial protein 
damage4, indicating their importance for mitochondrial quality control. However it is not 
clearly understood how mitochondrial fusion determines individual mitochondrial 
turnover in the cell. In this regard turnover consists of both integration of new protein 
into the individual mitochondrion and removal of old protein (or the entire 
mitochondrion). Addressing this issue has been difficult due to the lack of methodologies 
to assess mitochondrial turnover on the subcellular level. Thus further studies are needed 
to fully elucidate the role of mitochondrial dynamics in coordinating turnover of 
individual mitochondria. Our previous research has shown that mitochondrial dynamics 
are altered during GLT-induced beta-cell dysfunction3, 56. Under GLT, beta-cells show 
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decreased mitochondrial fusion capacity and mitochondrial morphology becomes 
fragmented. Restoring the balance of mitochondrial dynamics with Fis1-RNAi in INS1 
cells is sufficient to rescue the GLT-induced cell death but not insulin secretion defect3. 
Therefore it remains unclear if the changes to mitochondrial dynamics under GLT are 
adaptive or maladaptive in preserving beta-cell funciton, especially in beta-cells of 
diabetic or obese humans. 
Studies investigating the key characteristics that determine mitochondrial fusion found 
that mitochondrial motility was the most important factor associated with subsequent 
fusion57; i.e. active motility promoted fusion. However the role of mitochondrial motility 
changes under GLT has not been fully addressed, specifically whether altered motility 
under GLT influences the arrest of mitochondrial dynamics, leading to impaired 
mitochondrial bioenergetics and quality control. Mitochondrial motility is a highly 
regulated process, which involves coordination of the microtubule cytoskeleton, motor 
proteins kinesin and dynein, and the mitochondrial motor adaptors. The mitochondrial 
proteins, Miro1 and Milton1, are the key molecular adaptors that facilitate binding to 
kinesin and dynein and ultimately the microtubules. Miro1 activity is known to be 
regulated by changes in cytosolic calcium concentration58, and through specific 
degradation by Parkin59. Regulation of Milton1 activity is not fully understood, although 
it has been demonstrated that Milton1 is an integral component  of the  motor adaptor 
complex for mitochondrial movement60.  
Research from a collaborating group at Boston Children’s Hospital indicate Milton1 
activity is regulated by O-linked N-acetylglucosamine (O-GlcNAc) post-translational 
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modification 61. Uridine diphosphate (UDP)-GlcNAc is the by-product of the hexosamine 
signaling pathway, through which ~5% of total glucose is metabolized. Fatty acids can 
also promote flux through the hexosamine pathway62.  The enzyme O-GlcNAc 
transferase (OGT) can subsequently transfer the UDP-GlcNAc to serine or threonine 
residues of target proteins, producing the O-GlcNAc modification which changes the 
activity of the protein63.  Under GLT, it is expected that increased flux through the 
hexosamine signaling pathway would significantly increase O-GlcNAcylation of target 
proteins, including mitochondrial proteins64-66. Importantly, it is not fully understood how 
increased O-GlcNAcylation under GLT would affect Milton1 and mitochondrial motility 
in the beta-cell, and how these motility changes may influence beta-cell function and 
viability. 
The final step for removal of damaged mitochondria is degradation through the 
autophagosome-lysosome (autophagy) system. The key steps of autophagy include 
autophagosome recruitment and engulfment of the targeted mitochondrion. The 
autophagosome then fuses with the lysosome to form an autolysosome. Lysosomal acid 
hydrolase enzymes ultimately degrade the contents of the autolysosome. Fusion of the 
autophagosome and lysosome requires a sufficiently acidic lysosome67, 68. Studies have 
shown that fatty acids or glucose stimulate autophagy in INS1 and beta-cells69, 70.  
However, studies in the Shirihai laboratory demonstrated that autophagosome formation 
is increased under GLT, but lysosomal defects inhibit overall autophagic flux, defined as 
autophagic degradation activity. Importantly autophagic flux is inhibited because 
lysosomal acidity is lost under chronic GLT, along with decreased activity of lysosomal 
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cathepsin enzymes56. In vivo data from another research group also demonstrates that 
autophagosome-lysosome fusion is inhibited in mice fed a high-fat diet71.  
GLT-induced lysosome alkalinization in beta-cells would inhibit flux through autophagy 
and inhibit mitochondrial turnover, creating a “back-log” in the mitochondrial life cycle. 
Accumulation of damaged mitochondrial material limits the bioenergetic capacity of the 
mitochondrial population, ultimately affecting beta-cell function and viability. In 
addition, lysosomes that have reduced acidity can leak iron into the cytosol, catalyzing 
Fenton-mediated oxidative damage of surrounding cellular components, eventually 
leading to cell toxicity and death72. Lysosomes thus represent an especially vulnerable 
arm of mitochondrial quality control, in which lysosome dysfunction not only inhibits 
clearance of damaged mitochondria but also incites further oxidative damage by iron-
mediated pathways. 
In summary, mitochondrial quality control is determined by the ability of the cell and 
mitochondrial network to efficiently segregate and eliminate mitochondrial damage, 
especially under conditions of increased stress such as GLT.  Alterations in mitochondrial 
dynamics, motility, and lysosomal acidity would greatly compromise mitochondrial 
quality control in the beta-cell under GLT, contributing to the pathogenesis of beta-cell 
dysfunction associated with type 2 diabetes. The proposed work will investigate the role 
of mitochondrial fusion and fission for efficient segregation of aged/damaged 
mitochondrial proteins, and how inhibited fusion under GLT compromises mitochondrial 
quality control. Additionally we will seek to understand how GLT affects mitochondrial 
motility, and nutrient-sensing machinery that may determine both acute bioenergetic 
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remodeling and long-term mitochondrial quality control in response to nutrient excess. 
Finally, the importance of lysosomal acidity for adequate autophagy-mediated turnover 
and beta-cell function will be investigated in the context of GLT-induced lysosomal 
alkalinization in the beta-cell. These three mitochondrial adaptive mechanisms, 
dynamics, motility, and lysosomes, must be well coordinated to promote appropriate 
mitochondrial function and quality control in the beta-cell (Fig. 1.1). When these 
mechanisms are altered under GLT, mitochondrial dysfunction can arise leading to 
compromised beta-cell insulin secretion and viability.  Thus, the three adaptive 
mechanisms represent potential therapeutic targets for restoring mitochondrial function in 
beta-cells under GLT.  
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 Figure 1.1. The mitochondrial life cycle is composed of adaptive mechanisms which 
promote quality control  
The networking phase of the life cycle comprises fusion between two mitochondria, 
which is dependent upon active mitochondrial motility. Following fission, one daughter 
mitochondrion may be depolarized and would enter the elimination phase, involving 
autophagosome (AP) engulfment and subsequent degradation after fusing to acidic 
lysosomes. The other daughter mitochondrion re-enters the networking phase after a 
solitary period, continuing the mitochondrial life cycle. Thus, the mitochondrial life cycle 
promotes quality control of the mitochondrial population.   
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CHAPTER TWO 
Part One: MitoTimer probe reveals the impact of autophagy, fusion, and motility on 
subcellular distribution of young and old mitochondrial protein and on relative 
mitochondrial protein age 
 
INTRODUCTION 
As major producers of energy and oxidative stress, the maintenance of the mitochondrial 
network is critically important for cells. Mitochondrial quality control is especially 
crucial for long-lived cells with high energetic demands, such as neurons 73. Little is 
known regarding how newly synthesized mitochondrial components are distributed with 
existing, aged materials.  
Previous methodologies for studying mitochondrial aging have severe limitations 
including a lack of spatial resolution and live-cell applicability 74. We present a novel 
approach based on a time-sensitive fluorescent protein that is targeted to the 
mitochondrial matrix (MitoTimer). Emitted fluorescence of newly translated Timer is 
green and over time the emission shifts to red 75. We fused the fluorescent Timer to the 
mitochondrial targeting sequence of Cox8a subunit, to form the MitoTimer construct. 
Our data identify mitochondrial turnover, fusion, and transport as factors involved in the 
equilibration of mitochondrial protein age. MitoTimer has utility as a read-out of 
mitochondrial maintenance with applicability across different tissues and disease 
contexts.   
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METHODS 
Culture of cell lines 
Matched ATG5+/+ (wild-type) and ATG5-/- (ATG5-KO) mouse embryonic fibroblasts 
(MEFs) transfected with pEF321-T and an SV40 large T antigen expression vector were 
a generous gift from N. Mizushima and were previously described 76.  Mfn1 and Mfn2 
double-knockout (Mfn1/2 KO) MEFs were described previously 77. The three MEF cell 
lines and COS cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin and 
streptomycin.  INS1 832/13 cells were cultured in RPMI 1640 media supplemented with 
10% FBS, 10mM HEPES buffer, 1mM pyruvate, 50µM β-mercaptoethanol, 50units/mL 
penicillin, and 50µg/mL streptomycin. Cells were plated on MatTek glass bottom dishes 
for confocal imaging and on 96-well plates for imaging with Celigo Imaging Cell 
Cytometer. 
Isolation and culture of primary hippocampal neurons 
Hippocampal tissue was harvested from timed pregnant (E14) CD1 mice and maintained 
in Neurobasal media with B27 supplement and Pen/Strep (Invitrogen, cat#17504044) 
with half-media changes every other day.  Neurons were cultured on poly-d-
lysine/laminin coated MatTek glass bottom dishes for confocal imaging.  With the 
exception of the live-cell time-course studies, cells were fixed with 4% paraformaldehyde 
in phosphate buffered saline (PBS) prior to imaging.   
Transfection 
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MEFs were transfected using Lipofectamine LTX (Invitrogen, cat#15338-100). Neurons 
were transfected with calcium phosphate on the seventh day of in vitro culture (DIV7).  
Doxycycline (1 µg/mL) was added to the media the day after transfection to induce 
MitoTimer expression. 
Creation of stable cell lines 
COS, INS1, MEF wild-type and Mfn1/2 KO cell lines were infected with MitoTimer 
lentivirus and exposed to doxycycline to induce MitoTimer expression. After 72 hours of 
doxycycline exposure, fluorescent cells were sorted into medium- and high-expressing 
populations with a BD FACSARIA II SORP cell sorter.  Cells were then maintained 
without doxycycline for 2-3 passages before cells were plated and used for experiments. 
In order to conduct experiments with cells expressing steady-state levels of MitoTimer, 
stable cell lines were exposed to doxycycline (1 µg/mL) for at least 5 days (doxycycline 
replaced daily) to obtain steady-state expression of MitoTimer before specific treatments 
or imaging was performed. 
OPA1 knockdown 
INS1 cells stably-expressing MitoTimer were infected with 2 different OPA1-shRNA 
lentiviruses targeted against different portions of the rat OPA1 sequence. Both viruses 
were proven effective at knocking down OPA1 levels in INS1 cells resulting in a 
fragmented mitochondrial architecture. Cells were cultured for 6-7 days after infection 
with OPA1-shRNA lentiviruses before imaging. 
Immunofluorescence 
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To assess MitoTimer colocalization with mitochondrial Tomm20, immunofluorescence 
staining for Tomm20 was performed on MEFs transfected with MitoTimer. Briefly, 
transfected cells were fixed with 4% paraformaldehyde for 15 minutes. After washing in 
PBS, cells were incubated with 3% BSA in PBS with 0.2% Triton-X-100 for 30 minutes. 
Cells were then incubated overnight at 4ºC with a polyclonal rabbit anti-Tomm20 
antibody (Abcam, cat# 78547) diluted 1:200 in PBS containing 1% BSA. After PBS 
washes, cells were treated with anti-rabbit Alexa Fluor 405 (Invitrogen, cat#A31566) 
secondary antibody diluted 1:200 in PBS containing 1% BSA. Cells were washed with 
PBS and imaged shortly after to visualize colocalization of MitoTimer with Tomm20 
staining. 
Imaging 
To quantify green and red fluorescence intensity per cell in MEFs, cells were imaged 
using the Celigo Imaging Cell Cytometer (Brooks Life Science Systems). Green (483/32 
excitation; 536/40 emission) and red (531/40 excitation; 629/53 emission) fluorescence 
channels were imaged for each well. 
For subcellular imaging of MitoTimer expression, MEF cells and primary hippocampal 
neurons were imaged by confocal microscope (Zeiss; LSM710) with a 63x oil immersion 
objective.   MitoTimer was excited with 488 nm argon and 543 nm helium-neon lasers.  
Green fluorescence emission was collected in the 497-531 nm range while red 
fluorescence emission was collected in the 583-695 nm range. We observed that the red 
fluorescence will bleach faster than the green during multiple acquisitions. To control for 
possible bleaching during multiple acquisitions, cells were imaged multiple times with 
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the laser settings used for experiments. Resulting images were then analyzed for the 
fluorescence intensity of red, green, and the red/green ratio in order to verify that 
successive imaging of the cells did not bleach either the green or red fluorescence. To 
observe individual mitochondria, z-stack images were acquired in series of six slices 
ranging in thickness from 0.5 to 0.8 µm. Tile imaging was performed to acquire the 
complete arborization of neurons, typically yielding 1-2 neurites per neuron used for 
analysis.  Data for comparisons in neurites of control, Miro1 WT and Miro1 KK groups 
were compiled from experiments done in replicate (3<n<5). 
Image analysis 
Analysis parameters for images acquired by Celigo Imaging Cell Cytometer were 
optimized to identify individual MEF cells based on fluorescence, and the average green 
and red fluorescence intensity per cell was determined at the different time points 
assessed.  Specifically, the “Target 1+2 Merge” application setting in the Celigo software 
was used to determine the average green and red fluorescence for each cell selected based 
on the analysis parameters.  Analysis settings were determined to identify fluorescent 
cells distinguishable from background fluorescence of cells not treated with doxycycline 
(no MitoTimer expression).  Exposure and analysis settings were kept constant for each 
time-course experiment.  Average fluorescence intensity per cell values were determined 
by the average integrated intensity per cell values in order to exclude error from 
background pixels included in identified cell regions. At least 1,000 cells were analyzed 
per well, with 3 well replicates per experiment. 
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To characterize MitoTimer fluorescence in individual mitochondria, a ratiometric image 
analysis approach was performed. An average of 8-12 cells was analyzed per experiment 
with experiments repeated at least 3 times (n=3). Image processing and analysis was done 
with Metamorph software (Molecular Devices). Red and green images were used to 
generate a ratio (red/green or green/red) image. A maximum intensity projection of 
original z-stack images was generated to visualize the entire mitochondrial volume. 
Minimum thresholding for mitochondrial areas was set at 15% of the maximum pixel 
intensity for red images. Prior to analysis, all images were scanned to verify that all 
intensity measurements were below saturation; therefore an upper threshold was not 
necessary. The thresholded images were then binarized and single pixels removed. The 
identified mitochondrial areas were then applied to the green image, and a ratio image 
was generated by dividing the red by the green image (or green divided by red for 
green/red ratio images). Pseudocoloring was used to visualize the variation in red/green 
ratio among mitochondria. Fluorescence intensity (red/green) values of identified 
mitochondria were then determined to assess the differences in MitoTimer fluorescence 
among mitochondria in MEF cells or primary neurons, thus generating an age profile.  
Statistics 
Unless stated otherwise, error bars indicate means S.D., and an unpaired t test was used 
to validate statistical differences between two conditions. To determine significance of 
multiple conditions, a one-way ANOVA was used. 
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RESULTS 
Characterization and Kinetics of MitoTimer  
The fluorescent Timer protein fluoresces green immediately post-synthesis. Within 24 
hours the emission spectra shifts to red fluorescence.  We fused the fluorescent Timer to 
the mitochondrial targeting sequence of Cox8a subunit, to form the MitoTimer construct.  
To control the timing of transcription of MitoTimer in cells, a doxycycline-inducible 
vector (pTRE-tight) was used to express MitoTimer. The resulting mitochondrial-targeted 
Timer localizes to mitochondria as assessed by co-localization with Tomm20 staining in 
MEF cells (Fig. 2.1.S1).   
Quantifying the time-dependent changes in green and red fluorescence of MitoTimer in 
MEF cells shows the initial green fluorescence 8 hours after induction of transcription by 
doxycycline.  After 24 hours, MitoTimer is a mixture of green and red fluorescence, 
producing an overall yellow appearance. Over 48-72 hours MitoTimer fluorescence 
becomes predominantly red (Fig. 2.1.1A & 1C).   Expressing MitoTimer in primary 
hippocampal neurons revealed similar time-dependent changes in green and red 
MitoTimer fluorescence (Fig. 2.1.1B).   
Using a Leica TCS SP8 system, lambda-square scans were performed for sequential 
excitations produced by a white-light tunable laser in 10nm steps and the maximal 
intensity recorded for the MitoTimer stably-expressed in INS1 cells. Supplementary 
Figure 2.1.S2 and S3 shows excitation-emission spectra for green and red MitoTimer 
fluorescence, respectively. Acute alterations in mitochondrial matrix pH under high 
glucose (reported pH~7.8) 78, oligomycin (reported pH~8) 79, or FCCP (reported pH≤7) 80 
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treatment did not affect green-to-red fluorescence ratio in INS1 cells stably-expressing 
MitoTimer, consistent with previous reports of the pH-independent fluorescence of the 
Timer protein (Fig. 2.1.1D and Fig. 2.1.S4A, n=10 cells) 75. In addition, MitoTimer red 
and green fluorescence was stable and unaffected by fixation (Fig. 2.S4B, n=3). Finally, 
the green-to-red color transition of MitoTimer was independent of protein expression, as 
average red and green MitoTimer fluorescence correlates similarly in INS1 cells with 
different overall expression (Fig. 2.1.S4C). Thus, MitoTimer green-to-red fluorescence 
transition can be used as a read-out of relative mitochondrial protein age in different cell 
types. 
 
Turnover regulates mitochondrial network age 
Rates of mitochondrial turnover depend on the balance between import of newly 
synthesized components and degradation of aged material.  Figure 2A outlines potential 
factors that would contribute to MitoTimer age profile within mitochondria, as 
represented by new (green), intermediate (yellow), and old (red) MitoTimer. In addition 
to the time-dependent transition from green to red, rates of synthesis/import and 
degradation will influence MitoTimer fluorescence.  To validate these associations, we 
quantified fluorescence in mitochondrial networks with pulsed MitoTimer synthesis or 
inhibited degradation by autophagy. 
Limiting synthesis of new MitoTimer with a 4 hour pulse-exposure to doxycycline 
altered the age profile relative to continuous 24 hours doxycycline treatment.  Pulsed 
expression shifted the age profile of MitoTimer in the mitochondrial network to increase 
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the proportion of red relative to green fluorescence compared with continuous 
doxycycline (Fig.2.1.S5A compared to Fig. 2.1.1C).  Plotting the red/green fluorescence 
ratio depicts the increased proportion of aged versus new MitoTimer protein over time 
(Fig. 2.1.2A; p<0.05, n=4).   
Similarly if import of new MitoTimer protein was limiting, then there should be a 
decrease in the amount of green MitoTimer fluorescence. We observed a modest yet 
significant decrease in MitoTimer green fluorescence after 3 hours of FCCP (10µM) 
treatment in COS cells stably-expressing MitoTimer (Fig. 2.1.2B; p<0.05, n=3). 
Importantly this decrease in green MitoTimer occurred only in the presence of 
doxycycline, which is required to allow transcription of new MitoTimer protein. Without 
doxycycline for the last 24 hours before imaging, there was no significant change in 
green MitoTimer fluorescence after FCCP treatment (Fig. 2.1.2B). FCCP treatment 
caused a small, non-significant decrease in red MitoTimer fluorescence as well, which 
may be due to the fact that FCCP-induced depolarization of mitochondria also may 
promote mitochondrial turnover via autophagy. Overall, this data suggests that FCCP-
induced depolarization prevents import of newly synthesized (green) MitoTimer protein 
into mitochondria. 
To validate the capacity of Timer protein to measure the relative age of mitochondria in 
the cell, we inhibited mitochondrial turnover and measured green and red emissions. 
Turnover was inhibited by blockage of the autophagic degradation pathway in MEF cells 
transiently-expressing MitoTimer for 48 hours. Inhibiting autophagy by preventing 
lysosome acidification with bafilomycin led to the accumulation of aged (red) material 
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without significantly changing the amount of newly synthesized (green) protein (Fig. 
2.1.S5B; p<0.05, n=3). Similar results were seen with chloroquine treatment, which 
neutralizes lysosomal acidity. In order to address the effects of inhibiting mitochondrial 
turnover on MitoTimer age profile in steady-state condition, we generated stably-
expressing MitoTimer COS cells via lentivirus infection. Treatment with bafilomycin or 
chloroquine similarly induced an accumulation of MitoTimer protein, with a greater 
proportion of red (old) protein accumulating (Fig. 2.1.2C, p<0.05, n=3). This effect was 
similar in cells that had not received doxycycline treatment for the last 24 hours, which 
suggests the effect of bafilomycin and chloroquine was via inhibition of autophagy and 
independent of transcriptional effects (Fig. 2.1.S5C). 
Inhibition of autophagy was also achieved upstream of the lysosome with genetic 
knockout of ATG5 in MEFs.  After 48 hours of continuous MitoTimer expression, 
mitochondrial networks in ATG5-KO MEFs displayed a significantly increased average 
red fluorescence compared to wild-type MEFs (Fig. 2.1.2D; p<0.05, n=3), confirming 
that reduced protein turnover by autophagy leads to the accumulation of red (aged) 
MitoTimer.  Collectively these findings are in agreement with the expected influence of 
mitochondrial turnover on accumulation of aged material within the mitochondrial 
network. 
 
Equilibration of protein age in the mitochondrial network requires fusion 
We next examined whether mitochondrial dynamics influences the equilibration of 
protein age among individual mitochondria within the network. While individual 
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mitochondria within the cell may import and degrade proteins at different rates, their 
involvement in continuous cycles of fusion and fission events may counter subcellular 
heterogeneity by allowing for the equilibration of matrix protein content. We rationalized 
that the ability to become engaged in fusion events may influence the level of 
heterogeneity in protein age among mitochondria in the cell.   
    Double-knockout MEFs lacking both Mfn1 and Mfn2 (Mfn1/2 KO) show significant 
subcellular heterogeneity of MitoTimer age profiles compared to wild-type MEFs (Fig. 
2.1.3B vs 3A).7 This MitoTimer heterogeneity was apparent in Mfn1/2 KO MEFs 
transiently-transfected with and expressing MitoTimer for 24 h (Fig. 2.1.S6A-B), but was 
even more striking in stably-expressing cells expressing MitoTimer for >5 days (Fig. 
2.1.3A-B). Assessing the average green and red fluorescence intensity of individual 
mitochondria (normalized to the average for the cell) reveals the heterogeneity of 
MitoTimer age profiles in Mfn1/2 KO cells compared to wild-type (Fig. 2.1.3C).  While a 
majority of the mitochondria in Mfn1/2 KO cells show similar relationships between 
green and red fluorescence as in wild-type, we observe a large number of appreciably 
redder or greener mitochondria in Mfn1/2 KO cells. Plotting the red/green ratio of 
individual mitochondria versus their size shows that the smallest units have the greatest 
heterogeneity of MitoTimer age profile in Mfn1/2 KO MEFs (Fig. 2.1.3D and Fig. 
2.1.S6C). Overall, MitoTimer heterogeneity in Mfn1/2 KO MEFs is significantly 
increased compared to wild-type MEFs (Fig. 2.1.3E and Fig. 2.1.S6D; p<0.01, n=3). We 
also determined that inhibition of mitochondrial fusion by Opa1 knock-down in INS1 
cells resulted in increased subcellular heterogeneity of MitoTimer age profile (Fig. 
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2.1.3F-G; p<0.05, n=17 cells for control, 27 cells for Opa1 knock-down from two 
independent infection procedures). Overall these data indicate the importance of 
mitochondrial fusion in equilibrating the levels of new and old protein within the 
network. 
    
Aged mitochondrial protein predominates in hippocampal neurites and is influenced by 
transport 
We next turned to primary hippocampal neurons to examine MitoTimer age profiles in a 
cellular system with complex morphology and large spatial dimensions.  As such, the 
neuron is a unique model in which one can study the impact of separate cellular 
compartments with disparate movement, fusion and biogenesis kinetics on the subcellular 
distribution of young and old protein.   
   MitoTimer expressed in primary hippocampal neurons for 24 h displays an overlap of 
green and red fluorescence in the soma producing an overall yellow appearance.  In 
contrast, mitochondria in distal regions of neurites appeared more orange or red in 
fluorescence compared to the soma (Fig. 2.1.4A).  This effect is illustrated with 
ratiometric images of the relative green to red intensities (Fig. 2.1.4B). Equilibration of 
young and old protein across the neurites is limited by distance as aged MitoTimer 
predominates in distal neurite regions, shown by plotting the green/red ratio versus 
distance from the soma for mitochondria in individual neurites (Fig. 2.1.4C).  This 
analysis typically produced an inverse relationship characterized by a negative slope of 
the best-fit line (Fig. 2.1.4D, control group). The majority of neurites analyzed showed a 
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negative slope while the rest show a slightly positive slope, indicating that neurons show 
heterogeneity of mitochondrial protein age in the neurites versus the soma.  
   Given that transport greatly influences subcellular spatial distribution of mitochondria, 
we chose to investigate the role of mitochondrial motility in the age equilibration pattern 
of MitoTimer in neurons. To increase mitochondrial transport we co-expressed 
MitoTimer with RHOT1 wild-type (RHOT1-WT) or a hyperactive, calcium-insensitive 
mutant of RHOT1 (RHOT1-KK).  RHOT1 is a motor adaptor protein that selectively 
facilitates mitochondrial movement along microtubules.8, 9 Expressing the RHOT1 
constructs altered the age distribution of MitoTimer in neurites (Fig. 2.1.4D; ANOVA, 
p=0.01).  Constitutively active RHOT1-KK increased homogeneity of the age profile 
between neurites and soma (distribution shifted toward zero). Over-expressing RHOT1-
WT significantly reversed the normal distribution of aged material between the neurites 
and soma (distribution shifted to the positive, p<0.05 vs control).  These data illustrate 
the importance of mitochondrial motility in equilibrating protein age between the soma 
and neurites.  
   To better understand the connection between spatial location and age heterogeneity, we 
performed time-lapse imaging to assess the dynamics of green and red MitoTimer in 
mitochondria located in the soma or neurites.  Over the 12 h imaging period (imaging 
started after 24 h of MitoTimer expression), red MitoTimer fluorescence intensity 
increases in the soma and neurites as MitoTimer in both compartments transitions to red 
(Fig. 2.1.5A-C).  Overall green intensity decreases earlier and more rapidly in 
mitochondria located in neurites compared to soma over the 12 h time-course (Fig. 
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2.1.5B-C; n=12 neurons).  This may reflect differences in rates of import of new (green) 
MitoTimer needed to balance the protein transitioning to red fluorescence. Thus, influx of 
new MitoTimer protein may be comparatively less for mitochondria located within 
neurites relative to those in the soma.  In summary, these data suggest that fusion and 
transport are insufficient to prevent disequilibrium and heterogeneity in the age of the 
mitochondrial network located outside the neuron soma.    
 
DISCUSSION 
Mechanisms for turnover of cellular constituents are central to the pathophysiology of 
age-related diseases.  MitoTimer represents a novel tool to study mitochondrial turnover 
at cellular and subcellular levels (see illustration in Fig. 2.1.6).  Control experiments with 
modulators of protein synthesis and autophagic degradation validate the age-dependent 
shift in fluorescence intensity as a read-out of turnover. We applied MitoTimer to test the 
influence of mitochondrial fusion on synchronization of mitochondrial protein age at a 
subcellular level.  Equilibration of young and old protein across the network occurs in 
part through content mixing between mitochondria during complete fusion events.81  
Heterogeneity in the MitoTimer age profile of individual mitochondria in cells lacking 
mitofusins reveals the necessity of fusion in equilibrating the age of proteins across the 
mitochondrial population.   
Hippocampal neurons also display dramatic heterogeneity amongst individual 
mitochondrial units, particularly in distal regions of neurites where aged MitoTimer 
predominates.  This indicates that mitochondrial access to newly synthesized protein by 
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either fusion events or by frequent visits to the soma is unlikely to contribute to 
biogenesis in mitochondria residing in the neurites.  Support for this hypothesis is 
garnered from literature demonstrating that fusion rates in healthy neuronal processes are 
low 81, 82, and that under normal conditions the majority of neurite mitochondria are 
stationary.58 Delivery of newly synthesized protein to isolated mitochondrial units in 
distal cell compartments, particularly of individual proteins with high turnover rates,83 
may be supplemented by localized translation. Such a mechanism would likely involve 
targeting sequences not found on MitoTimer, as it is not a native mitochondrial protein.  
Given this possibility, it is noteworthy that variation in MitoTimer age profiles between 
soma and neurite can be influenced by microtubule transport activity. It has been 
demonstrated that mitochondrial motility is a significant determinant of fusion 57. 
Specifically, we demonstrate that enhancing motility by expression of wild-type RHOT1 
shifts age profiles towards greater distribution of newly synthesized (green) MitoTimer. 
Recent studies also support this finding by showing that increased mitochondrial motility 
in neurons by RHOT1 over-expression increases fusion.84 RHOT1-WT, but not 
hyperactive RHOT1-KK, reversed the distribution of aged MitoTimer in neurites, 
suggesting calcium signaling that regulates RHOT1 activity may be crucial for proper 
distribution of contents throughout the mitochondrial network. Collectively these findings 
highlight the potential of therapies aimed at enhancing mitochondrial transport in treating 
conditions associated with impaired mitochondrial turnover in neurons, such as 
Parkinson’s disease.  
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Though MitoTimer represents a novel fluorescent probe to study mitochondrial 
maintenance, certain considerations have to be taken into account when assessing and 
interpreting results with this construct. Any changes to the readout of MitoTimer green, 
red, or red/green fluorescence intensity can only be interpreted when compared to a 
control condition at the same time point and image acquisition settings.  Importantly, 
changes to MitoTimer fluorescence cannot be interpreted as a specific alteration of 
mitochondrial biogenesis, degradation, dynamics, or motility per se.  All of these 
processes can potentially affect the age profile of MitoTimer in the cells (see illustration 
in Fig. 2.1.6); thus experimental conditions found to alter MitoTimer age profiles have to 
be further studied, with proper controls used, to determine which aspect of mitochondrial 
biology is actually affected. In addition, the read-out of increased red versus green 
MitoTimer does not necessarily indicate increased damaged or dysfunction of 
mitochondria. Thus, MitoTimer can be used to assess relative changes to mitochondrial 
protein turnover and equilibration in different conditions or within the mitochondrial 
network. 
Our work demonstrates how directly altering mitochondrial turnover, dynamics, or 
motility change the age profile of MitoTimer. These conditions may represent 
experimental controls for further studies. Concurrent with this idea, MitoTimer is 
targeted to the mitochondrial matrix with a short mitochondrial-targeting sequence. Thus 
it does not indicate the distribution or turnover of any specific mitochondrial protein, but 
rather acts as a marker for mitochondrial matrix protein content. It was recently shown 
that half-lives of mitochondrial proteins are very heterogeneous;83 thus it will be 
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interesting for further studies to assess Timer kinetics and age profile when targeted to 
other mitochondrial compartments or tagged to specific mitochondrial proteins. 
In summary, we report the characterization and applicability of a novel MitoTimer 
fluorescent probe, which can be used to study mitochondrial turnover and aging both on a 
cellular and subcellular level. Importantly we show that mitochondrial age as assessed by 
MitoTimer is dependent on mitochondrial turnover, fusion, and transport. Consequently, 
MitoTimer may be valuable as a fluorescent tool to investigate conditions where 
mitochondrial protein turnover is altered in different cells or pathologies.  
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FIGURES 
Figure 2.1.1. Localization and kinetics of MitoTimer. 
(A) MitoTimer was expressed in MEF cells by transfection followed by induction by 
doxycycline. Mitotimer showed mitochondrial localization and changed in color from 
green to red over time. Scale bar = 20 µm.  (B) Primary hippocampal neurons were 
transfected and imaged at the different time points after doxycycline induction.  
MitoTimer showed similar localization to mitochondria and kinetics of green to red 
transition as in MEF cells.  Scale bar = 20 µm.  (C) Quantification of green and red 
fluorescence intensity over time after doxycycline (DOX) induction in MEF cells (n=3).  
(D) MitoTimer green and red fluorescence (green/red ratio) was stable over a range of 
mitochondrial matrix pH conditions, achieved by acute exposure to 20 mM glucose, 
oligomycin (Oligo), or FCCP in INS1 cells stably-expressing MitoTimer (n=10 cells). 
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Figure 2.1.2. Relative abundance of young and aged MitoTimer protein is 
dependent on synthesis, import and autophagy.  
(A) As compared to continuous MitoTimer induction, limiting MitoTimer induction to 4 
h of doxycycline pulse results in increased red/green ratio values (*=p<0.05, n=4).  (B) 
Effect of FCCP (10 µM, 3 h) on the abundance of green (green bar) and red (red bar) 
MitoTimer in the presence or absence of ongoing doxycycline-mediated MitoTimer 
synthesis. FCCP treatment in COS cells stably-expressing MitoTimer induced a 
significant decrease in green MitoTimer fluorescence (green bar) only in cells where 
active MitoTimer synthesis is ongoing (+DOX) (*=p<0.05, n.s.=non-significant, n=3).  
(C) Inhibition of autophagy with bafilomycin (Baf; 100 nM for 16 h) or chloroquine 
(Chq; 30 µg/mL) in COS cells stably-expressing MitoTimer leads to significant 
accumulation of red fluorescence (red bar) relative to red fluorescence of control-
untreated cells (red asterisk). Green fluorescence (green bar) in chloroquine-treated cells 
was significantly increased (green asterisk) compared to control-untreated cells. In 
chloroquine-treated cells, the proportional increase in red was significantly greater 
(pound sign) than the increase in green MitoTimer (*=p<0.05, #=p<0.05, n=3).  (D) Cells 
deficient in autophagy (Atg5 KO) show increased proportion of red MitoTimer after 48 h 
of expression, compared to wild-type (WT) MEFs (*=p<0.05, n=3). 
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Figure 2.1.3. Fusion within the mitochondrial network mixes old and new proteins 
thus equilibrating MitoTimer age profiles.   
 (A) Wild-type (WT) MEFs stably-expressing MitoTimer show relatively uniform yellow 
fluorescence in the mitochondrial network, indicating even distribution of old and new 
protein among mitochondria. Scale bar = 10 µm.  (B) Mitochondrial fusion-deficient 
(Mfn1/2 KO) MEFs stably-expressing MitoTimer display heterogeneity of MitoTimer 
red/green ratio among individual mitochondria compared to wild-type MEFs. Insets show 
high magnification of white boxes where small red and green mitochondria are apparent.  
(C) Graph depicts average green and red fluorescence intensity of individual 
mitochondria (normalized to the average green and red for the cell) in wild-type and 
Mfn1/2 KO cells. MitoTimer age profiles vary widely in Mfn1/2 KO cells (mitochondria 
from 4 representative cells).  (D) Plotting the red/green ratio versus area of individual 
mitochondria (mitochondria from 2 representative cells) shows the smaller mitochondria 
tend to display the greatest deviation from the average red/green ratio values in Mfn1/2 
KO MEFs (white diamonds) compared to wild-type MEFs (WT, black diamonds).  (E) 
Subcellular heterogeneity in MitoTimer age (standard deviation of red/green ratio for all 
mitochondria in the cell) is increased in Mfn1/2 KO MEFs compared to wild-type (WT) 
(*=p<0.01, n=3).  (F) INS1 stably-expressing MitoTimer and infected with Opa1 knock-
down lentivirus for 7 days showed intracellular heterogeneity of MitoTimer age profile 
compared to control-infected (Con) cells. Scale bars = 10 µm.  (G) Subcellular 
heterogeneity in MitoTimer age is increased in Opa1 knock-down (KD) INS1 cells 
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compared to control (*p<0.05, n=17 cells for Control, 27 cells for Opa1 KD from two 
independent infection procedures). 
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Figure 2.1.4. Aged MitoTimer is increased in hippocampal neurites and is regulated 
by mitochondrial motility. 
(A) Primary hippocampal neurons after 24 h of MitoTimer expression with mitochondria 
displaying overlap of green and red fluorescence.  On the right, a high magnification of 
distal neurites is shown. Mitochondria with relatively little green fluorescence in neurites 
are designated with white arrows. Scale bar = 50 µm. At the bottom is a high 
magnification of proximal neurite. Note that proximal neurites have a relatively lower 
red/green ratio, indicative of younger MitoTimer protein.  (B) Ratiometric (green/red) 
image of hippocampal neuron illustrating the predominance of aged MitoTimer in distal 
neurites. Scale bar = 100 µm.   (C) Example of neurite age vs distance trace analysis. All 
mitochondria within a single neurite were plotted based on green/red ratio intensity and 
distance from the nucleus.  (D) Graph showing the distribution of slopes derived from the 
neurites age-vs-distance trace analysis.  The influence of mitochondrial motility is 
demonstrated by comparing baseline transport (Control) and enhanced transport 
(RHOT1-WT and RHOT1-KK) (ANOVA, p=0.01 with Control vs RHOT1-WT, p<0.05). 
  
  
38 
 
  
  
39 
Figure 2.1.5.  Kinetics of MitoTimer green-to-red color transition differs between 
neurites and soma. 
(A) Example of neuron in the live-cell imaging experiments used for the comparison of 
MitoTimer fluorescence kinetics in the neurites (B) versus the soma (C). Graphs depict 
changes in MitoTimer green and red fluorescence over time for a representative neuron 
(n=12 neurons). Scale bar = 10 µm. 
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Figure 2.1.6.  Illustration of mechanisms that can contribute to the distribution of 
aged (red) and young (green) MitoTimer protein.  
The vertical axis represents the effect of protein biogenesis and turnover on the overall 
cellular MitoTimer age. Mitotimer is formed green and turns to red with time. Since 
biogenesis generates only green MitoTimer while turnover removes both red and green, 
increased turnover will result in an increase in the portion of green mitochondria.  The 
horizontal axis shows the processes that equilibrate young and aged MitoTimer across the 
cell. Reduced fusion activity either due to inhibition of fusion proteins, reduced motility 
or compartmentalization of a subgroup of mitochondria can all contribute to 
heterogeneous distribution of old and young mitochondrial proteins. 
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Supplementary Figure 2.1.S1.  MitoTimer localizes to mitochondria in MEF cells. 
MitoTimer construct was transfected into MEF cells, and 24 h later cells were fixed and 
stained for TOMM20 conjugated with AlexaFluor405 secondary antibody (pseudo-
colored magenta). MitoTimer is co-localized to mitochondria stained with TOMM20.  
Scale bar = 20 µm. 
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Supplementary Figure 2.1.S2.  Excitation/emission spectra of MitoTimer green 
fluorescence. 
Lambda-square scans were performed for sequential excitations produced by a white-
light tunable laser in 10 nm steps and the maximal intensity recorded. 
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Supplementary Figure 2.1.S3.  Excitation/Emission spectra of MitoTimer red 
fluorescence. 
Lambda-square scans were performed for sequential excitations produced by a white-
light tunable laser in 10 nm steps and the maximal intensity recorded. 
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Supplementary Figure 2.1.S4.  MitoTimer green and red fluorescence is unaffected 
by pH changes or protein expression level. 
(A) Images of INS1 cells stably-expressing MitoTimer showing red and green 
fluorescence at basal glucose levels. MitoTimer fluorescence was not affected by acute 
exposure to high glucose (20 mM glu, 15 minutes), oligomycin (5 µM, 15 minutes), or 
FCCP (2 µM, 15 minutes).  Scale bar = 10µm.  (B) COS cells stably-expressing 
MitoTimer were imaged and the red/green MitoTimer ratio was assessed. After fixation 
with 4% paraformaldehyde for 15 minutes followed by subsequent imaging, the red/green 
MitoTimer ratio was unchanged.  (C) INS1 cells stably-expressing MitoTimer were 
analyzed by flow cytometry. Red and green MitoTimer fluorescence intensity (F.I.) 
increased with a linear relationship. 
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Supplementary Figure 2.1.S5.  Limited synthesis or inhibition of autophagy increase 
the relative proportion of aged MitoTimer. 
(A)   Pulsing MitoTimer production with 4 h of doxycycline (DOX) induction increases 
the proportion of red fluorescence over-time compared to continuous doxycycline 
induction (as shown in Fig. 1D).  (B) Inhibition of autophagy with bafilomycin (Baf; 100 
nM for 16 h) or chloroquine (Chq; 30 µg/mL) in MEF cells transiently expressing 
MitoTimer for 48 h leads to the accumulation of red MitoTimer fluorescence (red bar) 
relative to green fluorescence (green bar) compared to control (Con) condition 
(*=p<0.05, n=3).  (C) COS cells stably-expressing MitoTimer via continuous 
doxycycline (DOX) induction except for the last 24 h before imaging show significant 
accumulation of red fluorescence (red bar) relative to red fluorescence of control-
untreated cells (red asterisk). Green fluorescence (green bar) in bafilomycin- and 
chloroquine-treated cells was also significantly increased (green asterisk) compared to 
control-untreated cells. In chloroquine-treated cells, the proportional increase in red was 
significantly greater (pound sign) than the increase in green MitoTimer (*=p<0.05, 
#=p<0.05, n=3). 
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Supplementary Figure 2.1.S6.  Lack of mitochondrial fusion in MEF or INS1 cells 
shows heterogeneity of MitoTimer age profile within the mitochondrial network.  
(A) Wild-type (WT) MEFs transiently expressing MitoTimer for 24 h show overall 
uniform yellow fluorescence of MitoTimer. Ratio image depicting red/green ratio of 
MitoTimer reveals relatively uniform age profiles among mitochondria in the cell. (B) 
Moderate heterogeneity of MitoTimer red/green ratio is seen in Mfn1/2 KO MEFs 
expressing MitoTimer for 24 h. Green and red arrows indicate small mitochondria that 
are comparatively more green and red, respectively, than the majority of the 
mitochondrial population. Scale bar = 10 µm.  (C) Graph shows that smaller 
mitochondrial units display greater heterogeneity of MitoTimer ratio in Mfn1/2 KO 
MEFs (white diamonds) compared to wild-type MEFs (WT, black diamonds) expressing 
MitoTimer for 24 h.  (D) MitoTimer heterogeneity (standard deviation of red/green ratio 
for all mitochondria in the cell) is increased in Mfn1/2 KO MEFs compared to wild-type 
(WT) (*=p<0.05, n=3). 
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Part Two: Measurement of mitochondrial turnover and life cycle using MitoTimer 
 
INTRODUCTION 
Perturbations to mitochondrial turnover are thought to contribute to the onset and 
progression of various human diseases, especially age-related diseases such as 
neurodegenerative diseases, diabetes, cardiovascular disease, and cancer 48, 73, 85. 
Degradation of mitochondria involves several cellular processes including proteases and 
the ubiquitin-proteasome system which can degrade individual mitochondrial proteins 86, 
mitochondrial-derived vesicles that remove selected parts of mitochondria 87, and 
autophagy which removes the entire organelle 88-91. Additional processes such as 
biogenesis, protein import, and mitochondrial dynamics will also affect the levels of new 
and old protein in the network 92-97, whereby contributing to the rate of mitochondrial 
turnover for the cell and for an individual mitochondrion. Pathological changes to any of 
these cellular mechanisms can influence mitochondrial turnover and resulting 
mitochondrial function, ultimately affecting cell health and function. 
Measuring changes to mitochondrial turnover has become an important parameter to 
characterize pathologies related to mitochondria. However, methodologies in use today 
are mostly limited to indirect assessments of mitophagy and pulse-chase labeling 
experiments measuring protein turnover. Methodologies to examine changes in 
mitophagy often employ genetic and pharmacological means to induce mitophagy 54; 
consequently, it is unclear how measurements under these conditions relate to 
physiological rates of mitophagy. Importantly, assessing mitophagy alone does not 
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account for other mechanisms that contribute to mitochondrial turnover 48, 83, 85. Pulse-
chase studies using metabolic labeling can define rates of protein turnover but use of 
different metabolic labels can over- or under-estimate protein half-lives 74. In addition, 
these measurements of protein turnover lack resolution at the cellular and organelle 
levels. The goal of the MitoTimer approach is to supplement current methodologies for 
assessing mitochondrial turnover with new approaches that can investigate changes in 
turnover rates while providing subcellular resolution.  
The MitoTimer fluorescent protein has been described in recent studies as a new probe to 
measure different aspects of mitochondrial turnover and efficacy of quality control 98-100. 
MitoTimer consists of the Timer fluorescent protein fused to the mitochondrial targeting 
sequence of COX8A subunit which targets MitoTimer to the mitochondrial matrix 99. 
Once assembled, Timer initially fluoresces green and over time the emission shifts from 
green to red 75. Consequently, mitochondria expressing MitoTimer can emit a range of 
colors from green to yellow to red, resulting from the combined fluorescence of both new 
(green) and old (red) protein within the matrix space. The observed MitoTimer color will 
depend on duration of Timer expression, rates of the mitochondrial protein incorporation 
and degradation, and of course the imaging settings 98, 99. MitoTimer color readout can be 
used in different applications to reveal alterations to mitochondrial turnover.  
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DISCUSSION 
Expressing MitoTimer in cells 
Since MitoTimer fluorescence readout is dependent upon the time of expression, it is 
beneficial to have experimental control of MitoTimer synthesis independent of the 
normally unsynchronized expression after transfection or transduction. In this regard, 
MitoTimer can be induced via a doxycycline-inducible promoter to better synchronize 
expression in cells. When MitoTimer is under control of a DOX promoter it is suggested 
that DOX be replenished every 2 days to continually express MitoTimer. A DOX 
concentration of 1 µg/mL should be used to induce suitable MitoTimer expression while 
avoiding any undesired effects of DOX exposure at higher concentrations, such as 
activation of mitochondrial unfolded protein response 101. Ideally, tetracycline-free serum 
should be used to limit “leak” of MitoTimer production in the absence of DOX, though 
any “leak” of MitoTimer synthesis in INS1 and COS7 cells is minimal with regular 
serum (unpublished data). Table 2.2.I lists reagents necessary for controlling MitoTimer 
expression when under DOX promoter. Though not necessary, control of MitoTimer 
expression by addition of DOX is useful for some applications with MitoTimer. 
DOX-inducible MitoTimer synthesis is useful for coordinating MitoTimer expression 
and/or “pulsing” MitoTimer synthesis so that new (green) MitoTimer production is 
stopped after washing out DOX (Fig. 2.2.1A cartoon). For example, treatment with FCCP 
to depolarize mitochondria significantly decreases the level of new (green) MitoTimer 
only in the presence of DOX (Fig. 2.2.1B). Removing DOX for 24 hours before FCCP 
treatment depletes the levels of available new protein and therefore the FCCP effect on 
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new protein import is lost. In this way, DOX-induction of MitoTimer can be used to 
control for effects on new (green) MitoTimer levels. In another example, inhibition of 
autophagy leads to an increase in red MitoTimer fluorescence (Fig. 2.2.1C). To support 
the finding that the increase in red is indeed an accumulation of old protein, the same 
treatments were applied in cells where DOX was removed for 24 hours. Since this 
resulted in the same increase in red MitoTimer fluorescence (Fig. 2.2.1C), it strongly 
suggests an accumulation of older protein due to inhibited degradation, rather than an 
increase in transcription, altered MitoTimer kinetics, etc. In addition, time-restricted 
induction of MitoTimer can be used to assess acute changes in biogenesis, using a second 
pulse of DOX in conjunction with a test stimulus.  Hernandez et al. showed that under 
these conditions, relatively little new MitoTimer protein was expressed and imported into 
mitochondria in un-stimulated cells; however, in response to a biogenic challenge such as 
statin administration, they observed a brisk increase in import of newly-synthesized 
MitoTimer 99.  Thus, controlling MitoTimer expression with the DOX-inducible promoter 
can be valuable for certain applications. 
The observed levels of MitoTimer green and red fluorescence will depend on the length 
of MitoTimer expression in cultured cells or tissue. Interestingly, we found that 
MitoTimer lifetime in COS cells is significantly longer than 2-3 days, as evidenced by 
the residual expression of red MitoTimer for >5 days after DOX has been washed from 
the medium (author’s observations; see also Hernandez et al. 2013, Figure 4). This 
indicates that although red MitoTimer is visible after 2-3 days of expression, this red 
fluorescence may not represent relatively “aged” MitoTimer protein. Thus the green-to-
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red conversion occurs early in the hypothetical lifetime of MitoTimer (Fig. 2.2.2A). As 
such, only in a stably-expressing cell (>5 days) is there a steady-state mixture of both 
young (green) and truly old (red) MitoTimer protein. MitoTimer can be transfected into 
cells as plasmid DNA or infected into cells via lenti- or adeno-virus. It is recommended 
that MitoTimer expression is monitored daily for up to a week in the cells of interest in 
order to determine if the overall levels of green and red per cell are stable, thereby 
verifying “steady-state” expression. Transient transfection of cells is generally limited to 
3-4 days of plasmid expression 102 and may not be suitable for achieving steady-state 
expression of MitoTimer. Thus it is recommended that MitoTimer expression be assessed 
at steady-state expression, ideally in cells stably-expressing MitoTimer. 
A remarkable pattern of steady-state MitoTimer expression was obtained in Mfn1/2 
double-knockout MEFs. While a subtle heterogeneity of MitoTimer age profile 
(red/green ratio) within these cells was noted 24-48hr after transient transfection (Fig. 
2.2.2B), this heterogeneity was quite dramatic after steady-state expression of MitoTimer 
was achieved (via lentivirus infection and continuous DOX exposure for >5 days). 
Ratiometric high-resolution image analysis of MitoTimer in these Mfn1/2-null cells 
revealed a distinctive subpopulation of mitochondria highly enriched for red MitoTimer 
(Fig. 2.2.2C). This striking heterogeneity is likely attributed to impaired fusion, 
preventing mixing of old and new MitoTimer protein in the mitochondrial population, 
combined with diminished ability to import new protein in the “old” mitochondria. This 
inhomogeneous distribution of new and old MitoTimer can only be observed in a stably-
transfected cell line in which MitoTimer mRNA is continuously expressed (e.g., under 
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continuous DOX induction).  Analysis of MitoTimer under these steady-state conditions 
can provide useful insights into mitochondrial dynamics and turnover.  As observed by 
Laker et al., the ratio of MitoTimer shifts towards red under conditions of impaired 
autophagy/mitophagy (high-fat diet) 103 and towards green under conditions of increased 
biogenesis (exercise) 104, although the authors attributed this to differences in oxidative 
stress 100. 
Lastly, one must confirm over-expression of MitoTimer does not alter normal cellular 
and mitochondrial function, since high over-expression of fluorescent proteins in 
mitochondria can have undesired effects on mitochondria and cells. Measuring cell 
proliferation, cell function (i.e. insulin secretion for pancreatic beta-cell lines), cell fate 
markers, and checking mitochondrial morphology and oxygen consumption can help 
confirm that MitoTimer expression does not have unwanted side effects in the cells of 
interest. If the cellular or mitochondrial phenotype is changed by MitoTimer expression, 
cells can be sorted based on low-to-high MitoTimer fluorescence in order to find a 
sutiable level of expression that does not affect cells. Taken together, these considerations 
for expressing MitoTimer in cells and tissues will increase the accuracy and 
reproducibility of experiments. 
 
Imaging MitoTimer  
Imaging of MitoTimer in cells can be conducted with via microscopy or flow cytometry. 
Excitation with 488nm laser is sufficient to excite the green and red forms of Timer due 
to the broad absorption spectrum. The red chromophores can also be excited with 543nm 
  
61 
laser 75, 105. Emission capture for the green (new) MitoTimer is collected in the 497–
531nm range while red (old) fluorescence emission is collected in the 583–695 nm range. 
During image acquisition one must also check for any bleaching effect of the MitoTimer 
98. If not accounted for, this bleaching effect could skew analysis of the red/green ratio. In 
addition to photobleaching, repetitive illumination can result in conversion of the green 
chromophore to the more stable red conformation. This must be accounted for in live cell 
imaging: the interposition of neutral density filters, short exposure times, and less 
frequent image acquisitions will help avoid photoconversion. Fixation (4% 
paraformaldehyde) also prevents photoconversion of MitoTimer. 
Certain considerations should be taken when imaging if the MitoTimer readout is to be 
analyzed on the cellular or subcellular level. For assessing MitoTimer fluorescence on the 
cellular level, lower magnification images can be taken and analyzed for the average 
green and red fluorescence signal per cell. If subcellular MitoTimer fluorescence is to be 
quantified then higher-resolution images, ideally with at least a 63x objective, need to be 
taken to accurately distinguish individual mitochondria. It is helpful to post-filter any 
analyzed images for mitochondrial regions that are too small or too large to be individual 
mitochondria (cutoff sizes determined initially by eye) in order to acquire accurate 
MitoTimer data for individual mitochondria units. The MitoTimer red/green ratio can 
then be calculated for individual mitochondria and a ratiometric image produced to show 
variation in MitoTimer red/green ratio among the mitochondrial network in the cell. 
MitoTimer red/green ratio of individual units can then be compared to other 
mitochondrial phenotypes, such as morphology or expression of another marker. Careful 
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experimental setup will allow for accurate analysis and interpretation of images when 
conducting cellular and subcellular imaging of MitoTimer-expressing cells. 
When assaying MitoTimer fluorescence for a single time-point, laser power and 
acquisition settings can be established while imaging the control cells first in order to 
yield an overall “yellow” appearance of MitoTimer signal in most cells (where both 
green and red signal are below saturation). This will allow for detection of either a shift 
towards younger (more green) or older (more red) MitoTimer under the experimental 
condition(s). Imaging settings should be consistent between the imaging of different 
conditions for a single experiment, and between different time points for time-course 
studies. Flow cytometry can also be utilized to assay MitoTimer readout on the cellular 
level, or even in isolated mitochondria 99. Use of flow cytometry allows for higher-
throughput analysis of changes to MitoTimer green and red average intensities per cell, or 
a shift in a population of cells. Settings again should be established in the “control” cells 
that will allow for detecting a change towards either more green or more red MitoTimer 
in the experimental cells. In this way, MitoTimer readout will allow detecting changes to 
mitochondrial turnover relative to the control condition.  
 
Interpreting MitoTimer readout 
Factors that do not affect MitoTimer readout  
MitoTimer fluorescent readout is potentially affected by several factors; thus it is 
imperative to determine what can and cannot influence MitoTimer fluorescence. Previous 
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studies were able to experimentally exclude several confounding factors that could 
potentially affect MitoTimer fluorescent readout. First, MitoTimer red/green ratio was 
independent of overall expression of MitoTimer. Additionally, the red and green 
fluorescence intensities of MitoTimer are unaffected by acute changes in mitochondrial 
pH induced by FCCP, oligomycin, and high glucose treatment 78-80, 98. Increased reactive 
oxygen species (ROS) formation also does not affect MitoTimer green and red 
fluorescence levels. Fig. 2.2.3 shows images of INS1 cells stably-expressing MitoTimer 
and exposed to 10 or 100µM H2O2 or 10µM menadione. Levels of MitoTimer green and 
red fluorescence remain identical to control-treated cells even after 2 hours of increased 
ROS. Thus, the MitoTimer should not be confused for an indicator of ROS levels. 
However one cannot rule out that longer-term alteration in mitochondrial pH, O2, or ROS 
levels may affect MitoTimer green-red transition. However studying long-term effects of 
altered mitochondrial pH, O2, or ROS may be difficult given that any treatments to 
change pH, O2, or ROS will also influence mitochondrial biogenesis, dynamics, and 
turnover and thus affect the MitoTimer readout. Following these findings, it can be 
reasonably assumed that MitoTimer green-red transition is constant; consequently, 
changes to mitochondrial turnover are most likely to affect MitoTimer readout. 
Factors that can affect MitoTimer readout  
The kinetics of the green-to-red fluorescence transition for Timer protein has been found 
to be consistent across a variety of cells, culture conditions, subcellular locations, and 
organisms, having been used in viruses, plants, flies, mammalian cell lines, and even 
mouse muscle after electroporation 75, 98-100, 106-112. The transition is delayed under 
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conditions of low oxygen tension and accelerated by photoirradiation 75, 99; however, 
besides these two variables the green-to-red transition will generally be constant. From 
this assumption, it can be proposed that levels of green MitoTimer will be determined 
principally by the incorporation of new (green) protein into mitochondria, which in turn 
can result from changes to MitoTimer synthesis, mitochondrial biogenesis or protein 
import. The levels of red (old) MitoTimer will be mainly affected by degradative 
pathways such as autophagy, mitochondrial proteases, or the ubiquitin-proteasome 
system. Although further work is needed, evidence to date suggests that 
autophagy/mitophagy has the largest impact on turnover of MitoTimer. In addition, the 
rate of green MitoTimer incorporation into mitochondria will influence the level of red 
since red is produced from green. On the subcellular level, the levels of green and red in 
an individual mitochondrion can be affected by sharing of new and old protein via 
mitochondrial dynamics and motility. With this framework in mind, it is possible to 
assess changes in MitoTimer fluorescence to derive valuable insights into specific aspects 
of mitochondrial turnover. These insights in turn can direct further investigations. 
As stated previously, the observed green and red emissions of MitoTimer are dependent 
on a number of factors, including mitochondrial biogenesis, protein import, inter-
organelle mixing, and mitochondrial degradation. These same factors also determine the 
lifetime of mitochondria and individual mitochondrial proteins. Thus, the MitoTimer 
readout can serve as a surrogate marker for mitochondrial turnover with the reservation 
that the half-lives of some mitochondrial proteins will be similar to the MitoTimer, while 
others differ considerably, as was recently reported 83. When evaluating experimental 
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conditions for changes in mitochondrial turnover, any observed changes to MitoTimer 
green or red fluorescence is only relative to the control condition. No specific rates of 
turnover can be determined as in pulse-chase assays 74, 83. Though observed changes to 
MitoTimer readout from a specific genetic modification or drug treatment can suggest 
that a particular turnover mechanism is involved, the results do not directly prove a 
specific alteration of mitochondrial biogenesis, import, degradation, dynamics, or 
motility. Since all of these processes can affect mitochondrial lifetime and resulting 
MitoTimer readout (Fig. 2.1.6), experimental conditions found to alter MitoTimer age 
profile have to be further studied to determine which aspect of mitochondrial biology is 
actually affected. Lastly, observing accumulation of aged (red) MitoTimer in different 
cellular systems or under certain experimental conditions does not signify mitochondrial 
dysfunction or damage. Appropriate follow-up experiments need to be performed to 
measure mitochondrial functional parameters. Correctly interpreting MitoTimer readout, 
both on a cellular and subcellular level, can reveal perturbations to mitochondrial lifetime 
and turnover in different cellular systems. 
Analyzing MitoTimer readout on the cellular level  
Most simply, analyzing MitoTimer green and red fluorescence per cell can be used to 
assess changes to overall rates of mitochondrial lifetime/turnover on the cellular level. 
The average green fluorescence and average red fluorescence can be determined per cell 
and an average green and red fluorescence can be assessed per condition: control, treated, 
etc. When green and red fluorescence levels are analyzed individually, it is possible to 
conclude (with assumptions) that a change to green MitoTimer levels indicates an 
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alteration to new protein incorporation (synthesis, biogenesis or import). A change to red 
MitoTimer levels may reflect changes to mitochondrial degradation if the level of green 
is unaffected between experimental groups. If both green and red MitoTimer fluorescence 
show significant changes than interpreting any specific effect on mitochondrial turnover 
is difficult (Table 2.2.II). As an example, inhibiting protein import via depolarization 
decreases new (green) MitoTimer per cell compared to control (Fig. 2.2.1B). In addition, 
inhibiting autophagy promoted the accumulation of both new (green) and old (red) 
MitoTimer per cell, with a greater accumulation of old protein (Fig. 2.2.1C). Since 
MitoTimer green and red fluorescence can vary between cells simply due to the level of 
MitoTimer expression, it is imperative to determine the average green and red intensity 
per cell values for a large, representative population of cells within a sample. Thus for 
such studies use of higher-throughput methodologies, such as high-throughput multi-well 
imaging systems or flow cytometry, is recommended if one is to determine average levels 
of green and red MitoTimer between different conditions. 
Alternatively, the average green and red MitoTimer fluorescence can be determined per 
cell, and the red/green (or green/red) ratio can be determined as the primary MitoTimer 
readout. The red/green ratio value thus gives the average MitoTimer “age” for a given 
condition. Experimental conditions can then be tested to see if they promote a decrease or 
increase in the ratio value, thus indicating a shift towards younger or older protein, 
respectively. The ratio value has the advantage of eliminating variation due to MitoTimer 
expression between cells. However, the ratio value cannot distinguish between conditions 
that induced an accumulation of older (red) protein (increased red/green ratio value) or a 
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decrease in the levels of younger (green) protein (still an increased red/green ratio value). 
Thus the red/green ratio value can only indicate a general change in the MitoTimer “age 
profile”, but not specifically changes in younger or older protein (Table 2.2.II). 
In summary, the MitoTimer readout on a cellular level, whether expressed as average red 
and green fluorescence values or the red/green ratio per cell, can differentiate 
mitochondrial lifetimes between experimental and control conditions. 
Analyzing MitoTimer readout on the subcellular level  
On the subcellular level, MitoTimer green and red fluorescence of mitochondria can 
reveal not only differences in mitochondrial turnover among mitochondria within the cell, 
but specific mitochondrial populations containing younger or older protein can be 
associated with other phenomena, including cellular localization, mitochondrial 
morphology, etc. MitoTimer green and red fluorescence intensity can be determined for 
individual mitochondria as in the whole cell; however, since the level of overall 
MitoTimer expression will vary among individual mitochondria, it is difficult to interpret 
changes to MitoTimer green or red intensity relative to other mitochondria. Calculating 
the red/green ratio of individual mitochondria can provide quantification of those 
mitochondrial subpopulations that are more or less “aged”, correlating with how they 
appear in the image as more red or more green, respectively.  
An important MitoTimer readout is the heterogeneity of the mitochondrial red/green ratio 
within the cell. This heterogeneity in red/green ratio value depicts how equilibrated 
mitochondria are in terms of sharing new and old protein. Expressing MitoTimer in most 
cells results in a homogeneous yellow color (depending on imaging settings) of most 
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mitochondria in the cell irrespective of overall MitoTimer intensity, indicating 
equilibration of young and old protein (Fig. 2.2.2B). However in cells deficient in 
mitochondrial fusion, MitoTimer red/green ratio varies greatly, signifying the 
desynchronizing of protein sharing and isolation rather than networking of mitochondrial 
units (Fig. 2.2.2D). Simply quantified, Mfn1/2 KO MEFs display significantly greater 
heterogeneity in MitoTimer red/green ratio compared to wild-type MEFs (Fig. 2.2.2C, E). 
These results demonstrate the vital role of mitochondrial fusion in creating a coordinated 
mitochondrial network for sharing protein and determining mitochondrial lifetimes 77. 
Overall, changes to MitoTimer red/green ratio heterogeneity on the individual 
mitochondrial level can provide insight into the state of mitochondrial dynamics and 
turnover in the cell. 
Additionally, subpopulations of mitochondria with disparate red/green ratios can be 
correlated with other important phenomena. The red/green ratio of individual 
mitochondria can be correlated with their respective size (98, Figure 3D), indicating that 
smaller, more fragmented mitochondria may contain older protein. In hippocampal 
neurons, mitochondria in the distal neurites of a given neuron tended to contain older 
MitoTimer compared to the soma (98, Figure 4A-C). In this respect MitoTimer red/green 
ratio can be correlated with distance from the soma for individual mitochondria, 
providing information about the dynamics of protein sharing between the two populations 
of mitochondria in the neuron. Importantly, promoting mitochondrial movement via 
Miro1 over-expression 58, 82 shifted the age profiles towards greater distribution of 
younger (green) MitoTimer in the neurites (98, Figure 4D). In summary, analyzing 
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MitoTimer readout on a subcellular level can provide a deeper level of insight into the 
regulation of mitochondrial protein age within the cell. 
 
Summary 
The MitoTimer probe represents a unique tool to assess and understand mitochondrial 
turnover dynamics on the cellular and subcellular level. MitoTimer offers unique 
applicability for mitochondrial turnover studies as all mechanisms regulating 
mitochondrial turnover will influence MitoTimer readout. Notably, one can assess 
changes to mitochondrial turnover on the cellular and subcellular level using MitoTimer 
probe. Upon carefully considering the experimental conditions as well as interpretation of 
data, novel insights into mitochondrial turnover can be revealed from MitoTimer 
assessment. Consequently, MitoTimer may be valuable as a fluorescent tool to explore 
conditions where mitochondrial turnover is altered. 
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TABLES 
Table 2.2.I. Reagents for controlling MitoTimer expression via doxycycline 
promoter. 
Reagents are listed that are needed for DOX-inducible expression of MitoTimer. 
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Reagent Experimental purpose Manufacturer 
pTRE-Tight-
MitoTimer 
Expresses MitoTimer protein under 
control of DOX-inducible promoter. 
Addgene 
Plasmid# 50547 
Tetracycline 
repressor protein 
plasmid 
(pcDNA6/TR vector) 
Must be co-expressed with 
MitoTimer to allow for DOX-
inducible expression (Expression 
occurs with DOX addition). 
 
Invitrogen  
Cat# V1025-20 
Doxycycline (DOX) Induces expression of MitoTimer 
when present (1µg/mL) in media. 
Sigma-Aldrich 
Cat# D9891 
Tetracycline-free 
fetal bovine serum 
Limits “leak” of MitoTimer 
expression when DOX is not present. 
Clontech 
Cat# 631106 
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Table 2.2.II. Interpreting MitoTimer readout. 
Table shows possible interpretations for the observed change to the indicated MitoTimer 
readout (red/green ratio, green level, or red level). Italics indicate less likely but possible 
changes affecting MitoTimer readout. 
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 MitoTimer readout 
Red/green ratio Red level Green level 
What does a 
decrease mean? 
 
Shift towards 
overall younger 
MitoTimer protein. 
Can be due to 
increased old (red) 
protein 
degradation, 
increased new 
(green) protein 
incorporation, or 
both. 
 
Increased 
degradation of old 
protein. 
If concomitant 
decrease in green 
levels then this 
may indicate 
decreased overall 
MitoTimer levels 
without change in 
old protein 
degradation. 
Decreased 
incorporation of 
new protein due to 
changes in 
synthesis, 
biogenesis, or 
import. 
Increased 
degradation of 
new protein. 
What does an 
increase mean? 
 
Shift towards more 
aged MitoTimer 
protein. Can be 
due to decreased 
degradation of old 
(red) protein, 
decreased 
incorporation of 
new protein, or 
both. 
Decreased 
degradation of old 
protein.  
If concomitant 
increase in green 
levels then this 
may indicate 
increased overall 
MitoTimer levels 
without change in 
old protein 
degradation. 
Increased 
incorporation of 
new protein due to 
changes in 
synthesis, 
biogenesis, or 
import. 
Decreased 
degradation of 
new protein. 
What does no 
change mean? 
 
No observed 
change indicates 
no change in 
relative turnover 
rates. 
No observed 
change could 
occur when both 
green and red 
levels are changed 
similarly (both 
decreased or 
increased to 
similar extent.  
No observed 
change indicates 
no effect on old 
protein 
degradation. 
No change could 
occur if 
incorporation of 
new protein is 
increased with a 
balanced increase 
in old protein 
degradation. 
No observed 
change indicates 
no alteration of 
new protein 
incorporation (no 
changes to 
synthesis, 
biogenesis, or 
import). 
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FIGURES 
Figure 2.2.1.  Using doxycycline promoter to control MitoTimer synthesis. 
A) Production of new (green) MitoTimer can be arrested with “pulse-chase” expression 
of MitoTimer in cells. The “chase” period begins when DOX is washed from the 
medium. Because DOX controls synthesis of new MitoTimer mRNA, production of new 
MitoTimer protein will persist for several hours after removal of DOX. Accordingly, 
levels of green MitoTimer fluorescence will decrease after DOX removal and levels of 
red MitoTimer will persist for several days. B) FCCP treatment (10µM, 3 hours) 
decreases the level of green (green bar) MitoTimer in the presence of continuous DOX-
mediated MitoTimer synthesis (+DOX) but not when DOX is removed from the medium 
(NO DOX) 24 hours prior to FCCP treatment (*=p<0.05, n.s.=non-significant). C) 
Treatment with bafilomycin (Baf; 100 nM) or chloroquine (Chq; 30 µg/mL) to inhibit 
autophagy-mediated degradation results in significantly increased red MitoTimer 
fluorescence (red bar, red asterisk) in the presence (+DOX) or absence (NO DOX) of 
DOX, signifying accumulation of MitoTimer protein due to decreased degradation. 
(*=p<0.05, #=p<0.05, n=3) All data from 98 with permission. 
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Figure 2.2.2.  Observing MitoTimer readout at steady-state. 
A) Illustration of the theoretical lifetime of a single MitoTimer protein.  After synthesis 
of new (green) MitoTimer, the conversion to red happens relatively early followed by 
degradation after several days. B) Mfn1/2 KO MEFs transiently-transfected and 
expressing MitoTimer for 48 hours show moderate heterogeneity of MitoTimer red/green 
ratio within the mitochondrial network compared to wild-type (WT) MEFs. C) 
Quantification of subcellular MitoTimer red/green ratio heterogeneity in Mfn1/2 KO and 
wild-type MEFs expressing MitoTimer for 48 hours (*=p<0.05 compared to WT MEFs). 
D) Expression of MitoTimer for >5 days in the same cells reveals even greater 
heterogeneity of MitoTimer red/green ratio in Mfn1/2 KO MEFs compared to wild-type 
(WT) cells. E) Quantification of subcellular MitoTimer red/green ratio heterogeneity in 
Mfn1/2 KO and wild-type MEFs expressing MitoTimer for >5 days. (*=p<0.01 
compared to WT MEFs). Scale bars = 10 μm. All data from 98 with permission. 
  
  
77 
 
 
  
  
78 
Figure 2.2.3.  Increase in ROS does not affect MitoTimer red and green 
fluorescence. 
Treatment with 10 or 100µM H2O2 or 10µM menadione for 30 or 120 minutes does not 
change levels of MitoTimer green and red fluorescence compared to control-treated cells. 
Scale bar = 20µm. 
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CHAPTER THREE: O-GlcNAc regulation of Milton1 activity coordinates 
mitochondrial dynamics and function to nutrient status in the pancreatic beta-cell 
  
INTRODUCTION  
Mitochondria are highly dynamic organelles that continuously change their shape from 
interconnected to fragmented units in response to various stimuli, including nutrient 
availability. Changes in mitochondrial shape and motility are tightly linked to change in 
mitochondrial function, and coordinating such changes to nutrient availability requires 
adaptive responses of mitochondrial fusion, fission, and motility. The molecular 
mechanism or “nutrient-sensor” linking changes to mitochondrial dynamics and nutrient 
availability in the beta-cell has not been fully detailed. Such a theoretical nutrient-sensor 
would need to be part of the mitochondrial fusion, fission, and/or motility machinery and 
its activity would need to be responsive to nutrient levels in a sensitive and robust way, 
suggesting some sort of nutrient-sensitive post-translational modification. One such post-
translational modification is O-GlcNAc modification of proteins, which is a by-product 
of nutrient availability and has been shown to control protein localization and activity, 
including mitochondrial proteins. OGT, the enzyme responsible for O-GlcNAcylation of 
target proteins, is highly expressed in pancreatic beta-cells 113. Interestingly, OGT is 
found in complex with Milton1 on the mitochondrial outer membrane 114.  
Milton1 (also referred to as OIP 106/98 and Trak1) is an integral component of the 
mitochondrial motor adaptor complex with Miro1 that couples kinesin and 
dynein/dynactin to mitochondria, ultimately determining mitochondrial attachment and 
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movement along microtubules 60, 115, 116. Recently it was shown that O-GlcNAcylation of 
Milton1 controls mitochondrial trafficking in axons according to glucose levels 61. In 
addition, Milton1 has been shown to promote mitochondrial fusion in less spatially-
confined cells than neurons 117; thus regulation of mitochondrial motility by Milton1 may 
also influence changes to both mitochondrial motility and dynamics. Lastly, SNPs 
associated with Milton1 are strongly implicated in the pathogenesis of hypertonia 118 and 
childhood absence epilepsy 119, and associated with type II diabetes 120. 
Previous studies have shown disruption to mitochondrial architecture in beta-cells from 
mice fed a high fat diet 37 as well as in beta-cells of human islets exposed to alternating 
normal (5mM) and high glucose (16.7mM) 121. Furthermore, evidence for altered 
mitochondrial morphology in islets of diabetic patients 122 and animal models, including 
in ZDF rats 123, 124, GK rats 125, 126, and diabetic MKR mice 127, have been reported. We 
have previously described that prolonged (>18 hours) exposure to high glucose and fatty 
acids, (GLT), synergistically induce mitochondrial fragmentation in INS1 cells. 
Importantly, it was shown that the GLT-induced mitochondrial fragmentation resulted 
from decreased fusion capacity of mitochondria in beta-cells 3. These different results 
strongly associate mitochondrial fragmentation as a key pathological event in beta-cells 
exposed to chronic nutrient excess, such as GLT or obesity. However it remains unclear 
if GLT causes mitochondrial fragmentation in human islets and whether this 
fragmentation plays a compensatory or pathological role during GLT-induced beta-cell 
dysfunction. 
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Conversely, mitochondrial fragmentation via induction of fission has been implicated in 
physiological response of mitochondria to acute glucose stimulation in the beta-cell 128. 
Related to this finding, multiple studies have demonstrated that genetic inhibition of 
fission inhibits GSIS 4, 128. This result is either interpreted that acute fission is necessary 
during GSIS 128, or that chronic inhibition of fission compromises mitochondrial quality 
control leading to reduced capacity for GSIS 4. These two interpretations are at odds with 
one another and currently remain unresolved.  
Importantly, mitochondrial motility has been shown to be an important regulator for key 
mitochondrial functions such as the distribution of mitochondria within cells, 
mitochondrial turnover and cellular bioenergetics 97, 115. Critically, mitochondrial motility 
has also been shown to be the strongest predictor of mitochondrial fusion 57, 129 and it is 
proposed that mitochondrial motility is coordinated with fission events 130. These 
different studies connect mitochondrial dynamics and motility as a vital axis adapting 
mitochondrial function to cellular conditions, yet it is not fully understood how motility 
dictates fusion/fission, and vice versa. Furthermore it has not been investigated whether 
alterations to mitochondrial motility play a role in mitochondrial and beta-cell response to 
nutrient excess. Thus we assessed how O-GlcNAcylation of Milton1 affects 
mitochondrial trafficking, dynamics, and function in pancreatic beta-cells, in the context 
of both chronic nutrient excess and acute nutrient stimulation.  
 
METHODS 
Human islet culture 
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Human islets were isolated from donor pancreata at the Alberta Diabetes Institute 
IsletCore (http://www.bcell.org/IsletCore.html) or the Clinical Islet Laboratory at the 
University of Alberta as previously described 131. Relevant patient data included age at 
time of death and body mass index. Islets were used for experiments as long as body 
mass index was in a healthy range (<30). Upon receiving human islets, the cells were 
cultured for at least  3 days in CMRL media (Invitrogen, Cat# 11530-037) consisting of 
10 mM niacinamide (Sigma Cat# N5535), 0.1% insulin-transferrin-sodium selenite 
supplement (Sigma, Cat# I1884), 16.7 µM zinc sulfate (Sigma, Cat# Z0251), 5mM 
sodium pyruvate (Invitrogen, Cat# 11360-070), 1% GlutaMAX (Invitrogen, Cat# 35050-
061), 25 mM HEPES, 10% FBS (Invitrogen, Cat# 16140-071), 50 units/ml penicillin, and 
50 g/ml streptomycin.  
Islet dispersion and re-aggregation to form “pseudo” islets 
Human or mouse islets were incubated with accutase (Invitrogen) for 10 min at 37 °C in 
order to disperse the islets into individual cells. To form each pseudo-islet, 5000 cells 
were plated in one well of a 96-well V-bottom plate. The plate was then centrifuged at 
1000 RPM for 3 min to pellet the cells and promote pseudo-islet formation. The pseudo-
islets were incubated overnight before starting experimental treatments. 
Oleate-palmitate complexed to BSA 
Palmitate and oleate were first dissolved in 150mM NaCl solution. Then this solution was 
dissolved at 37 °C in 150mM NaCl solution containing 16.75% fatty acid-free BSA to 
make a 10 mM (10X) stock of OP:BSA. A 10X BSA-control stock was prepared 
simultaneously but palmitate and oleate were excluded. 
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For treatment of human islets, the 10X stocks were added to human islet media described 
previously but with 1% FBS. Glucose was added to raise from 5.5 mM (control media) to 
11.5 mM glucose. For control-treated islets, the 10X BSA stock (no fatty acid) was added 
to 1% FBS human islet media (5.5 mM glucose). The pH of the treatment medias was 
then adjusted to 7.4 followed by sterile filtration before treating the human pseudo-islets 
for 96 hours.  
For treatment of mouse islets, the 10X OP:BSA or BSA stocks were added to RPMI 1640 
media containing 1% FBS, 50 units/ml penicillin, and 50 g/ml streptomycin and glucose 
at 10 mM. For HG+OP:BSA media glucose was added to raise from 10 mM to 20 mM 
glucose. The pH of the treatment medias was then adjusted to 7.4 followed by sterile 
filtration before treating the mouse pseudo-islets for 48 hours. 
Palmitate complexed to BSA 
Palmitate was dissolved in DMSO and then this solution was dissolved at 45 °C in RPMI 
1640 media containing 6.7% fatty acid-free BSA (Calbiochem) to make a 4 mM (10X) 
stock. For control BSA conditions a 10X stock of RPMI 1640 media containing 5% BSA 
and 1% DMSO was used. For the treatment conditions, the 10X stocks were added to 
RPMI 1640 media containing 1% FBS, 50 units/ml penicillin, and 50 g/ml streptomycin 
and glucose at 10 mM. For HG+Palm:BSA media glucose was added to raise from 10 
mM to 20 mM glucose. The pH of the treatment medias was then adjusted to 7.4 
followed by sterile filtration before treating the INS1 cells for 20 hours. 
Cell culture 
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INS1 832/13 cells were cultured in RPMI 1640 media (Invitrogen, Cat# 31800-089) 
supplemented with 10% fetal bovine serum (Invitrogen, Cat#16000-044), 10 mM HEPES 
buffer (Cellgro, Cat#25-060-Cl), 1 mM pyruvate (Cellgro, Cat#25-000-Cl), 50 µM β-
mercaptoethanol (Invitrogen, Cat#21985), 1% penicillin and streptomycin. Cells were 
used between passage 60 and 75. The MEF and COS cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) (Invitrogen, Cat#10569-069) supplemented with 10% 
heat-inactivated fetal bovine serum (Invitrogen, Cat#10437-028) and 1% penicillin and 
streptomycin (Invitrogen, Cat# 15140-122).  Cells were plated on MatTek glass bottom 
dishes (MatTek, Cat#P35G-1.5-14-C) for confocal imaging. 
Animals 
Islet isolation was performed on 12- to 13-week-old C57Bl6 male mice. They were 
housed in accordance with the Boston University Institutional Guidelines for Animal 
Care (IACUC no. 14855) in compliance with United States Public Health Service 
Regulation. Animals were fed standard chow and kept at normal housing conditions (19-
22 °C and a 14:10-h light-dark cycle) until death by CO2 asphyxiation and cervical 
dislocation. 
Islet isolation and culture 
Mouse islets of Langerhans were isolated as described previously 132. Shortly, the 
pancreata were inflated with RPMI media containing collagenase (Roche Applied 
Science). After 10 min of digestion at 37 °C, the islets were isolated using Histopaque-
1077 (Sigma) gradient. Isolated islets were cultured in RPMI 1640 media supplemented 
with 10% FBS, 50 units/ml penicillin, and 50 g/ml streptomycin.  
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Insulin secretion for human and mouse pseudo-islets 
Prior to glucose-induced insulin secretion, islets were pre-incubated for 30 min in 
DMEM (XF Assay medium from Seahorse Biosciences, Billerica, M.A.) containing 
2mM glucose, 0.05% BSA, pH 7.4. This was followed by incubation in media containing 
either 2.8 mM or 16.7 mM glucose for 30 minutes for mouse islets or 60 minutes for 
human islets. Media was collected and stored at –20°C for insulin measurement. Insulin 
was measured by HTRF insulin assay (Cisbio bioassays). 
Insulin secretion for INS1 cells 
Prior to glucose-induced insulin secretion, cells were cultured for two hrs in RPMI 
containing 2 mM glucose without serum. Cells were then washed and pre-incubated for 
30 min in DMEM (XF Assay medium from Seahorse Biosciences, Billerica, M.A.) 
containing 2mM glucose, 0.05% BSA, pH 7.4. This was followed by 60 min incubation 
in media containing either 2 mM or 12 mM glucose. Media was collected and stored at –
20°C for insulin measurement. Insulin was measured by HTRF insulin assay (Cisbio 
bioassays). For Western blot experiments where protein lysates were collected after the 
glucose-stimulated insulin secretion protocol, cells were subject to standard insulin 
secretion protocol with 15 minutes of 16.7 mM glucose stimulation before protein was 
isolated. 
Fluorescent Probes 
Cells were incubated 200 nM MitoTracker Green (MTG, a membrane potential-
independent dye) and 8nM tetramethylrhodamine-ethyl-ester-perchlorate (TMRE, a 
membrane potential-dependent dye) for 60 minutes, then washed 3 times with media 
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containing 8nM TMRE and incubated with media containing 8nM TMRE for 15 minutes 
prior to imaging.  The double staining approach facilitates proper identification of 
fluorescence intensity from mitochondria at different z planes. TMRE was kept in the 
medium while imaging.  All dyes were obtained from Molecular Probes (Eugene, OR).   
Confocal Microscopy 
Cells were imaged live under confocal microscopy to image mitochondria using a Zeiss 
LSM 710 Meta microscope (Carl Zeiss, Oberkochen, Germany) with a 63x oil immersion 
objective.  Cells were kept at 37°C in a 5% CO2 humidified microscope stage chamber.  
MTG was subjected to 488 nm argon laser excitation and emission was recorded through 
a band pass 500 to 550 nm filter.  TMRE was subjected to 543nm helium/neon laser 
excitation and emission was recorded through a band-pass 650 to 710 nm filter.  To 
observe individual mitochondria Z-stack images were acquired in series of 6 slices per 
cell ranging in thickness from 0.5 – 0.8μm per slice. For time-series imaging of 
mitochondrial motility, INS1 cells were imaged every 20 seconds ten times 
consecutively. 
Mitochondrial Morphology Analysis 
Quantitative analysis of mitochondrial morphology was conducted using computer-
assisted morphometric analysis application for calculation of Form Factor (FF) and 
Aspect Ratio (AR) values. Acquired images of mitochondria were analyzed using NIH-
developed Image J software (Wayne Rasband, NIH) by first processing with a median 
filter to obtain isolated and equalized fluorescent pixels.  Mitochondria were subjected to 
particle analysis for acquiring FF values (4π*Area/perimeter2). FF value of 1 corresponds 
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to a circular, un-branched mitochondrion, and higher FF values indicate a longer, more-
branched mitochondrion.   
Mitochondrial Membrane Potential Heterogeneity Analysis  
To characterize mitochondrial membrane potential heterogeneity, a ratiometric imaging 
approach was used by dual staining with the membrane potential-dependent dye TMRE 
and the membrane potential-independent dye MTG.  TMRE is highly permeable across 
the mitochondrial membrane so equilibration is rapid, and at low concentrations TMRE 
does not inhibit mitochondrial respiration.  The ratio product of TMRE dye to MTG dye 
maintains the voltage dependency of TMRE and is independent of the exact focal plane.  
Thus, even though the fluorescence intensity of TMRE and MTG is variable, the ratio of 
fluorescence intensity of TMRE to MTG dye is essentially independent of focal plane. 
Images were analyzed for membrane potential of individual mitochondrion using 
deviation of fluorescence intensity values for the ratio of red (TMRE) to green (MTG) 
dye for several mitochondria within each cell. By applying modified versions of the 
Nernst equation the relative membrane potential of a single mitochondrion within a cell 
was calculated. Within each cell the standard deviation of all mitochondrial membrane 
potentials was calculated to derive the overall membrane potential heterogeneity. 
Mitochondrial motility analysis 
Time-lapse images of mitochondria Images of labeled mitochondria were taken 20 
seconds apart. Mitochondria in image of time-point 1 were thresholded and a binary 
image was created and pseudocolored green. Mitochondria in image of time-point 2 were 
similarily thresholded, binarized, and pseudocolored red. An overlay image of the two 
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time-points was generated 133. In the overlay image, yellow pixels depict mitochondria 
that did not move, while green and red pixels indicate mitochondria that have changed 
positions. A value for mitochondrial displacement between the two time-points was 
calculated as the amount of green+red/yellow pixels in the overlay image. Subsequent 
time-points were then thresholded, binarized, and pseudo-colored red, followed by 
generation of a new overlay image by merging each successive time-point with the 
original time-point 1. The mitochondrial displacement value was calculated for each 
time-point and plotted over time. The slope of the best-fit line of mitochondrial 
displacement over time was calculated and this slope value was used as the value for 
mitochondrial motility or average mitochondrial displacement over time. Larger values 
thus correspond to more movement (Supp. Figure 2A-B). 
Analysis of mitochondrial clustering 
The feature defining the Milton1-induced mitochondrial aggregation was observed as a 
large percentage of the mitochondrial population being localized far away from the 
nucleus. To quantify this phenotype, a value for distal aggregation of mitochondria for 
each cell was generated which was dependent on both the size of the mitochondrial areas 
and their distance from the nucleus. Mitochondria in images of INS1 cells were 
thresholded and mitochondrial areas defined. Of the defined mitochondrial areas, the 
three largest areas were identified as the mitochondrial aggregation phenotype could 
manifest in 1-3 aggregates in one cell. For each of the three largest areas, their area 
(defined as fraction of total mitochondrial area) was multiplied by its distance from the 
nucleus (distance from nucleus was normalized to a 10-point scale). These three values 
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were then added together to give the value for distal aggregation score for each cell 
(Supp. Figure 4A).  
hMilton1 constructs 
Constructs for wild-type hMilton1, quadruple mutant hMilton1, kinesin-binding domain 
mutant hMilton1, and OGT were described previously 61. 
TMRE depolarization analysis 
To determine connectivity of mitochondria in INS1 cells stained with TMRE, targeted 
laser depolarizations were made at a single discrete 15 x 15 pixel area of mitochondria. 
Areas were chosen so that multiple mitochondria would be contained within the 
depolarization area. Initial images were taken followed by the targeted depolarization, 
and then an after image was acquired. To analyze the percent depolarization of TMRE 
between the two images, a median filter (radius = 3 pixels) was applied to the images, 
then mitochondria in the images were thresholded and total mitochondrial area was 
quantified. The percent change in thresholded mitochondrial area was calculated between 
the before and after images. 
Transfection 
INS1 cells were transfected using Lipofectamine 2000 (Invitrogen, cat#11668) according 
to manufacturer’s instructions. 
Adenovirus for hMilton1 over-expression 
Adenovirus for hMilton1 constructs were generated by Welgen Inc. INS1 were 
transduced with MOI 10 for experiments, unless otherwise noted. Mouse islets were 
transduced with MOI 100 for experiments.  
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Immunoprecipitation 
INS1 cells were plated and transduced with the indicated hMilton1 adenoviruses the next 
day. After two days, cells were washed once with ice-cold phosphate-buffered saline 
(PBS) containing 1 mM PUGNAC and lysed in 600ml buffer containing: 1% Nonidet P-
40 (Calbiochem, San Diego, CA, USA), 15 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
EDTA, 40mM GlcNAc, 1 mMPUGNAC, (Sigma-Aldrich, Saint Louis, MO), 1 mM DTT 
(GBiosciences), 0.1 mg/ml PMSF and protease inhibitor cocktail (Calbiochem, San 
Diago, CA, USA) at 1:1000. Lysates were centrifuged 10 min at 13,000 x g at 4°C and 
the supernatants collected. Lysates were incubated with 1.2 mg anti-myc antibody  
incubated for 2 hr at 4°C with 500 ml of whole-cell lysates, then 1 more hour with 
protein-A-Sepharose beads. Beads were washed three times with lysis buffer and 
resuspended with 1xLaemmli buffer. Immunoprecipitates were then subject to Western 
blot.  
Cellular Oxygen Consumption 
Oxygen consumption rates of INS1 cells were measured by XF24 bioenergetic assay 
(Seahorse Bioscience, Billerica, MA, USA) as previously (REF). Briefly, cells were 
plated and grown on an XF24-well microplate (Seahorse Bioscience). Assays were 
initiated by removing growth medium, replacing with low-buffered RPMI 1640 medium 
containing 1mM phosphate (Molecular Devices, Sunnyvale, CA) and incubating at 37°C 
for 60 minutes to allow temperature and pH to reach equilibrium.  The microplate was 
then assayed in the XF24 Extracellular Flux Analyzer (Seahorse Bioscience) to measure 
extracellular flux changes of oxygen and pH in the media immediately surrounding 
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adherent cells.  After obtaining steady state oxygen consumption and extracellular 
acidification rates, glucose (12 mM), oligomycin (5µM), which inhibits ATP synthase, 
and  proton ionophore FCCP (carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone; 
2µM), which uncouples mitochondria, were injected sequentially through reagent 
delivery chambers for each cell well in the microplate to obtain values for maximal 
oxygen consumption rates.  Finally, a mixture containing 5 µM antimycin A (inhibitor of 
mitochondrial complex I) was injected in order to confirm that respiration changes were 
due mainly to mitochondrial respiration. 
The values of oxygen consumption reflect the metabolic activities of the cells and the 
number of cells, so oxygen consumption rates were normalized to the total amount of 
cells in each well. Immediately after completion of the Seahorse assay, cells were fixed in 
4% paraformaldehyde in PBS. Cells were then washed with PBS and stained with 1.5 µM 
DAPI and cell number per well was quantified using Celigo imaging cytometer. 
Flow cytometry for cell death 
Flow cytometry analysis of INS1 cells was done with 620 FACScan. FACS data analysis 
was performed using FACScalibur (Beckman Coulter). Cell debris was excluded by 
gating on the forward and side scatter plot. The cells were trypsinized, washed twice with 
PBS by centrifugation, and then subjected to flow cytometry. For cell death 
measurements, 1 µg/mL propidium iodide (Invitrogen) was added to the PBS solution of 
the resuspended cells before flow cytometry.  
Western blot 
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Samples were prepared as described previously 134. Breifly, cells were placed on ice and 
washed once with ice-cold PBS. Cells were then lysed in RIPA lysis buffer (Santa Cruz, 
Cat# sc-24948) with 1X protease inhibitor cocktail and 1mM PMSF. The samples were 
supplemented with 4x LDS sample buffer and boiled at 95 °C for 10 minutes. The 
samples were loaded in 4-12% polyacrylamide gel (Invitrogen) and transferred onto a 
polyvinylidene difluoride membrane (Invitrogen) using a wet (tank) transfer machine. 
VDAC (Abcam, Cat# ab16816), C-IV (Santa Cruz, Cat# sc-58348), C-I (Invitrogen, Cat# 
459210), C-V (Invitrogen, Cat# 459240), Phospho-DRP1 Ser637 (Cell Signaling, Cat# 
4867S), Phospho-DRP1 Ser616 (Cell Signaling, Cat# 3455S), DRP1 (BD Biosciences, 
Cat# 611739), GAPDH (Cell Signaling, Cat# 2118), O-GlcNAc (Abcam, Cat# ab2739), 
Myc (Cell Signaling, Cat# 2278), and Actin (Abcam, Cat# 179467) antibodies were used 
according to the manufacturer’s instructions. 
Immunofluorescence 
To assess mitochondrial co-localization with DRP1, immunofluorescence staining for 
DRP1 was performed on INS1 transfected with Mito-DsRED. Briefly, transfected cells 
were fixed with 4% paraformaldehyde for 15 minutes. After washing in PBS, cells were 
incubated with 3% BSA (Millipore, Cat#126575) in PBS with 0.2% Triton-X-100 
(Sigma, Cat#T8787) for 30 minutes. Cells were then incubated overnight at 4ºC with 
mouse anti-DRP1 antibody (BD Biosciences) diluted 1:100 in PBS containing 1% BSA. 
After PBS washes, cells were treated with anti-mouse Alexa Fluor 488 (Invitrogen) 
secondary antibody diluted 1:500 in PBS containing 1% BSA. Cells were washed with 
PBS and imaged shortly after to visualize colocalization of mitochondria with DRP1. 
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Statistics 
Unless stated otherwise, error bars indicate means S.E., and an unpaired t test was used to 
validate statistical differences between two conditions. To determine significance of 
multiple conditions, a one-way ANOVA with post hoc Tukey’s test was used. 
 
RESULTS 
Chronic high glucose and fatty acid exposure causes adaptive fragmentation of 
mitochondria in beta-cells with concurrent decrease in mitochondrial motility 
The reported GLT-induced change in mitochondrial morphology was shown to be a result 
of reduced fusion activity 3. It is known that mitochondrial movement directly influences 
mitochondrial fusion 57, 129; however the effect of GLT on mitochondrial motility has not 
been fully elucidated. In this study we sought to determine if GLT results in 
mitochondrial fragmentation in primary human and mouse beta-cells, and whether these 
alterations are concomitant with changes to mitochondrial motility. Exposure to high 
glucose and fatty acids inhibited GSIS (Fig. 3.S1A-B) and induced mitochondrial 
fragmentation in both human (Fig. 3.1A) and mouse islets (Fig. 3.S1C). Calculating 
average form factor values confirmed significant alteration of mitochondrial morphology 
towards more fragmented, round morphology (Fig. 3.1B-C). Concurrently mitochondrial 
membrane potential showed greater intracellular heterogeneity under GLT (Fig. 3.1D), 
suggesting less functional coordination within the mitochondrial network. Thus exposure 
to chronic GLT is sufficient to induce mitochondrial fragmentation in mouse and human 
islets. 
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Preventing GLT-induced fragmentation by expressing dominant-negative construct of 
mitochondrial fission protein, DRP1 (Drp1-D/N), further disrupts MMP and causes 
significant accumulation of depolarized mitochondria in human beta-cells (Fig. 3.S2A-
C). Moreover, GLT-induced inhibition of GSIS is further decreased in human islets 
expressing Drp1-D/N (Fig. 3.S2D). Thus, preventing mitochondrial fragmentation in 
response to GLT further perturbed mitochondrial membrane potential and GSIS, 
suggesting that fragmentation is a compensatory adaptation to GLT insult, which works 
to preserve mitochondrial and beta-cell function. 
To determine if altered mitochondrial morphology is concomitant with changes in 
mitochondrial motility, mitochondrial movement was quantified by time-lapse imaging of 
mitochondria followed by analysis of mitochondrial displacement over time (Methods, 
Fig. 3.S3A-B). Attempts to quantify mitochondrial motility in primary mouse or human 
beta-cells were prone to significant error because mitochondrial movement into and out 
of the focal plane contributed greatly to displacement quantification. The flatter INS1 
cells were much less prone to such artifact. GLT exposure of 20 hours (20mM glucose 
and 0.4mM palmitate:BSA) significantly fragmented mitochondria  (Fig. 3.1E-F), as 
reported previously 3. Furthermore, GLT significantly inhibited mitochondrial motility in 
INS1 cells, as quantified by mitochondrial displacement analysis (Fig. 3.1E and G). 
Nocodazole was used a positive control to arrest mitochondrial motility via inhibition of 
microtubule polymerization. The combination of high glucose and fatty acid had the 
strongest arrest of mitochondrial movement compared to fatty acid or high glucose alone 
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(Fig. 3.1G). These results indicate that GLT induces arrest of mitochondrial motility 
concomitant with decreased fusion and fragmentation of mitochondria. 
 
O-GlcNAc regulation of Milton1 determines mitochondrial motility and architecture in 
response to nutrients in pancreatic beta-cells 
Recently it was reported that activity of Milton1, a component of the mitochondrial motor 
adaptor complex, is regulated by glucose levels via O-GlcNAcylation 61; also Milton1 is 
associated with OGT at the mitochondrial outer membrane suggesting a strong nutrient-
dependent regulation of mitochondrial motility. Based on reported effects of O-
GlcNAcylation on Milton1 activity, we expect that higher GlcNAcylation of Milton1 
under GLT would reduce its activity, possibly leading to decreased mitochondrial 
movement and fusion under excess nutrient. We first sought to over-express wild-type 
Milton1 in INS1 cells.  Since the main function of Milton1 is tethering mitochondria to 
the microtubule cytoskeleton, we would expect that high Milton1 activity or expression 
would result in changes either to mitochondrial cellular distribution/architecture or 
mitochondrial motility. Indeed, Milton1 over-expression in INS1 cells induced a striking 
aggregation of mitochondria at the periphery of the cell, as compared to mitochondria 
distributed throughout the cytoplasm in control-transfected cells (Fig. 3.2A). Higher 
resolution imaging revealed distinct “ball-and-chain” mitochondrial morphologies in 
INS1 cells, and this phenotype was very predominate in mouse and human beta-cells 
(Fig. 3.2B). Interestingly, this gross change to mitochondrial architecture was 
concomitant with overall reduced mitochondrial movement in INS1 cells (Fig. 3.S3C).  
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This Milton1-induced elongated mitochondrial morphology and aggregation was 
previously reported in COS-7 cells, although the mitochondria in the Milton1 
overexpression cells aggregate in a peri-nuclear arrangement 117 (Fig. 3.S4A). We 
investigated levels of kinesin and dynein in INS1 and COS-7 cells to see if this balance 
may affect the positioning of Milton1-induced aggregation. INS1 cells showed a greater 
ratio of kinesin to dynein compared to COS-7 cells, which may influence the positioning 
of Milton1-induced mitochondrial aggregates in the different cell types (Fig. 3.S4B). 
Since the INS1 phenotype of mitochondrial aggregation at the periphery of the cell 
represents a clearly discernible morphological phenotype, we quantified this phenotype in 
order to determine if it is reversible upon alteration of Milton1 activity (Methods, Fig. 
3.S5A). The degree of mitochondrial aggregation was inversely related to mitochondrial 
movement (Fig. 3.S5B) and was dependent on Milton1 over-expression level as assessed 
by cellular fluorescence intensity of co-transfected EGFP (Fig. 3.S5C). We next 
investigated whether this Milton1-induced change in mitochondrial architecture is 
dependent upon increased mitochondrial movement along microtubules. Over-expression 
of Milton1 lacking the kinesin binding domain did not induce any noticeable aggregation 
of mitochondria (Fig. 3.2D-E). Therefore, the Milton1-induced mitochondrial 
aggregation is dependent upon increased kinesin-mediated mitochondrial movement 
along microtubules. 
Since it was shown that nutrient-dependent O-GlcNAcylation of Milton1 regulates its 
activity (Fig. 3.2C) 61, we sought to test if the Milton1-induced mitochondrial aggregation 
was modified by increasing cellular GlcNAc levels. Accordingly, treatments which 
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increase cellular O-GlcNAcylation, co-expression of OGT, PUGNAc treatment (inhibitor 
of O-GlcNAcase, the enzyme that removes O-GlcNAc), or high glucose exposure for 24 
hr (Fig. 3.2C), reversed the mitochondrial aggregation phenotype in INS1 over-
expressing Milton1 (Fig. 3.2D-E). In addition, exposure to palmitate also reversed the 
Milton1-induced phenotype (Fig. 3.S5D), consistent with the ability of fatty acids to 
promote flux through the hexosamine pathway 66, 135. To assess to directly the O-GlcNAc 
levels of Milton1, the myc-tagged Milton1 construct was over-expressed in INS1 cells, 
followed by immunoprecipitation of myc-Milton1 and O-GlcNAc levels were assessed 
by Western blot. Milton1 accumulates O-GlcNAc when exposed to PUGNAc or when 
grown in high (20mM) glucose for 24 hours (Fig. 3.2F-G). Thus, increasing O-
GlcNAcylation of Milton1 decreases its activity which subsequently reverses the 
mitochondrial aggregation phenotype in INS1 cells.  
 
Milton1 activity determined by O-GlcNAcylation regulates mitochondrial fusion 
To verify that O-GlcNAcylation of Milton1 specifically is responsible for the reversal in 
phenotype, we utilized a mutant of Milton1 in which 4 serine residues that are targets of 
O-GlcNAcylation are mutated to alanine and accordingly cannot be O-GlcNAcylated 
(Milton1-Qmut) 61. Milton1-Qmut is resistant to increased O-GlcNAcylation by 24 hr 
exposure to PUGNAc, thus maintaining low O-GlcNAc levels even under high GlcNAc 
conditions (Fig. 3.3A-B). Importantly, INS1 cells over-expressing Milton1-Qmut showed 
a similar mitochondrial aggregation phenotype, and this aggregation induced by Milton1-
Qmut was insensitive to high glucose treatment (Fig. 3.3C-D). Thus the mitochondrial 
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clustering phenotype is a result of high Milton1 activity, and under a high glucose 
environment O-GlcNAcylation of Milton1 inhibits its activity. 
Next we sought to investigate whether the Milton1-dependent mitochondrial 
elongation/aggregation was consistent with increased mitochondrial connectivity. First, 
fusion status of the mitochondrial clusters was investigated in INS1 cells expressing 
mito-PAGFP to reveal accurately the dimensions of individual mitochondria 136, 137. 
Milton1-Qmut-induced mitochondria clusters were indeed hyperfused structures (Fig. 
3.3E). Second, targeted laser pulses were performed on mitochondria labeled with TMRE 
and the percentage of the network that simultaneously depolarized was quantified. In 
INS1 expressing Milton1-WT or Milton1-Qmut, the percent connectivity of the 
mitochondrial network was significantly greater than in control cells (Fig. 3.3F-G). These 
results demonstrate that Milton1 activity promotes mitochondrial hyper-fusion. 
 
Milton1 O-GlcNAcylation regulates mitochondrial dynamics in response to chronic 
nutrient excess in the pancreatic beta-cell 
Since Milton1-Qmut is able to maintain high Milton1 activity under high nutrient levels, 
we next investigated if expressing Mil-Qmut would restore mitochondrial dynamics and 
connectivity under GLT. INS1 cells expressing Mil-Qmut, but not Mil-WT, and exposed 
to GLT were restored to similar levels of mitochondrial connectivity as in cells grown in 
control media, as assessed by TMRE depolarization experiments (Fig. 3.4A-B). Thus, 
promoting hyper-active mitochondrial movement with Mil-Qmut is sufficient to increase 
mitochondrial connectivity under GLT. Furthermore, these results implicate O-
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GlcNAcylation of Milton1 as a potential mechanism determining reduced mitochondrial 
dynamics induced by GLT.  
We then assessed how preserving mitochondrial connectivity with Mil-Qmut would 
regulate beta-cell viability and function in response to GLT. Mil-Qmut expression 
significantly preserved beta-cell viability under GLT compared to control-transfected 
INS1 cells or cells expressing Mil-WT (Fig. 3.4C). However, INS1 cells expressing Mil-
Qmut showed similar levels of GLT-induced inhibition of GSIS as INS1 cells expressing 
LacZ control virus or Mil-WT (Fig. 3.4D).In conclusion, promoting increased 
mitochondrial movement under GLT via Milton1-Qmut is sufficient to increase 
mitochondrial connectivity and preserve beta-cell viability, but not GSIS. Since GSIS 
involves mitochondrial response to acute nutrient exposure, we next investigated if O-
GlcNAcylation of Milton1 plays any role during beta-cell response to acute glucose 
stimulation. 
 
Milton1 O-GlcNAcylation regulates mitochondrial bioenergetics during acute glucose 
stimulation. 
Since Milton1 O-GlcNAcylation regulates mitochondrial dynamics, we investigated the 
role of Milton1 O-GlcNAcylation in the context of GSIS in INS1 cells and primary 
mouse islets. Interestingly, Milton1-Qmut over-expression significantly inhibited GSIS in 
INS1 and mouse islets, whereas INS1 or mouse islets over-expressing Milton1-WT 
maintained normal GSIS compared to control cells over-expressing LacZ (Fig. 3.5A-B). 
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Thus, the inability of Milton1-Qmut to sense levels of glucose results in reduced insulin 
secretion response during acute glucose stimulation.  
To determine if O-GlcNAcylation of Milton1 occurs upon acute (30 min.) exposure to 
increased glucose, O-GlcNAc levels of Milton1 were assessed by immunoprecipitating 
myc-Milton1 over-expressed in INS1 and immunoblotting for GlcNAc levels. INS1 cells 
were first incubated in 2.8mM glucose media for 2 hours, then switched to 16.7mM 
glucose for 30 minutes followed by protein isolation. O-GlcNAcylation of Milton1 was 
significantly increased after 30 minutes of 16.7mM glucose in INS1 cells expressing 
Milton1-WT, but cells expressing Milton1-Qmut were insensitive to the acute glucose 
exposure (Fig. 3.5C-D).  
Subsequently, it was investigated whether the Milton1-mediated acute changes to 
mitochondrial dynamics were important for mitochondrial functional response to glucose 
stimulation. Over-expression of Milton1-WT did not significantly affect basal oxygen 
consumption rate (OCR), glucose-stimulated OCR, or maximal OCR induced by FCCP 
in INS1 cells, although maximal OCR did trend towards being reduced (Fig. 3.5E-F). In 
contrast, glucose-stimulated and maximal OCR in INS1 cells was significantly decreased 
upon over-expression of Milton1-Qmut by either transfection (Fig. 3.5E-F) or adenovirus 
(Fig. 3.S6A-B). Neither oligomycin-resistant OCR (Fig. 3.S6C-D) nor mitochondrial 
membrane potential (Fig. 3.5G) were found to be significantly affected in either Milton1-
WT or Milton1-Qmut over-expressing cells. Thus, increased O-GlcNAcylation of 
Milton1-WT allows for mitochondrial architecture remodeling and increased OCR during 
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GSIS; and this process is inhibited upon expression of Milton1-Qmut, which is 
insensitive to O-GlcNAcylation. 
At 72 hours of over-expression, levels of mitochondrial proteins VDAC, complex V, 
complex IV and complex I were significantly decreased, indicating potential reduction in 
mitochondrial mass (Fig. 3.5H-I). However at 48 hours these proteins, excluding 
complex I, were not significantly altered (Fig. 3.5H-I). Thus we investigated capacity for 
GSIS at the 48 hour time-point. Expression of Milton1-Qmut significantly inhibited GSIS 
also at the 48 hour time-point compared to LacZ control or Milton1-WT (Fig. 3.5J). 
Furthermore, mouse islets over-expressing Milton1-Qmut, which showed similar 
inhibition of GSIS, did not show any change in complex I at 72 hours of expression (Fig. 
3.5K).  
 
Milton1 O-GlcNAcylation coordinates mitochondrial dynamics through regulation of 
Drp1 activity. 
The hyper-fused, ball-and-chain morphology of mitochondria in cells over-expressing 
Milton1-WT or Qmut strongly resembles a block in fission (Fig. 3.2B) 4. To determine 
what step of DRP1-mediated fission may be altered by Milton1-Qmut, we first 
investigated if DRP1 is able to be recruited to mitochondria in cells expressing Milton1-
Qmut. Staining for DRP1 in INS1 cells revealed that DRP1 is present on mitochondria in 
cells over-expressing Milton1-Qmut. Interestingly DRP1 is localized at the “tips” of 
mitochondrial aggregates in INS1 cells (Fig. 3.6A). Super-resolution microscopy 
revealed that DRP1 was not abnormally aggregated on mitochondria but appeared to still 
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be forming fission complexes at different sites on mitochondria (Fig. 3.6B). Co-
localization or percent overlap of DRP1 signal on mitochondria is not significantly 
disrupted by Milton1-Qmut over-expression in INS1 cells (Fig. 3.6D). In addition, DRP1 
is more uniformly localized on mitochondria in MEF cells over-expressing Milton1-
Qmut, which show the same “ball-and-chain” mitochondrial morphology (Fig. 3.6C). 
Thus Milton1 does not interfere with DRP1 translocation to mitochondria. Next the 
phosphorylation status of DRP1 was investigated, as this has been shown to be a key 
regulatory determinant of DRP1-mediated fission. Phosphorylation of DRP1 Ser-637 was 
strongly increased at 48 hr of Milton1-WT or Qmut over-expression (Fig. 3.6E-F), 
suggesting rapid inhibition of DRP1 activity with increased Milton1 activity. 
Phosphorylation of DRP1 Ser-616 was not significantly altered at any time-point of 
DRP1 over-expression (Fig. 3.S7). Therefore, Milton1 activity allows for DRP1 
recruitment to mitochondria, but inhibits its activity by hyper-phosphorylation of the 
inhibitory Ser-637.  
Finally we sought to determine if the Milton1-mediated regulation of DRP1 activity 
played a role during GSIS in the beta-cell, since changes to mitochondrial dynamics are 
thought to be involved in beta-cell response to acute glucose stimulation 128. Interestingly, 
we observed that phosphorylation of DRP1 Ser-637 was significantly decreased after 15 
minutes of acute glucose stimulation in control INS1 cells (Fig. 3.6G-H). Importantly, 
INS1 cells expressing Milton1-WT showed a significant reduction in DRP1 Ser-637 
phosphorylation after 15 minutes of stimulatory glucose; however cells expressing 
Milton1-Qmut were unable to decrease DRP1 Ser-637 phosphorylation after stimulatory 
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glucose (Fig. 3.6G-H). Thus Milton1 O-GlcNAcylation regulates DRP1 Ser-637 
phosphorylation during acute glucose stimulation, and this nutrient-sensing mechanism 
acts to coordinate acute changes to mitochondrial motility and fission during glucose 
stimulation. 
 
DISCUSSION 
Herein we describe how Milton1, an integral component of the mitochondrial motor 
adaptor complex, regulates both mitochondrial motility and fusion status to nutrient 
availability. The nutrient-responsive component of this system is the post-translational O-
GlcNAc modification of Milton1 by OGT, which will be directly influenced by the 
availability of nutrients, including glucose and fatty acids. Under chronic exposure to 
high glucose and fatty acids (GLT), increased O-GlcNAcylation of Milton1 decreases 
Milton1 activity and mitochondrial movement, which results in mitochondrial 
fragmentation and reduced connectivity. Maintaining high Milton1 activity with O-
GlcNAc-insensitive mutant Milton1 (Mil-Qmut) prevents GLT-induced cell death but 
does not restore the deficit in beta-cell function (GSIS). However we also determine that 
O-GlcNAcylation of Milton1 during GSIS is a crucial mechanism regulating 
mitochondrial fission response to acute glucose. Disabling this mechanism by expressing 
Mil-Qmut inhibits GSIS in INS1 and mouse islets, and this mechanism is dependent upon 
Milton1-regulated decreased phosphorylation of DRP1. Overall the results demonstrate 
that O-GlcNAcylation of Milton1 is a key determinant of mitochondrial motility, fusion, 
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and fission in response to either acute or chronic nutrient over-supply in the pancreatic 
beta-cell. 
It has been shown that mitochondrial motility influences the chance of fusion events 57, 129 
and yet other studies have suggested a close coordination between fission events and 
subsequent mitochondrial movement 59, 130, 138-140. Thus there is a close coordination 
between mitochondrial motility and fusion/fission in cells. Our work reveals how 
nutrient-induced arrest of mitochondrial motility occurs in the pancreatic beta-cell, and 
this is concomitant with mitochondrial fragmentation and decreased connectivity. 
Previous work has examined mitochondrial movement rates with the conclusion that 
GLT induces mitochondrial fragmentation but does not alter mitochondrial motility 3. 
However these studies measured the velocity of single mitochondria, which may show 
more variability than the displacement analysis we performed in our study. One 
significant remaining question is whether the decreased motility is sufficient to inhibit 
mitochondrial fusion or promote fission. Several studies have highlighted how altering 
mitochondrial movement does indeed impact fusion rates 84, 129, 141. Importantly 
mitochondrial adaptation to different nutrient environment may require changes to both 
their movement and fusion/fission status. Our data place Milton1 as a potential mediator 
that dually regulates both mitochondrial movement and fusion/fission events in 
accordance with nutrient status. 
Mitlon1 (TRAK1) has been implicated in endosome-lysosome trafficking, mitochondrial 
trafficking, as well as mitochondrial network remodeling 116, 117, 142. Recent work has 
shown the glucose-sensitive regulation of Milton1 by O-GlcNAc modification, and how 
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this pathway determines glucose-induced mitochondrial motility arrest in neuronal axons 
61. Our work describes how O-GlcNAcylation of Milton1 represents a nutrient sensor 
linking changes in mitochondrial motility and dynamics to nutrient availability in the 
beta-cell. However the nutrient-induced changes to mitochondrial motility and dynamics 
could be regulated by other mechanisms other than O-GlcNAcylation of Milton1. 
Cytosolic calcium levels have been shown to determine mitochondrial trafficking, 
particularily through regulation of Miro1, which is the adaptor protein between Milton1 
and mitochondria 133, 141. Calcium-mediated regulation of Miro1 has even been implicated 
in beta-cell response to excess nutrient insult, though the relationship to mitochondrial 
motility and dynamics changes were not investigated 143. Interestingly DRP1 has also 
been shown to be regulated by O-GlcNAcylation 144, where increased O-GlcNAcylation 
increases its activity, which would fit mechanistically with a more fragmented 
mitochondrial network under GLT. Certainly additional research is required to fully 
understand the interplay between these different nutrient-sensing mechanisms and their 
effects on mitochondrial dynamics and motility. It is especially interesting that OGT is 
found in complex with Milton1 at the outer mitochondrial membrane 145, 146, and further 
research is required to understand the importance of this nutrient-sensing “hub” at the 
interface between mitochondria and the cytoskeleton. 
Mitochondrial dynamics plays an important yet not clearly-defined role for regulating 
beta-cell metabolism during exposure to acute or chronic excess nutrient. It has been 
reported that mitochondrial fragmentation occurs in response to chronic (>24 hours) 
exposure to excess glucose and fatty acids, and in this study we report that mitochondrial 
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fragmentation also occurs in human islets exposed to GLT. Importantly the fragmentation 
was found to be a compensatory adaptation to GLT, as preventing fragmentation by 
blocking fission exacerbated GLT-induced disruption of mitochondrial membrane 
potential and GSIS in human islets. The fragmentation of mitochondria has been shown 
to be a result of decreased fusion, and thus under GLT the mitochondrial network is less 
connected 3. In the present study we found that expressing the O-GlcNAc-insensitive 
Milton1 maintained mitochondrial connectivity. Doing so prevented GLT-induced cell 
death yet did not rescue the deficit in GSIS. Interestingly it was also shown that 
maintaining mitochondrial connectivity by knock-down of Fis1 also rescued cell viability 
but not GSIS induced by GLT in islets 3. Thus increased O-GlcNAcylation of Milton1 
may be a key regulator of mitochondrial dynamics changes under GLT. 
Interestingly it was also reported that mitochondrial fragmentation occurs within 15 
minutes of glucose exposure during GSIS 128. Since the fragmentation happens rapidly, it 
was believed to be a result of increased fission; however no clear mechanism was 
established. Our data shows that during GSIS, phosphorylation of DRP1 on Serine 637 is 
decreased which would relieve DRP1 inhibition and allow for fission. Importantly 
preventing DRP1-mediated fission has been shown in several studies to inhibit GSIS 4, 
128; yet it is unclear if this is because fission is physiologically necessary during GSIS or 
chronically blocking fission decreases mitochondrial quality control. In our current study 
we observed that Milton1-mediated regulation of fission is indeed necessary during 
GSIS. Expressing the O-GlcNAc-insensitive mutant Milton1 inhibited glucose-stimulated 
mitochondrial respiration and GSIS whereas expression of wild-type Milton1 resulted in 
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mostly normal response to glucose stimulation. Reduction in mitochondrial mass or 
complex I levels is not sufficient to explain the inhibition of GSIS in INS1 and mouse 
islets expressing Milton1-Qmut, since GSIS was inhibited at 48 hours of over-expression 
(when mass was not changed) and complex I levels were not decreased in mouse islets. 
Rather the data may point to a novel mechanism regulating beta-cell insulin secretion, 
whereby increased glucose increases O-GlcNAcylation of Milton1, decreasing its activity 
and in turn triggeringde-phosphorylation of DRP1 serine 637. These events allow for 
acute fission and appropriate mitochondrial metabolism during acute glucose stimulation, 
ultimately promoting insulin secretion. Strong evidence exists supporting a link between 
mitochondrial architecture changes and bioenergetic capacities 147, yet more research is 
needed to exactly how the acute mitochondrial fragmentation may influence bioenergetic 
responses to glucose stimulation in the beta-cell. Of course prolonged inhibition of 
fission by Milton1 over-expression could compromise mitochondrial quality control; 
however our specific system comparing O-GlcNAc-insensitive hMilton1 to wild-type 
hMilton1 resolves the role of fission in response to the acute glucose stimulation in beta-
cells. Yet to be uncovered is how Milton1 is specifically regulating DRP1 activity, which 
will require further study.  
Collectively, our findings suggest that changes to mitochondrial motility under a chronic 
high nutrient environment may contribute to mitochondrial and beta-cell dysfunction. 
Importantly, nutrient-sensing of Milton1 activity via O-GlcNAc modification is a key 
player connecting nutrient status to mitochondrial motility and dynamics in the pancreatic 
beta-cell.  
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FIGURES 
Figure 3.1: High glucose and fatty acids synergistically induce mitochondrial 
fragmentation and decrease mitochondrial movement in INS1 cells and human beta-
cells. 
A) Images of human islets were grown for 4 days in control BSA media (5.5 mM 
glucose) or high glucose (11.5 mM) media containing 500 µM oleate and palmitate 
complexed to BSA (HG+Ol:Palm). Cells were then stained with MTG and TMRE to 
visualize mitochondrial morphology and membrane potential and imaged via confocal 
microscopy. Scale bar = 20µm. B) Mitochondrial morphology in human islets grown in 
control BSA media or HG+Ol:Palm for 4 days was quantified as average Form Factor 
(FF) values. * = p≤0.01 vs. Control. (n=10 donors). Exposure to HG+Ol:Palm significant 
reduced average FF values for mitochondria in human islets, indicating mitochondrial 
fragmentation. C) The graph shows the fraction of cells with fragmented mitochondria 
(average FF<1.75) for human islets grown in BSA or HG+Ol:Palm. * = p≤0.001 vs. 
Control. (n=10 donors). D) Mitochondrial membrane potential (MMP) heterogeneity is 
calculated as the standard deviation of MMP values for all mitochondria identified within 
the cell. Increased MMP heterogeneity under HG+Ol:Palm is concurrent with 
mitochondrial fragmentation, suggesting a disrupted mitochondrial network induced by 
excess nutrient environment. * = p≤0.05 vs. Control. (n=10 donors). E) Representative 
overlay images showing mitochondrial displacement after (red) a 20 second interval 
(green is before position) in INS1 cells exposed to control BSA conditions or HG+Palm 
for 20 hours. Scale bar = 10µm. F) The graph shows average FF values for mitochondria 
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of INS1 cells grown in control (BSA) media or HG+Palm. Mitochondrial fragmentation 
was induced by exposure to HG + Palm:BSA in INS1 cells. * = p≤0.05 vs. Control. (n = 
4 experiments). G) Average displacement values were calculated for mitochondrial 
motility time-lapse images (as described in Methods and Supp. Figure 2A-B) for INS1 
cells grown in the indicated nutrient conditions. Nocodazole (Noco) was used as a control 
to arrest mitochondrial motility via inhibition of microtubule polymerization. Exposure to 
HG+Palm significantly reduced mitochondrial motility as seen by decreased 
displacement values compared to control condition. * = p≤0.05 Control. Number of cells 
analyzed for each group indicated above respective bars, 2-4 separate experiments total. 
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Figure 3.2: O-GlcNAc regulation of Milton1 coordinates mitochondrial movement 
and architecture to nutrient levels in pancreatic beta-cells 
A) Images of INS1 cells co-transfected with EGFP and control (empty vector) DNA or 
hMilton1. Cells were stained with TMRE to visualize mitochondria and imaged via 
confocal microscopy. Milton1 over-expression induced mitochondrial clustering at the 
periphery of INS1 cells. Scale bar = 10µm. B) High-resolution confocal imaging of 
mouse (Ms) or human (Hu) islet cells, or INS1 cells, expressing hMilton1 (via adenoviral 
transduction) and stained with TMRE to visualize mitochondrial morphology. Insets 
show zoomed-in images of distinct “ball-and-chain” mitochondrial morphologies, which 
were observed in all three cell types. Scale bars = 10µm. C) First cartoon depicts Milton1 
as part of the motor-adaptor complex linking mitochondria to microtubules (MT). The 
kinesin-binding-domain (KBD) and 4 serine (S-OH) sites of O-GlcNAcylation of 
Milton1 are shown. The second cartoon shows the abbreviated hexosamine pathway 
whereby glucose and fatty acids (FAs) are metabolized to UDP-GlcNAc, which can then 
be used for O-GlcNAcylation of Milton1. PUGNAc is the inhibitor of O-GlcNAcase 
(OGA). D) Images of INS1 cells co-transfected with EGFP and control DNA or hMilton1 
lacking the kinesin-binding domain (Mil-Kdel) and stained with TMRE to visualize 
mitochondria architecture. Alternatively, INS1 cells were transfected with wild-type 
hMilton1 (Mil-WT) and exposed to different conditions that raise intracellular GlcNAc 
levels, including high (20mM) glucose, co-expression of OGT, or treatment with 
PUGNAc (inhibitor of O-GlcNAcase). Scale bar = 10µm. E) Images from (C) were 
quantified for fraction of cells showing distally-aggregated mitochondria (calculations 
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described in Methods and Supp. Figure 4A) in the indicated groups. Mil-Kdel over-
expression did not induce mitochondrial clustering, suggesting the clustering is 
dependent upon Milton1-induced mitochondrial movement. Raising intracellular GlcNAc 
levels reversed Milton1-induced clustering, indicating decreased activity of Milton1 upon 
high GlcNAc levels. * = p≤0.05 vs. 10mM glucose, no PUGNAc; ** = p≤0.01 vs. 10mM 
glucose, no PUGNAc. (n=3 experiments). F) Wild-type Myc-hMilton1 (Mil-WT) was 
expressed in INS1 cells and cells were exposed to either 24 hours high (20mM) glucose 
or treated with 100µM PUGNAc. Myc-hMilton1 was immunoprecipitated via Myc 
antibody and immunoprecipitates were probed with anti-GlcNAc and anti-myc 
antibodies. G) GlcNAc intensities were normalized to corresponding Myc bands for the 
immunoprecipitates and plotted with baseline value of 1 for Mil-WT 10mM glucose to 
show relative changes. Increased O-GlcNAcylation of Milton1 was seen upon exposure 
to elevated glucose and PUGNAc treatment. * = p≤0.05 vs. 10mM glucose, no PUGNAc; 
** = p≤0.01 vs. 10mM glucose, no PUGNAc. (n=3 experiments). 
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Figure 3.3: Low levels of Milton1 O-GlcNAcylation promotes mitochondrial hyper-
fusion 
A) Wild-type Myc-hMilton1 (Mil-WT) or quadruple mutant Myc-hMilton1 (Mil-Qmut, 4 
serines identified to be O-GlcNAcylated were mutated to alanine) were expressed in 
INS1 cells followed by treatment with or without 100µM PUGNAc for 24 hours. Myc-
hMilton1 was immunoprecipitated via Myc antibody and immunoprecipitates were 
probed with anti-GlcNAc and anti-myc antibodies. B) GlcNAc intensities were 
normalized to corresponding Myc bands for the immunoprecipitates and plotted with 
baseline value of 1 for Mil-WT control to show relative changes. Mil-Qmut is insensitive 
to increased O-GlcNAcylation upon PUGNAc treatment. * = p≤0.01 vs. Mil-WT No 
PUGNAc. (n=3). C) Images of INS1 cells co-transfected with EGFP and wild-type 
hMilton1 (Mil-WT) or O-GlcNAc-insensitive quadruple mutant hMilton1 (Mil-Qmut). 
Cells were treated with or without 100µM PUGNAc for 24 hours and then stained with 
TMRE and hoescht dye to visualize mitochondria and nuclei, respectively, and subjected 
to confocal imaging. D) Images from (C) were quantified for fraction of cells showing 
distally-aggregated mitochondria in the indicated groups. Cells expressing Mil-Qmut 
show mitochondrial clustering and the phenotype is resistant to elevated glucose levels. * 
= p≤0.05 vs. Mil-WT 10mM glucose. (n=4). E) Represenative image showing INS1 cells 
stably expressing mito-PAGFP, transfected with Mil-Qmut, and stained with TMRE. The 
2-photon laser was used to photo-activate (PA) a small portion of the distally-located 
mitochondrial aggregate in Mil-Qmut expressing cells, and subsequent diffusion of mito-
PAGFP through the mitochondrial aggregate was imaged immediately after the PA event. 
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Scale bar = 10 µm. F) INS1 cells were co-transfected with EGFP and control DNA, Mil-
WT, or Mil-Qmut followed by staining with TMRE and imaging via confocal 
microscopy. Small, targeted laser-induced depolarizations were applied to a small portion 
of the mitochondrial network (white boxes, arrows) and the cells were imaged before and 
after the targeted depolarizations. Scale bar = 10µm. G) Mitochondrial connectivity was 
assessed by calculating the fraction of the total mitochondrial network that was 
depolarized after laser-induced depolarizations such as in (F) images. The fraction of the 
mitochondrial network that simultaneously depolarizes (loss of TMRE) indicates 
mitochondrial that are electrically connected. Cells expressing Mil-WT and Mil-Qmut 
showed greater mitochondrial network connectivity than control cells. * = p≤0.05 vs. 
control DNA (n=3). 
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Figure 3.4: Milton1 O-GlcNAcylation regulates mitochondrial dynamics in response 
to GLT in the pancreatic beta-cell.  
A) Images of TMRE depolarization experiments in INS1 transfected with control DNA, 
Mil-WT, or Mil-Qmut DNA. Cells were exposed to control (BSA) media or high glucose 
(20mM) and high fatty acid (400µM palmitate:BSA) media for 20 hours, then stained 
with TMRE and imaged. Initial images of mitochondrial networks were followed by 
targeted laser-induced depolarizations (white boxes indicated by arrows). Images were 
then taken immediately after to determine the fraction of the total mitochondrial network 
that simultaneously depolarized. B) Quantification of the fraction of total mitochondrial 
network that depolarized in (A) images. Exposure to HG+Palm decreases mitochondrial 
connectivity in control DNA-transfected cells indicated by decrease in simultaneously 
depolarizing area. INS1 cells expressing Mil-Qmut show higher mitochondrial 
connectivity under HG+Palm. * = p≤0.01 vs. Con. DNA control media (n=3 experiments 
with 20-30 cells analyzed per experiment). C) Cell death was assessed in INS1 cells 
transfected with control DNA, Mil-WT, or Mil-Qmut and exposed to high glucose and 
high fatty acid media (HG+Palm). Fold-change in cell death was normalized to control 
DNA-transfected cells exposed to control BSA media (dashed line = 1). Expression of 
Mil-Qmut protected INS1 cells from cell death induced by HG+Palm. * = p≤0.05 vs. 
Con. DNA HG+Palm (n=3 experiments). D) GSIS measurements in INS1 cells 
expressing control virus, Mil-WT, or Mil-Qmut and exposed to the indicated control BSA 
media or high glucose and fatty acid media. * = p≤0.05 vs. Con. DNA under control BSA 
media (n=3).  
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Figure 3.5: Milton1 O-GlcNAcylation regulates mitochondrial bioenergetics during 
acute glucose stimulation.  
A) Graph showing glucose-stimulated insulin secretion (GSIS) for INS1 cells transduced 
with control LacZ, Mil-WT, or Mil-Qmut adenovirus and grown in normal medium for 3 
days. Cells expressing Mil-Qmut, but not Mil-WT, show significant decrease in GSIS 
compared to LacZ control cells. *=p<0.05 vs. LacZ control (n=4 experiments). B) Graph 
showing GSIS for primary mouse islets transduced with control LacZ, Mil-WT, or Mil-
Qmut adenovirus and grown in normal medium for 3 days. In mouse islets expression of 
Mil-Qmut, but not Mil-WT, significantly reduces GSIS. *=p<0.05 vs. LacZ control (n=4 
experiments with islets from 4 different sets of mice). C) Mil-WT or Mil-Qmut was 
expressed in INS1 cells for 3 days followed by GSIS protocol with 30 minutes of glucose 
stimulation before isolating protein for immunoprecipitation. Myc-hMilton1 was 
immunoprecipitated via Myc antibody and immunoprecipitates were probed with anti-
GlcNAc and anti-myc antibodies. D) GlcNAc intensities were normalized to 
corresponding Myc bands for the immunoprecipitates and plotted with baseline value of 1 
for Mil-WT 2mM glucose to show relative changes. O-GlcNAcylation of Milton1 is 
significantly increased after glucose stimulation in cells expressing Mil-WT but not Mil-
Qmut. *=p<0.05 vs. Mil-WT 2mM glucose, n.s. = not significant vs. Mil-Qmut 2mM 
glucose (n=5 experiments). E) Graph depicts oxygen consumption rate (OCR) over time 
for a representative experiment with INS1 cells transfected with control (empty vector; 
Con. DNA), Mil-WT, or Mil-Qmut DNA. After basal OCR was established, 12mM 
glucose (glu) was injected to assess glucose-stimulated mitochondrial respiration. This 
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was followed by injection of 5µM oligomycin (Oligo) to assess ATP-linked OCR, then 
2µM FCCP to induce maximal OCR via uncoupling of oxygen consumption from 
mitochondrial proton gradient. Finally 5µM antimycin A (AA) was injected to determine 
levels of non-mitochondrial OCR. F) Graph shows average OCR values for the indicated 
groups and indicated conditions. Cells expressing Mil-Qmut, but not Mil-WT, show 
inhibition of glucose-stimulated and maximal OCR. *=p<0.05 vs. Con. DNA (n=4 
experiments). G) INS1 cells transfected with control DNA, Mil-WT, or Mil-Qmut 
adenovirus were stained with TMRE and imaged. Average TMRE intensity from the 
images was calculated to determine changes to MMP. No changes in average TMRE 
intensity were detected across the different groups. Number of cells analyzed for each 
group indicated above respective bars, 2separate experiments total. H) Representative 
Western blot image of samples from INS1 cells transduced with control LacZ, Mil-WT, 
or Mil-Qmut adenovirus. Expression levels of mitochondrial proteins VDAC, complex 
IV (C-IV), complex V (C-V), and complex I (C-I) were assessed and compared to 
cellular GAPDH levels. I) Graph depicts fold-change to mitochondrial protein levels 
(corrected to GAPDH) at 24, 48, and 72 hours of Mil-WT or Mil-Qmut over-expression 
(O/E). Values were normalized to LacZ-transduced cells at the matched time-points. 
Levels of mitochondrial proteins are reduced at 72 hours, but not 48 hours, suggesting 
reduced mitochondrial mass after 72 hours of Milton1 over-expression. (n=3 
experiments). J) Graphs showing GSIS for INS1 cells transduced with control LacZ, Mil-
WT, or Mil-Qmut adenovirus and grown in normal medium for 48 hours. GSIS is 
significantly inhibited in cells expressing Mil-Qmut for 48 hours. *=p<0.05 and 
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**=p<0.001 vs. LacZ control (n=4 experiments). K) Western blot for complex I (C-I) 
levels in mouse islets transduced with LacZ or Mil-Qmut adenovirus for 3 days. C-I 
protein levels were corrected to GAPDH and normalized to LacZ cells. A trend towards 
increased C-I protein was seen in mouse islets expressing Mil-Qmut for 72 hours. Thus 
the reduced C-I protein induced by Mil-Qmut expression seen in INS1 cells is not 
sufficient to explain the reduced GSIS in Mil-Qmut islets. p=0.08 vs. LacZ control (n=3 
experiments from 3 different sets of mice). 
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Figure 3.6: Low levels of Milton1 O-GlcNAcylation promotes mitochondrial hyper-
fusion through inhibition of Drp1 activity 
A) INS1 cells were co-transfected with mito-DsRED and control DNA or Mil-Qmut. 
Fixed cells were stained with DRP1 antibody followed by AlexaFluor-488 secondary and 
imaged via confocal microscopy to visualize DRP1 and mitochondrial co-localization. B) 
Super-resolution imaging for cells from (A) to better visualize DRP1 localization within 
mitochondrial aggregates. DRP1 is located on mitochondria in INS1 cells expressing Mil-
Qmut. C) Correlation coefficient and % area overlap of DRP1 and mitochondrial signals 
were calculated from INS1 images in (A). No significant change in DRP1 co-localization 
was seen, indicating DRP1 recruitment is not limiting upon Mil-Qmut expression. (n=20-
30 cells analyzed total from 2 experiments). D) MEF cells were co-transfected with mito-
DsRED and control DNA or Mil-Qmut. Fixed cells were stained with DRP1 antibody 
followed by AlexaFluor-488 secondary and imaged using confocal microscopy to 
visualize DRP1 and mitochondrial co-localization. DRP1 localization to mitochondria is 
clearly seen in MEF cells expressing Mil-Qmut. E) INS1 cells transduced with control 
LacZ, Mil-WT, or Mil-Qmut adenovirus for 24, 48, or 72 hours were assessed for DRP1 
phosphorylation on serine 637 (pSer637), total DRP1, and GAPDH levels by Western 
blot. Forskolin (Frsk) was used as a control treatment to strongly induce DRP1 Ser637 
phosphorylation. G) Levels of DRP-pSer637 were determined by correcting to total 
DRP1 levels, followed by normalizing to control LacZ group at the matched time-points 
of over-expression (O/E).  Expression of Mil-WT or Mil-Qmut strongly increased 
phosphorylation of Drp1 on serine 637, especially at 48 hours of over-expression. (n=3 
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experiments). H)  INS1 cells transduced with control LacZ, Mil-WT, or Mil-Qmut 
adenovirus for 48 hours were subjected to standard GSIS protocol with just 15 minutes of 
16.7mM glucose stimulation before isolating protein for Western blot. I) Levels of DRP-
pSer637 at basal (2mM) and stimulatory (16.7mM; stim) glucose were determined by 
correcting to total DRP1 levels, followed by normalizing to control LacZ group at basal 
glucose. DRP1 phosphorylation on serine 637 is significantly decreased after glucose 
stimulation in control LacZ and Mil-WT cells; however Mil-Qmut cells did not show the 
glucose-induced serine 637 phosphorylation change. *=p<0.05 vs. 2mM glucose of the 
respective group, n.s.=non-significant (n=4 experiments for Mil-WT and Mil-Qmut cells, 
n=5 experiments for LacZ cells). 
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Supplementary Figure 3.S1: GLT fragments mitochondria in mouse islets and 
inhibits GSIS in human and mouse islets and INS1 cells. 
A) Assessment of GSIS in human islets exposed to control BSA or high glucose 
(11.5mM) with high fatty acid (500µM oleate and palmitate) for 4 days. Exposure to high 
glucose with high oleate/palmitate (HG+Ol:Palm) for 4 days inhibits GSIS in human 
islets. B) Assessment of GSIS in mouse islets exposed to control BSA or high glucose 
(20mM) with high fatty acid (500µM oleate and palmitate) for 2 days. Exposure to high 
glucose with high oleate/palmitate (HG+Ol:Palm) for 2 days inhibits GSIS in mouse 
islets. C) Images of mouse islet cells cultured in control BSA media or high glucose 
(20mM) with high fatty acid (500µM oleate and palmitate; HG+Ol:Palm) for 2 days. For 
imaging of mitochondria, cells were stained with MTG and TMRE to visualize 
mitochondrial morphology and membrane potential and imaged via confocal microscopy.  
  
  
128 
 
  
  
129 
Supplementary Figure 3.S2: Mitochondrial fragmentation in response to nutrient 
excess represents a compensatory adaptation to maintain human beta-cell function. 
A) Human islets were cultured in media with normal nutrients (5mM glucose, 10% BSA) 
or media with high glucose (11.2 mM) and fatty acids (1mM oleate and palmitate) for 4 
days (GLT). Mitochondrial fission was inhibited by expressing dominant-negative 
construct of mitochondrial fission protein, DRP1 (DRP1-D/N). Mitochondrial 
morphology and membrane potential were assessed by confocal imaging. B) 
Mitochondrial morphology was assessed by assessing average Form Factor values of 
mitochondria in islets. Lower Form Factor values indicate mitochondrial fragmentation. 
(n=4 experiments with islets from 4 different human donors). C) The standard deviation 
of mitochondrial membrane potential was determined from images of mitochondria in 
(A). Increased values indicate heterogeneity of membrane potential and discordance 
among the mitochondrial population. *=p<0.05 vs. the indicated condition (n=4 
experiments with islets from 4 different human donors). D) GSIS was assessed in human 
islets expressing control LacZ adenovirus or Drp1-D/N and exposed to control nutrient 
media or GLT. GLT-induced inhibition of GSIS is further decreased in human islets 
expressing Drp1-D/N. *=p<0.05 vs. the indicated condition (n=5 experiments with islets 
from 5 different human donors).   
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Supplementary Figure 3.S3: Assessment of mitochondrial motility in INS1 cells. 
A) Cartoon demonstrating time-lapse imaging strategy to assess mitochondrial 
displacement over time. An overlay image is generated from the t=1 image (pseudo-
colored red) and the t=2 image (pseudo-colored green). In the overlay image, yellow 
pixels indicate regions of mitochondria that did not move between the time-points, while 
red and green pixels indicate displaced mitochondrial regions. Theoretical examples of 
full, partial, and no (stationary) displacement are shown. B) The amount of red + 
green/yellow pixels in each overlay image of the successive time-points and the t=1 time-
point are plotted over time. The slope of the best-fit line is used as the quantification of 
mitochondrial motility or displacement for that cell. C) Average mitochondrial 
displacement values for INS1 cells transfected with control DNA or Mil-WT. 
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Supplementary Figure 3.S4: INS1 express higher levels of kinesin compared to 
COS7 cells 
A) Image of COS7 cell co-transfected with mito-DsRED and Mil-WT then fixed and 
stained for Myc (Milton1) to visualize architecture and positioning of mitochondria. 
Milton1 induces peri-nuclear mitochondrial aggregation in COS7 cells. B) Western blot 
images of protein lysates from INS1 or COS7 cells showing kinesin (KHC) and dynein 
(DIC) protein levels. Levels of Actin were used as loading control. Graph shows 
quantification of kinesin (KHC) and dynein (DIC) protein levels, normalized to Actin 
loading control, in INS1 and COS7 cells. **=p<0.01 and n.s. = non significant (n=3 
experiments).  
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Supplementary Figure 3.S5: Analysis and quantification of Milton1-induced 
mitochondrial distal aggregation.  
A) Representative image of INS1 cell over-expressing EGFP and Mil-WT and stained 
with TMRE to visualize mitochondria. Mitochondrial areas were defined by thresholding, 
and the position of the nucleus marked (star). From the analyzed mitochondrial areas a 
Distal Aggregation Value was determined for the cell according to the indicated formula. 
B) Graph shows Displacement Value vs Distal Aggregation Value for a representative set 
of INS1 cells either transfected with control DNA or hMilton1 (Mil-WT). C) Graph 
shows the Distal Aggregation Value vs co-transfected GFP levels for a representative set 
of INS1 cells expressing Mil-WT. D) Images showing reversal of Milton1-induced 
clustering by palmitate. 
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Supplementary Figure 3.S6: Effects of Milton1-WT and Qmut adenoviral over-
expression on mitochondrial respiration in INS1 cells. 
A) Graph depicts oxygen consumption rate (OCR) over time for a representative 
experiment with INS1 cells transduced with control LacZ, Mil-WT, or Mil-Qmut 
adenovirus. After basal OCR was established, 12mM glucose (glu) was injected to assess 
glucose-stimulated mitochondrial respiration. This was followed by injection of 5µM 
oligomycin (Oligo) to assess ATP-linked OCR, then 2µM FCCP to induce maximal OCR 
via uncoupling of oxygen consumption from mitochondrial proton gradient. Finally 5µM 
antimycin A (AA) was injected to determine levels of non-mitochondrial OCR. B) Graph 
shows average OCR values for the indicated groups and indicated conditions. Cells 
expressing Mil-Qmut, but not Mil-WT, show inhibition of glucose-stimulated and 
maximal OCR. *=p<0.05 vs. LacZ control (n=4 experiments). C) Levels of oligomycin-
resistant OCR was determined in INS1 transfected with control DNA (Con. DNA), Mil-
WT or Mil-Qmut. (n=4 experiments). D) Levels of oligomycin-resistant OCR was 
determined in INS1 transduced with control LacZ, Mil-WT, or Mil-Qmut adenovirus. No 
significant changes in oligomycin-resistant OCR (proton leak) was seen by Milton1 over-
expression either by transfection or adenoviral transduction. (n=4 experiments).  
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Supplementary Figure 3.S7: Drp1 Ser616 phosphorylation is not altered by Milton1 
activity. 
INS1 cells transduced with control LacZ, Mil-WT, or Mil-Qmut adenovirus for 1, 2, or 3 
days were assessed for DRP1 phosphorylation on serine 616 (pSer616), total DRP1, and 
GAPDH levels by Western blot.  
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CHAPTER FOUR: Restoring lysosomal acidity and autophagic flux with photo-
activatable, acidic nanoparticles protects from lipotoxicity in pancreatic beta-cells 
 
INTRODUCTION 
Autophagy is an essential cellular maintenance mechanism by which cells target 
and degrade long-lived proteins and organelles. This cellular house-keeping process is 
especially critical in non-proliferating cells and tissues which rely on autophagy to 
remove damaged material that accumulates with aging 48, 148, 149. The two key steps of 
autophagy are autophagosome formation and engulfment of the cellular contents to be 
degraded, followed by autophagosome fusion with the acidic lysosome. Both fusion of 
lysosomes with autophagosomes as well as activation of lysosomal hydrolases are 
dependent on proper lysosome acidification 67, 68. Thus, lysosome acidity is essential for 
adequate autophagic flux in cells. Lysosomal defects can lead to decreased autophagic 
flux in neurodegenerative disorders, cardiac disease, and lysosomal storage diseases 148, 
150, 151. In insulin-secreting beta-cells lysosomal defects occur as a result of lipotoxicity 
(LT) - a pathologic state of beta-cell dysfunction caused by exposure to high levels of 
fatty acid 103, 152. Lysosomal acidity is compromised under chronic LT, resulting in 
decreased activity of lysosomal cathepsin enzymes. LT-induced lysosome alkalinization 
in beta-cells inhibits flux through autophagy, resulting in decreased turnover of proteins 
and organelles integral to beta-cell function 103. Thus, treatments to restore lysosomal 
acidity may provide a significant therapeutic advance for treating diabetes-related beta-
cell dysfunction and other diseases in which documented defects in autophagic flux 
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contribute to the pathology. However, it is yet unclear if impaired lysosome acidification 
is upstream of any of the pathogenic processes associated with beta-cell dysfunction and 
if restoring lysosomal acidification will improve autophagic flux and other cellular 
function such as insulin secretion. 
Addressing this question would require an approach to deliver acid to the 
lysosome in a robust, organelle-specific, dose-dependent and time-controlled manner. 
One approach to deliver acid into the lysosome and control its release involves the use of 
polymeric nanoparticles (NPs). A significant body of work has demonstrated that NPs are 
readily internalized into cells of many types (e.g. healthy, tumorigenic, pathologic) via 
broad, non-specific endocytosis pathways 153-158. Subsequent localization of NPs into 
cellular endosomes, and eventually to lysosomes, provides an ideal means of treating 
lysosomal dysfunction, either through delivery of a drug or by the action of the 
NP/material itself.  For example, Baltazar et al. demonstrated that when poly(DL-lactic-
co-glycolide acid) (PLGA) and poly(DL-lactide) NPs are given to ARPE-19 cells 
affected with lysosomal dysfunction, degradation of the PLGA-NPs into acidic 
byproducts facilitated re-acidification of lysosomes 153. 
Building from this concept, we have developed a stimulus-responsive NP that 
allows for externally triggered activation and acidification of the autophagosome. While 
stimuli-responsive NPs have frequently been used in other contexts, such as drug 
delivery, this is the first study to use such a system to provide active control over 
lysosomal and autophagic recovery in which the NP itself is the active agent 159-164. 
Specifically, we use NPs that, upon exposure to UV-light, undergo a compositional 
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change resulting in: 1) the de-protection of two carboxylic acid moieties on each polymer 
unit; and, 2) an overall conformational change from hydrophobic-to-hydrophilic that 
results in particle swelling and expansion. These particles are thus termed UV-responsive 
expansile NPs (eNPs) (Fig. 4.1A). An o-nitrobenzyl moiety was selected as the UV-labile 
protecting group due to its short UV-responsive half-life (<5 min) under conditions 
approximating a relevant physiological environment as well as its ease of synthesis. 
Herein, we describe the synthesis and characterization of the UV-responsive eNP 
which, in the presence of water and light, swells and becomes acidic. We utilize both 
primary islets and INS1 cells exposed to LT in order to determine if eNP-mediated 
acidification of the lysosomes acutely reverses lysosomal/autophagosomal dysfunction. 
We investigate the internalization and localization of eNPs in INS1 cells as well as the 
subsequent effect of eNP activation on recovery of both lysosomal pH and size. To 
monitor the ability of eNPs to restore autophagic flux, we follow both intracellular levels 
of LC3-II, a marker for autophagosomes, as well as p62, a substrate of autophagic 
degradation 165. Lastly, we examine how eNP treatment affects the ability of beta-cells to 
secrete insulin, a functionality that is depressed in cells under LT 3, 35, 103. 
 
METHODS 
Nanoparticle synthesis and characterization 
All synthetic procedures were performed with minimal exposure to light.  Prophylactic 
measures included covering the reacting vessel with aluminum foil and in general 
reducing the amount of light exposed to the reagents and products.  All photo-decaging 
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procedures used 365 nm UV-light from a Spectroline ENF-240C handheld lamp with 115 
V, 60 Hz, and 200 mA (Spectronics, Corp.). Detailed nanoparticle synthesis is described 
in SI Materials and Methods. 
Synthesis of 1-(2-nitrophenyl)ethanol (1).   
To a dried round-bottom flask under nitrogen atmosphere was added 10 mL of dry 
dichloromethane and 2-nitrobenzaldehyde (1.51 g, 10 mmol, 1.0 eq.).  The solution was 
stirred and cooled to 4 °C, upon which 10 mL of 2M trimethylaluminum in hexanes (2 
eq.) was added to the stirring solution over 10 minutes.  The solution was allowed to 
warm to room temperature and stir for an additional 3 h.  Subsequently 10 mL of 0.01 M 
NaOH was added drop-wise to the red-orange stirring solution over an ice bath.  The 
solution was allowed to effervesce, warm to room temperature, and stir for an additional 
1 h.  The solution was extracted using 0.01 M HCl and dichloromethane to yield a 
yellow-orange viscous liquid without further purification (96% yield). 
Synthesis of 4-(1-(2-nitrophenyl)ethoxy)-4-oxobutanoic acid (2).   
Succinic anhydride (201 mg, 2.0 mmol, 2.0 eq.) and 4-dimethylaminopyridine (DMAP, 
catalytic amount) was added to a solution of dry pyridine under a nitrogen atmosphere at 
room temperature.  A solution of 1 was made using dry pyridine (152 mg, 1.0 mmol, 1.0 
eq, in 2 mL of solvent).  The anhydride was allowed to fully dissolve, upon which the 
solution of 1 was added via syringe.  The solution was allowed to stir for 36 hours, at 
which time 1 M phosphate buffer solution (PBS) at pH = 7.4 was added to the solution (5 
mL).  The solution was allowed to stir for another 4 hours, at which point it was subject 
to high vacuum to evaporate the pyridine.  The resulting viscous liquid was subject, 
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twice, to rotovap evaporation with toluene to azeotrope the residual pyridine.  Finally, an 
extraction was performed using 0.01 M HCl solution and dichloromethane.  The final 
solution was purified on a silica column to yield a tan solid (81% yield). 
Synthesis of O,O'-(2-(hydroxymethyl)-2-methylpropane-1,3-diyl) bis(1-(2-
nitrophenyl)ethyl) disuccinate (3).   
A solution of 2-((tert-butyldimethylsilyloxy)methyl)-2-methylpropane-1,3-diol 
(previously prepared, 1.0 mmol, 236 mg, 1.0 eq.) and 2 (2.2 mmol, 588 mg, 2.2 eq.) in 
dichloromethane (20 mL) was prepared under an atmosphere of nitrogen and allowed to 
cool to 4 °C. A catalytic amount of DMAP was added to the stirring solution.  Finally, 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI, 372 mg, 2.4 mmol, 2.4 eq.) was 
added to the stirring solution, which was then allowed to stir overnight.  The solution was 
extracted once with 0.01 M HCl solution and dichloromethane.  The organic layer was 
collected and evaporated to yield a viscous yellow liquid.  Without further purification, 
the yellow liquid was re-suspended in wet tetrahydrofuran (THF, 20 mL) and placed over 
an ice bath with stirring.  To this solution was added 1 M tetrabutylammonium fluoride in 
THF (2 mL, 2 eq.), which was then allowed to stir for an additional 6 hours.  The solution 
was evaporated and extracted with 0.01 M NaOH solution and dichloromethane thrice.  
The organic layers were collected, evaporated, and the sticky, brown liquid was subject to 
column chromatography to yield the desired product (yellow viscous liquid, 58% yield). 
Synthesis of O,O'-(2-((methacryloyloxy)methyl)-2-methylpropane-1,3-diyl) bis(1-(2-
nitrophenyl)ethyl) disuccinate (4).   
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A solution of methacryloyl chloride (1.1 mmol, 110 μL, 1.1 eq.) was made in 10 mL of 
dry dichloromethane under a nitrogen atmosphere and allowed to cool to 4 °C.  A 
solution of 3 (1.0 mmol, 687 mg, 1 eq.) and triethylamine (1.5 mmol, 220 μL, 1.5 eq.) 
was suspended in dry dichloromethane in a separate vial.  The solution of 3 was added 
drop-wise over 30 minutes and allowed to stir overnight.  The solution was then extracted 
with 0.01 M HCl solution and dichloromethane twice; the organic layers were collected, 
and evaporated to yield a viscous, orange-brown liquid.  This liquid was then subject to 
column chromatography, to afford the desired product (yellow viscous liquid, 81%). 
Synthesis of 4-(benzyloxy)-4-oxobutanoic acid (5).  
To a solution of dry pyridine under a nitrogen atmosphere was added succinic anhydride 
(10 mmol, 1.14 g, 1 eq.).  To this stirring solution was added benzyl alcohol (11 mmol, 
1.03 mL, 1.1 eq.).  The solution was allowed to stir for 48 hours, at which point 1 M PBS 
was added to the solution (10 mL).  The solution was allowed to stir for another 4 hours, 
at which point it was subject to high vacuum to evaporate the pyridine.  The resulting 
viscous liquid was subject, twice, to a rotovap evaporation with toluene to azeotrope the 
residual pyridine.  Finally, an extraction was performed using 0.01 M HCl solution and 
dichloromethane.  The final solution was purified on a silica column (1:1 ethyl acetate-
hexanes) to yield a white crystalline solid (88% yield). 
Synthesis of dibenzyl O,O'-(2-(hydroxymethyl)-2-methylpropane-1,3-diyl) disuccinate (6).  
A solution of 2-((tert-butyldimethylsilyloxy)methyl)-2-methylpropane-1,3-diol 
(previously prepared, 1.0 mmol, 236 mg, 1.0 eq.) and 5 (2.2 mmol, 458 mg, 2.2 eq.) in 
dichloromethane (20 mL) was prepared under an atmosphere of nitrogen and allowed to 
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cool to 4 °C.  A catalytic amount of DMAP was added to the stirring solution.  Finally, 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI, 372 mg, 2.4 mmol, 2.4 eq.) was 
added to the stirring solution, which was then allowed to stir overnight.  The solution was 
extracted once with 0.01 M HCl solution and dichloromethane.  The organic layer was 
collected and evaporated to yield a viscous clear liquid.  Without further purification, the 
liquid was re-suspended in wet tetrahydrofuran (THF, 20 mL) and placed over an ice bath 
with stirring.  To this solution was added 1 M tetrabutylammonium fluoride in THF (2 
mL, 2 eq.), which was then allowed to stir for an additional 6 hours.  The solution was 
evaporated and extracted with 0.01 M NaOH solution and dichloromethane thrice.  The 
organic layers were collected, evaporated, and the sticky, tan liquid was subject to 
column chromatography to yield the desired product (white solid, 64% yield). 
Synthesis of dibenzyl O,O'-(2-((methacryloyloxy)methyl)-2-methylpropane-1,3-diyl) 
disuccinate (7).   
A solution of methacryloyl chloride (1.1 mmol, 110 μL, 1.1 eq.) was made in 10 mL of 
dry dichloromethane under a nitrogen atmosphere and allowed to cool to 4 °C.  A 
solution of 6 (1.0 mmol, 500 mg, 1 eq.) and triethylamine (1.5 mmol, 220 μL, 1.5 eq.) 
was suspended in dry dichloromethane in a separate vial.  The solution of 6 was added 
drop-wise over 30 minutes and allowed to stir overnight.  The solution was then extracted 
with 0.01 M HCl solution and dichloromethane twice, the organic layers were collected, 
and evaporated to yield a viscous, orange-brown liquid.  This liquid was then subject to 
column chromatography, to afford the desired product (clear viscous liquid, 76%). 
Synthesis of 1,4-O-methacryloylhydroquinone (8).   
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Hydroquinone (1.0 g, 9.09 mmol, 1.0 eq.) and triethylamine (4.68 mL, 3.4 g, 3.33 mmol, 
3.7 eq.) were dissolved in 75 mL of CH2Cl2 and chilled to 0 °C.  Methacryloyl chloride 
(3.28 mL, 3.52 g, 3.33 mmol, 3.7 eq.) was then added drop wise to the solution while 
stirring.  The reaction mixture was allowed to warm to room temperature while stirring 
overnight.  The mixture was washed thrice with 1 M NaOH, once with brine, and then 
dried over anhydrous sodium sulfate.  The solvent was subsequently removed using 
rotovap evaporation, and the product was purified by silica gel chromatography using 
10:1 hexanes:ethyl acetate to give 2.24 g (white fluffy solid, 100%). 
UV-decaging kinetics of O,O'-(2-((methacryloyloxy)methyl)-2-methylpropane-1,3-diyl) 
bis(1-(2-nitrophenyl)ethyl) disuccinate (4).  
To assess the decaging kinetics of the UV-responsive monomer and control monomer, 50 
μM solutions of compound 4 and compound 7, dissolved in 1:1 MeCN:H2O, were 
subjected to continuous long wave 365 nm UV-irradiation.  As a positive control for UV-
decaging of the nitrophenyl group, 4-(1-(2-nitrophenyl)ethoxy)-4-oxobutanoic acid was 
also investigated.  Aliquots were removed and analyzed using liquid chromatography-
mass spectrometry. 
UV-responsive nanoparticle synthesis by mini-emulsion polymerization.   
UV-deprotection of the o-nitrobenzyl group was monitored via liquid chromatography-
mass spectrometry with results confirming rapid photolysis under 365 nm light (t1/2 ~2.5 
min) (SI Fig. 2).  Having demonstrated that the monomer was capable of undergoing the 
photolysis reaction to afford carboxylic acids, we synthesized the eNPs following our 
previously published procedure with an oil-in-water, mini-emulsion, base-catalyzed 
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polymerization.7 Resulting particles were small with relatively monodisperse populations 
(100-200 nm, PDI < 0.1).  
Synthesis of UV-responsive nanoparticle followed procedures previously reported by 
Griset et al.166  Briefly, 50 mg of compound 4 and 0.5 mg of crosslinker 8 (1% w/w) were 
dissolved in 460 μL of dichloromethane (DCM).  A separate aqueous solution of 5 mg 
(10% w/w) of sodium dodecylsulfate (SDS) was dissolved in 2.0 mL of pH 7.4 phosphate 
buffer (5 mM).  The organic and aqueous phase were then combined and sonicated for 10 
minutes at 80 W with a 1 second pulse, 2 second delay under argon atmosphere to create 
an oil-in-water emulsion suspension. Following sonication, 20 μL of 0.2 M ammonium 
persulfate and 2 μL of tetramethylethylenediamine were added with vigorous stirring 
under argon atmosphere.  The system was opened to the air after 2 hr and left stirring 
overnight, and dialyzed for 24 hours in pH 7.4 phosphate buffer (5 mM) to remove 
excess surfactants and salts.  When synthesizing rhodamine-labeled nanoparticles, 0.05 
mg of PolyFluor™ 570 (Methacryloxyethyl Tricarbonyl Rhodamine B) (Polysciences, 
Inc.) was dissolved in the DCM along with the monomer and crosslinker before addition 
of the organic phase to the aqueous phase. When synthesizing PaxOG loaded-
nanoparticles, 0.1 mg of paclitaxel Oregon Green-488 Conjugate (Invitrogen) was 
dissolved in the DCM along with the monomer and crosslinker before addition of the 
organic phase to the aqueous phase.  
Dynamic light scattering (DLS).   
UV-responsive nanoparticles and controls were diluted 300X and exposed to UV 
irradiation.  At each time point, aliquots were removed and sized using a Brookehaven 
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dynamic light scattering instrument.  All measurements were performed in triplicate or 
with N time ≥ 3 repeats. 
Scanning electron microscopy (SEM).   
UV-responsive nanoparticles were diluted 1,000X and exposed this suspension to 0, 2.5, 
or 10 minutes of long-wave UV irradiation.  At each time point aliquots were plated on 
silicon wafers and allowed to air dry in the dark overnight.  The wafers were then affixed 
to aluminum stubs with copper tape and sputter coated with 5 nm Au/Pd.  These samples 
were then imaged using a Zeiss Supra 55VP field emission SEM with an accelerating 
voltage of 2 kV and working distance of 5 cm. 
Light microscopy.   
Nanoparticles were diluted 1000X and, due to the net-negative surface charge of our 
nanoparticles, were immobilized on poly-L-lysine coated microscope glass slides. 
Approximately 10 μL of the diluted solution was placed on the slide and a non-coated 
glass cover slip was placed on top. We used an Olympus IX81 photo-activation system 
for this study. The camera was programmed to take one still image after every 15 seconds 
of UV irradiation, with the entire duration of the study being 20 minutes. An internal long 
wave UV light source (λ = 365 nm) was used for continuous irradiation of the 
experiment. For image acquisitions, an excitation wavelength of λ = 548 nm was used, 
with an observed wavelength of λ = 570 nm. Only one light source was active in either 
the radiation or imaging phase. Thermostatic control was used throughout to maintain 
room temperature throughout the experiment.  
Zeta potential.   
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UV-responsive nanoparticles and controls were diluted 300X in de-ionized water (final 
concentration of polymer 750 µg/mL) at room temperature and exposed to UV 
irradiation.  At each time point, aliquots were removed and zeta potential measured using 
a Brookehaven zeta sizer instrument.  All measurements were performed in triplicate or 
with N time ≥ 3 repeats. 
Cell culture 
INS1 832/13 cells were cultured in RPMI 1640 media supplemented with 10% FBS, 
10mM HEPES buffer, 1mM pyruvate, 50 µM 2-beta-mercaptoethanol, 50 units/ml 
penicillin, and 50 g/ml streptomycin. Cells were used between passage 60 and 75. 
Animals 
Islet isolation was performed on 12- to 13-week-old C57Bl6 male mice. They were 
housed in accordance with the Boston University Institutional Guidelines for Animal 
Care (IACUC no. 14855) in compliance with United States Public Health Service 
Regulation. Animals were fed standard chow and kept at normal housing conditions (19-
22 °C and a 14:10-h light-dark cycle) until death by CO2 asphyxiation and cervical 
dislocation. 
Islet isolation and culture 
Islets of Langerhans were isolated as described previously 132. Shortly, the pancreata were 
inflated with RPMI media containing collagenase (Roche Applied Science). After 10 min 
of digestion at 37 °C, the islets were isolated using Histopaque-1077 (Sigma) gradient. 
Isolated islets were cultured in RPMI 1640 media supplemented with 10% FBS, 50 
units/ml penicillin, and 50 g/ml streptomycin.  
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Islet dispersion and re-aggregation to form “pseudo” islets 
After overnight incubation following isolation, islets were incubated with accutase 
(Company) for 10 min at 37 °C in order to disperse the islets into individual cells. To 
form each pseudo-islet, 5000 cells were plated in one well of a 96-well V-bottom plate. 
The plate was then centrifuged at 1000 RPM for 3 min to pellet the cells and promote 
pseudo-islet formation. The pseudo-islets were incubated overnight before starting fatty 
acid treatment for two days. 
Palmitate complexed to BSA 
Palmitate was dissolved in DMSO and then this solution was dissolved at 45 °C in RPMI 
1640 media containing 6.7% fatty acid-free BSA (Calbiochem) to make a 4 mM (10X) 
stock. For control BSA conditions a 10X stock of RPMI 1640 media containing 5% BSA 
and 1% DMSO was used. For the treatment conditions, the 10X stocks were added to 
RPMI 1640 media containing 1% FBS, 50 units/ml penicillin, and 50 g/ml streptomycin 
and glucose at 10 mM. The pH of the treatment medias was then adjusted to 7.4 followed 
by sterile filtration before treating the INS1 cells for 20 hours. 
Oleate-palmitate complexed to BSA 
Palmitate and oleate were first dissolved in 150mM NaCl solution then this solution was 
dissolved at 37 °C in 150mM NaCl solution containing 16.75% fatty acid-free BSA to 
make a 10 mM (50X) stock. For the treatment conditions, the 10X stocks were added to 
RPMI 1640 media containing 1% FBS, 50 units/ml penicillin, and 50 g/ml streptomycin 
and glucose at 10 mM. The pH of the treatment medias was then adjusted to 7.4 followed 
by sterile filtration before treating the mouse pseudo-islets for 48 hours. 
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Treatment of INS1 and mouse islets with eNPs and fatty acids 
Prepared eNPs were kept in dark so as not to expose to excess light. Briefly before 
treatment, eNPs were vortexed for 10 seconds before diluting into the treatment medias. 
Cells were then incubated with eNPs for the indicated times, concurrent with fatty acid or 
BSA treatment. Cells were washed with media or PBS before assaying. 
The UV-eNP dose per cell in INS1 cells was estimated at ~1 µg/104 cells as calculated: 
UV-eNPs were diluted to 25 µg/mL in 100uL of solution (for 1 well of a 96-well plate), 
which contained ~25,000 cells/well. The mouse islet experiments used only 5000 
cells/well (in 1 well of a 96-well plate) in the same 100uL volume of media, so the 
effective concentration of UV-eNPs to equate to ~1 µg/104 cells would be 5 µg/mL for 
the mouse pseudo-islets. 
UV activation of eNPs in cells was performed using a compact UV lamp, with long wave 
UV at 365nm, 115V (Model UVL-21 Blak Ray Lamp, UVP, Upland, California). UV 
exposure was performed for 5 minutes at room temperature with plate lids removed and 
the lamp placed above cells on the culture plates. The non-UV control plates were left at 
room temperature for the same 5 minutes but kept in the dark. Cells and eNP stocks were 
kept in the dark as much as possible to prevent ambient light exposure. 
Flow cytometry 
Fluorescence-activated Cell Sorting (FACS) Analysis—INS1 cells were infected with 
lentivirus encoding either for GFP-LC3 (12). The cells expressing GFP-LC3 were then 
sorted according to GFP intensity using MoFlo Cell Sorter. GFP-LC3 expressing INS1 
cells were then imaged using a confocal microscope to visualize GFP-LC3 punctate dots 
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within cells. GFP-LC3 was excited with 488nm laser and emission was captured from 
495-530nm. 
FACS analyses of rhodamine-labelled eNP-treated cells was done with 620 FACScan. 
FACS data analysis was performed using FACScalibur (Beckman Coulter). Cell debris 
was excluded by gating on the forward and side scatter plot. The cells were trypsinized, 
washed twice with PBS by centrifugation, and then subjected to flow cytometry. For cell 
death measurements, 1 µg/mL propidium iodide (Invitrogen) was added to the PBS 
solution of the resuspended cells before flow cytometry.  
Lysosensor staining and image analysis  
Cells were stained with 1 µM LysoSensor yellow/blue for 5 min followed by confocal 
imaging using a 360 nm excitation and collecting images at the yellow wavelength range 
(510–641 nm) and at the range of blue wavelength (404–456 nm). The ratio between 
yellow and blue was calculated using Metamorph software.  
Western blot 
Samples were prepared as described previously 134. They were loaded in 4-12% 
polyacrylamide gel (Invitrogen) and transferred onto a polyvinylidene difluoride 
membrane (Invitrogen) using a wet (tank) transfer machine. LC3 (Cell Signaling), 
GAPDH (Cell Signaling), and p62 (Cell Signaling) antibodies were used according to the 
manufacturer’s instructions. 
Insulin secretion for INS1 cells 
Prior to glucose-induced insulin secretion, cells were cultured for two hrs in RPMI 
containing 2 mM glucose without serum. Cells were then washed and pre-incubated for 
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30 min in DMEM (XF Assay medium from Seahorse Biosciences, Billerica, M.A.) 
containing 2mM glucose, 0.05% BSA, pH 7.4. This was followed by 60 min incubation 
in media containing either 2 mM or 12 mM glucose. Media was collected and stored at –
20°C for insulin measurement. Insulin was measured by HTRF insulin assay (Cisbio 
bioassays). 
Insulin secretion for mouse pseudo-islets 
Prior to glucose-induced insulin secretion, islets were pre-incubated for 30 min in 
DMEM (XF Assay medium from Seahorse Biosciences, Billerica, M.A.) containing 
2mM glucose, 0.05% BSA, pH 7.4. This was followed by 30 min incubation in media 
containing either 2.8 mM or 16.7 mM glucose. Media was collected and stored at –20°C 
for insulin measurement. Insulin was measured by HTRF insulin assay (Cisbio 
bioassays). 
Statistics 
Unless stated otherwise, error bars indicate means S.E., and an unpaired t test was used to 
validate statistical differences between two conditions. To determine significance of 
multiple conditions, a one-way ANOVA with post hoc Tukey’s test was used. 
 
RESULTS  
Synthesis of the UV-responsive monomer and eNPs 
The 1-(2-nitrophenyl)ethan-1-ol group was selected for protecting the carboxylic 
acid functionality due to its fast deprotection reaction upon photolysis and ease of 
synthesis. The synthesis of the UV-eNP monomer is shown in Fig. 4.S1. Briefly, the 
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light-sensitive caging moiety was prepared through methylation of 2-nitrobenzaldehyde.  
The subsequent secondary alcohol was added to succinic anhydride to afford the photo-
caged succinic acid. This succinate product was then subjected to carbonyl conjugation 
with the mono-protected tris(hydroxymethyl)ethane.  Upon deprotection of the silyl 
protecting group, the mono-alcohol product was added to methacryloyl chloride to afford 
the final light-sensitive monomer.  
Characterizing UV-deprotection, eNP synthesis and particle swelling 
UV-deprotection of the o-nitrobenzyl group was monitored via liquid 
chromatography-mass spectrometry (LC-MS) with results confirming rapid photolysis 
under 365 nm light (t1/2 ~2.5 min) (Fig. 4.S2).  Having demonstrated that the monomer 
was capable of undergoing the photolysis reaction to afford carboxylic acids, we 
synthesized the eNPs following our previously published procedure with an oil-in-water, 
mini-emulsion, base-catalyzed polymerization.7 Resulting particles were small with 
relatively monodisperse populations (100-200 nm, PDI < 0.1).  
To confirm eNP deprotection and swelling, we exposed particles to UV-
irradiation (365 nm) for 10 minutes and then imaged an aliquot of particles using 
scanning electron microscopy (SEM). Particles demonstrated an increase in size as well 
as an apparent increase in porosity (Fig. 4.1B). Increased porosity occurs due to 
decreasing particle density. Upon swelling, the same mass of material occupies an 
increased volume. To confirm that swelling occurred to the eNP population at large, and 
not merely to individual particles visualized using SEM, dynamic light scattering (DLS) 
was also used to monitor particle size as a function of UV-irradiation and time. Fig. 4.1C 
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demonstrates a significant three to five-fold increase in overall eNP diameter with time 
when exposed to UV-light but no size change without UV-exposure. Lastly, the surface 
charge (i.e., zeta potential) of eNPs was monitored during UV-exposure and shown to 
confirm the deprotection process (Fig. 4.1D). The Zeta potential becomes increasingly 
negative with additional UV-irradiation reflecting the deprotection of greater numbers of 
carboxylic acid groups, which yield negative ionic charges at neutral physiological pH.  
 
Cytotoxicity, endocytosis, and intracellular localization of eNPs   
The cytotoxicity of eNPs was determined in the INS1 insulinoma line. Briefly, 
cells were exposed to eNPs for 4 hours and then irradiated (or not irradiated) with UV-
light for 5 min, followed by an additional 20 hours of incubation. Viability was 
determined using propidium iodide staining and flow cytometry. No significant 
cytotoxicity was observed up to 25 µg/mL with or without UV-irradiation (Fig. 4.2A). 
However, at a dose of 250 µg/mL there was a significant toxicity that was entirely absent 
in cells treated with UV in the absence of eNPs and in cells treated with eNPs but without 
exposure to UV. This demonstrates the UV-dependent activation of the particles in intact 
cells. A dose of 25 ug/mL was selected for all further studies in order to achieve the 
highest concentration of eNPs possible without incurring cytotoxic effects upon UV-
irradiation. 
 To investigate cellular uptake and intracellular distribution of eNPs in INS1 cells 
and primary mouse islet cells, we employed confocal microscopy and flow cytometry. 
Using the previously selected 25 ug/mL dose, rhodamine-labeled eNPs were incubated 
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with INS1 cells for different durations. Flow cytometry demonstrated rapid cellular 
uptake of eNPs (Fig. 4.2B). Over 80% of cells showed eNP uptake within 30 minutes and 
nearly 100% of cells as early as 3 hours. Furthermore, cells showed a dose-dependent 
uptake of eNPs (Fig. 4.S3). Finally, we sought to determine the localization of eNPs 
within the cell, as the specific size of the eNPs (~100 nm) should determine their uptake 
and localization within the endosome-lysosome system 167. Co-localization imaging with 
Lysotracker dye confirmed cellular trafficking of eNPs into lysosomes in INS1 (Fig. 
4.2C-D) and primary mouse islet (Fig. 4.2E-F) cells.  
 
Acute re-acidification with eNPs restores lysosomal acidity and function in beta-cells 
exposed to fatty acids 
Autophagy plays an essential role in beta-cell homeostasis and function, 
supporting various cell processes including proper nutrient metabolism and turnover of 
damaged intracellular proteins and organelles 70, 103, 152. We have previously reported that 
both oleate and palmitate can inhibit autophagic flux, which in turn affects beta-cell 
viability and function. Importantly, it was determined that fatty acid-induced impairment 
of lysosomal acidity was concomitant with decreased clearance of autophagosomes after 
16-24 hours of LT 103. Thus, having demonstrated eNP function and cellular uptake into 
lysosomes, the essential remaining question for these studies was whether eNPs could 
restore lysosomal acidity and whether this would be sufficient to promote autophagic flux 
and rescue beta-cell function.  
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Restoration of lysosomal acidity using the eNPs was first examined in INS1 cells 
exposed to palmitate. INS1 cells were exposed to 0.4 mM palmitate complexed to BSA 
(Palm:BSA) at a 4:1 ratio or a control amount of BSA for 20 hours and concurrently 
incubated with or without 25 µg/mL eNPs. After 20 hours, cells were either UV-
irradiated for 5 minutes (+UV) or left untreated (NO UV); one hour later lysosomal 
acidity was assessed by Lysosensor staining and confocal imaging (Fig. 4.3A). To 
demonstrate specificity of Lysosensor staining of lysosomes, cells were treated with 
bafilomycin (100µM) for 2 hours before imaging, which shows no Lysosensor staining 
due to neutralization of lysosomal pH. Palmitate exposure significantly increased 
lysosomal pH and size compared to control BSA-treated cells (Fig. 4.3B-C). Treatment 
with eNPs without UV-irradiation had no significant effect on changing lysosomal pH or 
average size in palmitate-treated cells. In contrast, treatment with eNPs that were 
subsequently UV-irradiated induced a significant decrease in lysosomal pH in palmitate-
treated cells (Fig. 4.3C). A reduction in average lysosomal size was also observed with 
eNPs that were UV-irradiated; however this was not statistically significant from the 
palmitate -treated cells. Thus, light-activated eNPs enable acute acidification of 
lysosomes within 1-2 hours of UV-irradiation.  
 
Lysosomal re-acidification with eNPs restores autophagic flux in beta-cells exposed to 
fatty acids 
To investigate whether restoration of lysosomal acidity relieved the inhibition of 
autophagic flux in INS1 cells exposed to palmitate, we monitored intracellular 
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accumulation of microtubule associated protein 1A/1B light chain 3 (LC3-II). During 
autophagosome formation, phosphatidylethanolamine is conjugated to cytosolic LC3 
(i.e., LC3-I) to form LC3-II, which is sequestered in autophagosome membranes. Thus, 
LC3-II accumulation serves as a surrogate marker for autophagosome accumulation 165. 
Western blot analysis of LC3-II demonstrated a significant accumulation of 
autophagosomes after palmitate treatment. Clearance of autophagosomes in palmitate-
treated cells was observed following treatment with eNPs and subsequent UV-irradiation 
(Fig. 4.4A-B). The reduction in the number of autophagosomes following treatment with 
eNP + UV irradiation was further confirmed by imaging GFP-LC3 puncta for 
autophagosomes in INS1 cells, which showed a decrease in number of autophagosomes 
in cells treated with eNP and UV-irradiation (Fig. 4.4D).  To further confirm the effect of 
treatment on autophagic degradation we monitored levels of p62 protein, a protein that is 
degraded during autophagy and is used as a marker for autophagic flux 165. Palmitate 
exposure increased p62 levels indicating inhibition of autophagic flux and accumulation 
of autophagic substrate. eNP treatment followed by UV-irradiation significantly 
decreased (i.e., returned toward control values) p62 levels, suggesting an increase in 
autophagic flux when lysosomal acidity is restored by UV-activation of eNPs (Fig. 4.4C). 
Thus, treatment with UV-responsive eNPs to acidify lysosomes was effective in 
promoting autophagosome clearance and restoring autophagic flux under palmitate 
treatment. 
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Promoting autophagic flux with eNPs increases glucose-stimulated insulin secretion in 
beta-cells exposed to fatty acids 
Lastly, having observed the recovery of both lysosomal acidity and autophagic 
flux, we investigated whether eNP treatment could improve beta-cell function (i.e., 
insulin secretion) in INS1 cells and primary mouse islets exposed to fatty acids. After 18 
hours of exposure to 0.4 mM palmitate, INS1 cells show inhibited GSIS, an indicator of 
beta-cell dysfunction. Treatment with eNPs followed by 5 minutes of UV-irradiation 
acutely restored GSIS in INS1 cells (Fig. 4.5A). Treatment with eNPs alone showed a 
trend towards increasing GSIS, but was not significant. 
 Next, we performed similar experiments on re-aggregated islets formed from 
primary mouse islets (see Methods), as the use of uniform re-aggregareted islets increases 
reproducibility by eliminating islet size and other characteristics as factors affecting islet 
function; furthermore, re-aggregated islets have been shown to retain functional GSIS 
and other islet characteristics 168. The islets were exposed to a mixture of 200 µM oleate 
and palmitate for 48 hours. The combination of oleate and palmitate (monounsaturated 
and saturated fatty acid, respectively) complexed to BSA at a 2:1 ratio represents a more 
physiological fatty acid mixture, rather than palmitate alone. Exposure to oleate-palmitate 
inhibited GSIS in mouse islets (Fig. 4.5B). Initially we found that treatment with 25 
µg/mL UV-eNPs further inhibited GSIS in mouse islets, possibly indicating toxic effects 
of UV-eNPs (Fig. 4.S4). We then re-calculated UV-eNP dose as (µg/cell) instead of 
(µg/mL), since this may be a more accurate indicator of UV-eNP exposure per cell. 
Accordingly the UV-eNP dose per cell in INS1 cells was estimated at ~1 µg/104 cells 
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(calculations detailed in Methods). An effective concentration of UV-eNPs to equate to 
~1 µg/104 cells would be ~5 µg/mL for the mouse islets. Treatment with UV-eNPs at 5 
µg/mL for 24 hours was well-tolerated in mouse islets; thus this dose was used for GSIS 
studies. Treatment with 5 µg/mL eNPs for 24 hours followed by 5 minutes of UV-
irradiation acutely restored GSIS in mouse islets exposed to oleate-palmitate (Fig. 4.5B).  
UV-activated eNPs increase turnover of mitochondria and improve mitochondrial 
function under fatty acids 
Finally we investigated whether eNP-induced lysosomal acidification improves 
GSIS through enhanced turnover of mitochondria, resulting in improved mitochondrial 
function. Palmitate increases mitochondrial mass as assessed by MitoTracker Green 
staining and flow cytometry 169 (Appendix Three, Fig. 4.S5A). The increase in mass is 
concomitant with reduced mitochondrial turnover under palmitate as measured by pulse-
chase labeling with MitoTracker Green and MitoTimer (Appendix Three). Treatment 
with eNPs followed by UV activation led to a significant decrease in mitochondrial mass 
under palmitate (Fig. 4.S5A), suggesting increased mitochondrial turnover upon 
lysosomal acidification. This effect is blocked by 1 hour pre-treatment with bafilomycin 
(200nM) before UV-irradiation, indicating that the eNP effect is dependent upon 
lysosomal acidification (Fig. 4.S5B). Furthermore palmitate exposure leads to altered 
mitochondrial oxygen consumption rate (OCR), characterized by reduced glucose-
stimulated OCR, reduced spare capacity, and increased OCR not linked to ATP synthesis 
(oligomycin-insensitive OCR) (Fig. 4.S5C-E). Treatment with eNPs followed by UV-
irradiation significantly increased mitochondrial spare capacity under palmitate (Fig. 
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4.S5D). UV-activated eNPs also trended towards increased glucose-stimulated OCR and 
trended towards decreased oligomycin-insensitive OCR under palmitate (Fig 4.S5C and 
E). Taken together the results may suggest that increased mitochondrial turnover upon 
lysosomal acidification positively affects mitochondrial function under palmitate 
exposure. 
 
DISCUSSION 
Impaired lysosomal acidification has been implicated as a causative event 
resulting in decreased autophagic flux and cellular function in several pathologies, 
including beta-cells exposed to LT. These findings raise the question whether restoring 
lysosomal acidity would alleviate the block in autophagy and promote proper cellular 
quality control and function. This question could not be addressed due to the lack of a 
technology to deliver acid into a specific subcellular compartment at a desired time. In 
this study, we have engineered, synthesized, and characterized a UV-responsive eNP 
designed to acidify in response to an external trigger (UV-irradiation) and thereby 
achieve acute restoration of lysosomal acidity and autophagic flux. In this work, we 
demonstrate the effects of eNP treatment in both INS1 cell lines exposed to fatty acids as 
well as a primary mouse islet model of LT-induced beta-cell dysfunction. Overall the 
experiments in INS1 cells and primary islets demonstrate the efficacy of eNPs in 
restoring lysosomal acidity and autophagic flux, which in turn partially reverses 
mitochondrial and beta-cell dysfunction under LT. Importantly the acute acidification of 
lysosomes occurred after 20 hours of fatty acid treatment, demonstrating the ability of 
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eNPs to acutely rescue autophagy and insulin secretion in INS1 and primary mouse beta-
cells. Thus targeting lysosomal acidity with eNPs represents a novel strategy to improve 
lysosome function and autophagic flux in pancreatic beta-cells and holds potential for 
treating lysosome dysfunction in other diseases where impaired autophagic flux 
contributes to the pathology.  
These results demonstrate that impaired lysosomal acidification and autophagic 
flux play a causative role as mediators of beta-cell dysfunction in response to LT. 
Furthermore, activation of eNPs was performed at a point where LT-induced beta-cell 
dysfunction had already occurred, and insulin secretion was assessed 2-3 hours after eNP 
activation. Thus, these results also demonstrate the possibility of using eNPs to acutely 
rescue lysosomal acidity and subsequently reverse beta-cell dysfunction in relation to 
obesity/type 2 diabetes. Interestingly the eNP-induced improvement of beta-cell function 
may depend upon increased mitochondrial turnover leading to improved mitochondrial 
function. Further studies are needed to further examine how lysosomal acidification by 
eNPs mediates mitophagy specifically, and whether remaining mitochondria do indeed 
display increased function. 
Interestingly, treatment with eNPs alone (NO UV) had a non-significant, but 
strong trend towards restoring GSIS in INS1 cells treated with palmitate but not mouse 
islets treated with oleate-palmitate. Treatment with different types of NPs has been 
reported to modulate autophagy 170, and in our study eNP treatment alone may increase 
autophagic capacity by upregulating autophagosome number (trend seen in Fig. 4.4A-B). 
Such an effect draws parallels to how rapamycin treatment, which will upregulate 
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autophagosome formation 165, 171, can also improve beta-cell function under fatty acid 
exposure 103. Augmenting total autophagic capacity by increasing autophagosome 
number represents a different strategy for modulating autophagic flux as compared to 
specifically targeting the deficit in lysosomal acidity. The photo-activatable eNPs show 
for the first time how, mechanistically, these strategies differ yet both can have effects on 
autophagic flux and beta-cell function during lipotoxicity. Importantly, rescuing 
compromised lysosomal acidity with UV-irradiation of eNPs robustly increases 
autophagic flux and restores GSIS.  It is possible that UV-activated eNPs may have 
effects through targets other than the lysosome, which will require more thorough 
investigation in order to assess any off-target effects. Also the eNPs alone, via uptake 
through the endosome-lysosome system, may exert effects independent of autophagy on 
beta-cells. Though more work is needed to fully understand any off-target effects of 
eNPs, our findings show how acute acidification of lysosomes with eNPs represents a 
novel strategy to improve lysosome function and autophagic flux in pancreatic beta-cells. 
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FIGURES 
Figure 4.1.  Characterization of UV-activation of eNPs.  
A) Schematic of eNP mechanism of UV-triggered acidification and swelling. B) 
Scanning electron micrograph images of eNPs before (left) and after (right) UV-
irradiation demonstrate UV-triggered swelling. C) Dynamic light scattering 
characterization of eNP diameter as a function of UV-irradiation and duration. eNPs 
exposed to UV-light (hashed bars) increase 350-500% in diameter; without UV-exposure, 
eNP diameter remains constant. D) Zeta potential (i.e., surface charge) of eNPs becomes 
more negative with additional UV-irradiation due to the deprotection of more carboxylic 
acid functionalities.  
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Figure 4.2.  eNP cytotoxicity, endocytosis, and localization in INS1 and mouse beta-
cells. 
A) Dependency of eNP toxicity on dose and UV-activation. Cells were incubated with a 
range of eNP concentrations for 4 hours. eNPs were then UV-activated by 5 minutes of 
cellular exposure to UV. eNPs at 250 µg/mL induced significant cell death only when 
UV-irradiated, indicating robust UV-activation of eNPs in intact cells. To avoid 
cytotoxicity of UV-irradiated eNPs, a treatment dosage of 25 µg/mL was chosen for 
further studies. Shown is the mean ± SD. * = p<0.01 v. NO UV 250 µg/mL eNP. (n = 3).  
B) Quantification of rhodamine-labeled eNPs (Rhod-UV-eNPs) uptake in INS1 cells by 
flow cytometry. Rhod-UV-eNP uptake occurs within 1 hour, with complete uptake after 
24 hours incubation. Shown is the mean ± SD. (n = 3). C) Confocal microscopy images 
of Rhod-eNPs in INS1 cells. Rhod-eNPs (red) localize within the lysosomal 
compartments (Lysotracker – green channel) of INS1 cells. Scale bar = 10 µm. D) 
Frequency scatterplot of Lysotracker (green channel) and Rhod-eNP (red channel) from 
(C) image. Rr value is Pearson’s coefficient which is consistent with high colocalization 
of Rhod-eNPs and lysosomes. E) Images of Rhod-eNPs in mouse islet cells. Rhod-eNPs 
(red) localize within the lysosomal compartments (Lysotracker – green channel) of 
primary mouse islet cells. Scale bar = 10 µm. F) Frequency scatterplot from (E) image.  
A high-degree of co-localization of Rhod-eNPs and lysosomes is observed.  
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Figure 4.3.  Effect of UV-activated eNPs on lysosomal pH in INS1 cells exposed to 
fatty acid.  
A) Schematic of experimental protocol for Palm:BSA and eNP treatment followed by 
acute UV-activation before assaying lysosomal acidity or cellular function. B) Confocal 
microscopy images of INS1 cells treated with the indicated conditions and stained with 
pH-sensitive Lysosensor dye to assess lysosome acidity. Bafilomycin (Baf, 100µM) was 
used to demonstrate specificity of Lysosensor staining of lysosomes. Scale bar = 10 µm. 
C) Average lysosomal pH and area per cell for cells exposed to control BSA, palmitate 
(Palm:BSA), or palmitate with eNP treatment (Palm:BSA+eNP), then UV-irraditiated 
(+UV) or no irradiation (NO UV). Average lysosomal pH is not significantly different 
between Palm:BSA and Palm:BSA+eNP groups when eNPs are not UV-activated. Cells 
treated with Palm:BSA+eNP and UV-irradiated show significant restoration of lysosomal 
pH compared to Palm:BSA cells. Shown is the mean ± SE. * = p<0.05 v. Palm:BSA. (n = 
3 for pH values and n = 2 for size values with 20-30 cells analyzed per experiment). 
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Figure 4.4.  Effect of eNP-induced lysosomal acidification on autophagic flux in 
INS1 cells exposed to fatty acid.  
A-C) Western blot analysis of LC3-II and p62 protein levels in INS1 cells.  Clearance of 
accumulated autophagosomes (LC3-II) and p62 protein is observed upon treatment with 
eNPs and 5 minutes of UV-irradiation in INS1 cells exposed to palmitate (Palm:BSA) 
compared to control (BSA)-treated cells. Shown is the mean ± SE. * = p<0.05 between 
indicated conditions. (n = 6). D) Confocal microscopy images of GFP-LC3 expressing 
INS1 cells. Treatment with UV-eNPs and 5 minutes of UV-irradiation decreased LC3-
GFP puncta accumulation under palmitate. Scale bar = 10 µm. 
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Figure 4.5. Effect of UV-activated eNPs on insulin secretion in INS1 cells and mouse 
islets exposed to fatty acid.  
A) GSIS measurements in INS1 cells exposed to palmitate (Palm:BSA) for 20 hours. 
Treatment with 25 µg/mL eNPs (~1 µg/104 cells) with UV-irradiation results in 
significant recovery of GSIS (Stim: 12mM glucose, Basal: 2mM glucose) after exposure 
to palmitate (Palm:BSA). Shown is the mean ± SE. (n = 5). B) GSIS measurements in re-
aggregated mouse islets exposed to oleate-palmitate (OP:BSA) for 48 hours Treatment 
with 5 µg/mL eNPs (~1 µg/104 cells) with UV-irradiation results in significant restoration 
of GSIS (Stim: 16.7mM glucose, Basal: 2.8mM glucose) after exposure to oleate-
palmitate (OP:BSA). Shown is the mean ± SE. * = p<0.05 between indicated conditions. 
(n = 5). 
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Supplementary Figure 4.S1. Schematic of eNP synthesis 
Synthesis schematic for: (top) UV-responsive monomer; (middle) non-UV-responsive 
control; (bottom) crosslinker. The different steps are detailed in the Methods section. 
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Supplementary Figure 4.S2. eNP deprotection kinetics 
Deprotection kinetics of UV-responsive monomer (blue diamonds) and non-UV-
responsive control (red squares) when exposed to 365 nm UV-radiation for 30 minutes. 
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Supplementary Figure 4.S3. Dose-dependent uptake of eNPs in INS1 cells 
Rhodamine-labeled eNP uptake was measured by flow cytometry and mean rhodamine 
intensity per cell. A dose-dependent uptake of eNPs was observed. 
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Supplementary Figure 4.S4. Titration of eNP dose in mouse islets 
Re-aggregated mouse islets were exposed to oleate-palmitate (OP:BSA) and treated with 
eNPs at the indicated doses, followed by assessment of GSIS. Treatment with 25 µg/mL 
eNPs inhibited GSIS, whereas 5 or 1 µg/mL eNPs were well-tolerated. 
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Supplementary Figure 4.S5. UV-activated eNPs determine mitochondrial mass and 
function under palmitate 
A) Mitochondrial mass was assessed by MitoTracker Green (MTG) staining and flow 
cytometry in INS1 cells. Treatment with eNPs followed by UV-irradiation reverses the 
accumulation of  mitochondrial mass under palmitate exposure. *=p<0.05 vs. No eNP/No 
UV condition for BSA and Palm:BSA, respectively. B) Mitochondria mass was again 
assessed with MTG staining followed by flow cytometry. Ptreatment with bafilomycin 
(Baf, 200nM) was conducted 1 hour before UV-irradition in cells treated with eNPs 
followed by UV-activaiton. Pre-treatment with bafilomcyin prevented the reduction in 
mitochondrial mass induced by eNP treatment. *=p<0.05 vs. No eNP/No UV condition 
for Palm:BSA. C) Glucose-stimulated oxygen consumption rate (OCR) was measured in 
INS1 cells by Seahorse extracellular flux analyses. D) Mitochondrial spare capacity was 
assessed as the % increase in OCR over basal upon FCCP treatment. Reduced spare 
capacity under palmitate is reversed by eNP treatment with UV-activation. *=p<0.05 vs. 
BSA No eNP/+UV. #=p<0.05 vs. Palm:BSA No eNP/+UV condition. E) The percent of 
basal OCR remaining after oligomycin treatment was quantified to determine rates of 
mitochondrial OCR not linked to ATP synthesis (oligomycin-insensitive OCR). 
*=p<0.05 vs. BSA No eNP/+UV. 
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CHAPTER FIVE: General Discussion 
Overall the main focus of this thesis work was to investigate the role of specific 
mechanisms responsible for determining mitochondrial function in the context of 
pancreatic beta-cells exposed to nutrient excess. In particular, the work investigated the 
processes of mitochondrial dynamics (fusion-fission), mitochondrial motility, and 
autophagy. Extensive research has described how these mechanisms determine 
mitochondrial function; thus these three different yet interconnected processes represent 
mitochondrial adaptive mechanisms. However there remain several knowledge gaps in 
understanding the relationship between these three adaptive mechanisms and what role 
each plays in both coordinating mitochondrial turnover and determining beta-cell 
adaptation to nutrient environment.  
In 2008 Twig et al. described how mitochondria undergo paired fusion-fission events 
(mitochondrial dynamics) 4. Importantly, after the fission event two dissimilar daughter 
mitochondria are generated. One daughter hyper-polarizes and is able to regain a normal 
membrane potential and re-enter the mitochondrial life cycle by undergoing subsequent 
fusion events. The major observation was that the other daughter mitochondrion could be 
depolarized and subsequently eliminated by autophagy. Thus mitochondrial dynamics 
were first shown to be essential for generating depolarized mitochondria as the substrate 
for mitophagy 6, 54. These related studies have used depolarization as a marker for 
impairment; however it is not fully understood whether damaged/aged proteins are 
particularly segregated and contained in mitochondria targeted for autophagy. 
Interestingly, E. coli are able to actively sort unfolded proteins and segregate the 
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aggregates into one daughter bacteria172, which begs the question if mitochondria have 
retained a similar mechanism. Fusion and fission have been implicated sorting and 
segregation of mitochondrial proteins 173, respiratory chain components 174, 175 and 
mtDNA 176, 177, which may represent the key substrates that would benefit from selective 
segregation and turnover via mitophagy. Therefore the bioenergetic status or membrane 
potential of the mitochondrion would represent the detectable phenotype that could be 
recognized by the cellular mitophagy machinery to target for turnover, but the true factor 
of selection would be mtDNA or respiratory chain. Indeed significant evidence supports 
this notion that dynamics and mitophagy may really be designed to select against 
different mtDNAs, including damaged mtDNA or those not fit to the cellular 
environment 5, 178-181. 
What remained ill-defined from these studies was what role fusion and fission play in 
determining turnover rates of individual mitochondria in the network. The majority of 
studies had utilized mitochondrial localization to lysosomes as a marker for mitochondria 
being removed via mitophagy 4, 54. However these studies do not address specifically 
whether the paired processes of fusion-fission actually regulate turnover rates either 
globally or spatially within cells. Indeed answering this question was not readily 
approachable due to the fact that methodologies to assess mitochondrial turnover rates 
did not have intracellular spatial resolution. The most frequently used approach for 
assessing protein turnover rates remains pulse-chase experiments using labelled tracers, 
usually amino acids; therefore determination of individual mitochondrial turnover rates 
are not possible. Other assays that approximate mitochondrial turnover are summarized in 
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Appendix Two; however these myriad of assays do not determine absolute or relative 
rates of mitochondrial turnover. To circumvent this methodological limitation, we 
developed a novel approach utilizing a time-sensitive fluorescent protein targeted to the 
mitochondrial matrix, MitoTimer. Use of MitoTimer expressed in cells allows for the 
first time to evaluate relative changes to mitochondrial turnover rates on the individual 
mitochondrion level.  
MitoTimer fluorescence switches from green-to-red over the course of ~18 hours in a 
time-dependent manner. These unique properties of the Timer protein 75 enabled the 
quantification of relative changes to mitochondrial turnover by comparing levels of new 
(green) and old (red) MitoTimer in individual cells or mitochondria. With this 
methodology come significant technical and interpretive considerations in order to reach 
appropriate conclusions about changes to mitochondrial turnover. These varying concerns 
were discussed previously at length in Chapter Two: Part Two of the thesis (also 
published Methods in Enzymology 182). We also point the reader to our collaborator’s 
work utilizing MitoTimer to study turnover in the heart, both in vitro 99 and in vivo 183. 
Thus the remainder of this discussion will focus on the insights into mitochondrial 
physiology revealed by MitoTimer and the resulting implications for cellular outcomes. 
Though paired fusion-fission events were found to be important for generating an 
individual depolarized mitochondrion to be removed by mitophagy, it remains unclear 
whether fusion-fission events control actual turnover rates of mitochondria. The 
alternative is that the role of fusion-fission is to occasionally cull one damaged 
mitochondria from the network. Turnover is determined by both degradative mechanisms 
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(mitophagy, proteases) and import of new protein into the mitochondria. MitoTimer 
allows for monitoring of both new protein import and degradation of old protein. 
Importantly, in cells lacking fusion (Mfn1/2 KO) it was found that mitochondrial 
turnover rates, as assessed by MitoTimer age profile, were widely disparate compared to 
wild-type cells. There was significant accumulation of old (red) mitochondria, indicating 
that fusion allows mediates the efficient removal of old mitochondrial protein from the 
network. Other studies have shown that disruption of fusion or fission impacts turnover 
rates of mitochondrial proteins 173, 181. Of relevance to GLT in beta-cells, we showed that 
palmitate, which inhibits fusion 3, decreases mitochondrial turnover as assessed by 
MitoTimer (Appendix Three). Thus without fusion or fission mitochondrial turnover is 
reduced, resulting in the accumulation of mitochondria with aged and potentially 
damaged protein. 
Interestingly the disparate MitoTimer age profiles also revealed possible mitochondrial 
“hubs” for protein import. These individual mitochondrial “hubs” are characterized as 
significantly larger, peri-nuclear mitochondria that contained both high levels of new 
(green) MitoTimer along with a high total protein level (green+red). The remaining 
mitochondria were significantly smaller than the “hub” mitochondria, and varied in color 
from mostly green to mostly red. It remains unclear how mitochondria may transition 
from larger, protein-rich “hubs” to smaller green, yellow, or red mitochondria, or if they 
remain as distinct populations. The latter possibility would have important implications 
for mitochondrial physiology as distinct “hubs” of protein import would then play a 
pivotal role in sharing new protein to the other mitochondria in the network. 
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Unfortunately these studies were not able to correlate MitoTimer age profile to other 
indicators of mitochondrial function such as membrane potential, which was also found 
to be widely disparate in the Mfn1/2 KO cells 77. Thus further studies are needed to 
understand more fully how the differences in mitochondrial protein age dynamics reflect 
different mitochondrial sub-populations, and what relevance these sub-populations 
“revealed” in the Mfn1/2 KO cells have for normal physiology. 
Lastly our MitoTimer studies also investigated the role of mitochondrial spatial 
distribution and motility in determining mitochondrial turnover rates in the cell. To 
address how individual mitochondrion turnover rates may be unequal in a spatially-
complex cell, we expressed MitoTimer in primary hipppocampal neurons from mice. We 
found that mitochondria in the axons contained proportionally older (red) MitoTimer than 
those closer to the soma. In the spatially-complex neuron this puts a high burden of 
mitochondrial quality control in the axons. The older mitochondria in the axons would be 
more susceptible to damaged-induced dysfunction. There is evidence that these 
mitochondria can be locally targeted to autophagosomes or can undergo retrograde 
transport back to the soma for autophagy-mediated removal 184-187. The exact balance 
between these two quality control fates is not currently understood. Our work showed 
that accelerating mitochondrial microtubule-based transport via over-expression of Miro1 
was sufficient to provide younger mitochondria farther out into the axons. Thus 
mitochondrial motility is a critical mechanism for ensuring distribution of younger 
mitochondria throughout the cell, and neurons may face a higher burden to maintain 
adequate mitochondrial quality control due to their spatially-complex architecture. 
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Our recent work demonstrates how MitoTimer readout can be affected by changes to 
mitochondrial protein synthesis and import, fusion/fission, motility, and autophagy. The 
findings demonstrate the key principle that the different mitochondrial adaptive 
mechanisms contribute to mitochondrial lifetime and turnover, both on the cellular level 
and for individual mitochondria. Limiting MitoTimer synthesis or depolarizing 
mitochondria to inhibit protein import both reduced the amount of green (new) 
MitoTimer incorporated into the network. Inhibiting autophagy resulted in the 
preferential accumulation of red (old) MitoTimer protein, demonstrating the decrease in 
turnover of aged mitochondrial protein. Cells deficient in mitochondrial fusion showed 
heterogeneous MitoTimer age among individual mitochondria in the cell, thus depicting 
how mitochondrial fusion acts to coordinate mitochondrial lifetimes among the network. 
Lastly, hippocampal neurons showed a predisposition for red (old) MitoTimer in the 
distal neurites, which could be partially overcome by increasing mitochondrial transport 
via Miro1 overexpression. Thus MitoTimer fluorescence readout can detect changes to 
any of the key mechanisms contributing to the mitochondrial life cycle. In the context of 
this thesis, the work showed the specific interplay of mitochondrial dynamics and 
motility and how they coordinate mitochondrial turnover in the cell. Accordingly, 
physiological or pathological alterations to mitochondrial dynamics or motility will have 
significant implications for mitochondrial turnover rates. 
Chapter Three of this thesis centered on the adaptive mechanism of mitochondrial 
motility, and its role in mediating beta-cell physiology and pathology during high nutrient 
exposure. The regulation of mitochondrial motility has been mainly investigated in 
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neurons due to the large spatial complexity of these cells 115. Important cellular signals 
including calcium and glucose have been implicated in the temporal and spatial 
regulation of mitochondrial movement 61, 133. However less is known about the 
importance of mitochondrial motility in more spatially-confined cells such as pancreatic 
beta-cells. Importantly it is unknown if changes to mitochondrial motility may play a role 
in beta-cell physiological and pathological response to nutrient environment. The thesis 
work investigated whether alterations to mitochondrial motility occur in the beta-cell 
exposed to GLT. A critical nutrient-sensing mechanism was uncovered whereby O-
GlcNAcylation of Milton1 controls mitochondrial dynamics and bioenergetics according 
to nutrient levels. 
The first key finding of Chapter Three was the observation that excess nutrient, or GLT, 
inhibited mitochondrial motility in pancreatic beta-cells, concurrent with mitochondrial 
fragmentation. Mitochondrial motility was significantly inhibited upon exposure to both 
high glucose and fatty acid, suggesting a synergistic effect of nutrient availability on 
mitochondrial motility inhibition. It is fitting that both glucose and fatty acids would feed 
into the hexosamine pathway, thus yielding higher levels of UDP-GlcNAc when both are 
present 66, 135. It was not directly investigated how acute mitochondrial motility is reduced 
upon nutrient exposure, though it was reported that acute glucose induces mitochondrial 
fragmentation 128. Rapid O-GlcNAcylation of Milton1 upon 30 minutes glucose 
stimulation was observed, suggesting rapid modulation of mitochondrial motility in 
response to nutrients. Accordingly GlcNAcylation of Milton1 could serve as a critical 
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and robust nutrient-sensing mechanism to link changes in mitochondrial dynamics and 
motility to changes in nutrients, both glucose and fatty acids. 
In addition to documenting the GLT-induced changes to mitochondrial dynamics and 
motility, the results also establish a novel mechanism regulating GSIS involving 
mitochondrial bioenergetic remodeling mediated by changes to dynamics and motility. 
Upon acute (30 min.) glucose stimulation, Milton1 is rapidly O-GlcNAcylated and 
mitochondrial motility is potentially arrested. At the same time this allows for de-
phosphorylation of DRP1 on its inhibitory serine 637, ultimately promoting fission of 
mitochondria in response to the glucose stimulation. The coordinated motility arrest and 
induced fission support necessary mitochondrial metabolism of the pyruvate from 
glucose, which in turn supports insulin secretion via the ATP-dependent mechanism of 
GSIS. The necessity for acute mitochondrial fission upon glucose stimulation has been 
previously suggested 128, and our work is the first to show that this process involves both 
O-GlcNAcylation of Milton1 and de-phosphorylation of DRP1 to allow fission. In 
addition we showed that blocking fission in human islets exacerbated the GLT-induced 
disruption of mitochondrial membrane potential and GSIS. Thus may represent an 
adaptive mechanism during acute glucose stimulation and chronic nutrient excess. These 
results fit with previous observations that blocking mitochondrial fission inhibits normal 
GSIS, although these previous findings were interpreted to be a result of cumulative 
suppression of mitochondrial quality control 3, 4. Taken together with these previous 
findings, our work does not exclude the fact that prolonged interruption of mitochondrial 
dynamics would indeed affect mitochondrial quality control. Indeed under chronic GLT 
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the initially adaptive fragmentation may ultimately compromise mitochondrial function 
by preventing adequate quality control. Collectively, these results place mitochondrial 
dynamics as a key determinant of bioenergetic remodeling in response to nutrient excess.  
The requirement for mitochondrial dynamics in acute bioenergetic responses raises the 
important question of why changing mitochondrial architecture and movement influence 
functional output of mitochondria. That is to say, what exactly is the bioenergetic 
remodeling conferred by modulating mitochondrial dynamics and motility? One 
proposed mechanism is that arrest of mitochondrial motility by GlcNAcylation serves to 
localize mitochondria where intracellular glucose is high. However in the spatially-
constrained beta-cell, as opposed to large, complex neurons, this may not be a 
physiological necessity since cytoplasmic glucose concentration may not vary 
significantly. In certain cases arrest of mitochondrial motility allows for targeting and 
removal of damaged mitochondria by mitophagy 59. However this mechanism is related 
to depolarization of mitochondria, which would not occur during acute nutrient 
stimulation. The alternative hypothesis is that arrest of movement and subsequent fission 
into fragmented units confers some bioenergetic advantage in order to utilize the nutrient 
appropriately. This may involve changes to cristae and respiratory chain composition that 
could influence efficiency of ATP generation. Studies in brown adipose tissue during 
norepinephrine stimulation demonstrated that the hormone-induced mitochondrial fission 
occurs acutely and influences mitochondrial uncoupled respiration to allow for 
appropriate brown fat activation 12. Thus mitochondrial dynamics and morphology can 
indeed dictate mitochondrial functional responses acutely. Importantly these clarify a 
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new understanding of mitochondrial dynamics, in which acute bioenergetic adaptations 
and long-term mitochondrial quality control compete for the same adaptive mechanisms 
of mitochondrial fusion, fission, and motility 94. 
Finally, Chapter Four of this thesis focused on autophagy, which is an essential cellular 
maintenance mechanism by which cells degrade long-lived proteins and organelles, 
especially mitochondria (mitophagy). This cellular house-keeping process is especially 
critical in non-proliferating cells and tissues which rely on autophagy to remove damaged 
material that accumulates with aging48, 148, 149. Autophagic dysfunction is reported in 
several different human diseases including neurodegenerative diseases, cardiomyopathy, 
NAFLD, diabetes, and lysosomal storage diseases, among others148. The common 
pathology linking these numerous diseases is the accumulation of damaged organelles 
and proteins due to inadequate autophagy-mediated degradation. The accumulated 
cellular waste exacerbates declines in cellular functions and viability, leading to 
progressive disease48. Current efforts to modulate autophagy involve targeting different 
steps of the autophagy-related intracellular signaling cascades, which can involve non-
specific changes to important metabolic signaling pathways independent of autophagy 
induction149, 188. Thus, more targeted approaches are needed to improve autophagic 
degradation in pathologies where it is perturbed. 
Notably, lysosomal defects have been shown to be the inciting event leading to decreased 
autophagic flux in several human diseases148. The two key steps of autophagy are 
autophagosome recruitment and engulfment of the cellular contents to be degraded, 
followed by autophagosome fusion with the lysosome. Degradation of the engulfed 
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material is carried out by hydrolase enzymes in the lysosome that are pH-dependent; 
moreover fusion with the autophagosome requires a sufficiently acidic lysosome67, 68. 
Thus lysosome acidity is critical for promoting adequate autophagic flux in cells. 
Notably, in both pancreatic beta-cells103, 152 and liver hepatocytes189-192, exposure to 
chronic high levels of fatty acids (lipotoxicity) is associated with inhibition of autophagic 
flux due to loss of lysosomal acidity and function. Additionally, in different genetic 
disorders as well as neurodegenerative diseases, disruption of autophagy is a well-
documented phenomenon and recently impaired lysosome acidification has been 
implicated as a contributing factor148, 193-196. The role of impaired lysosomal acidification 
in the development of the cellular and organismal pathologies characteristic of 
diabetes197, 198, NAFLD199, 200, and other diseases could not be addressed until now since a 
mechanism to restore acidification has not been developed. Addressing the role of 
impaired acidification in these pathologies is critical for identifying the downstream 
consequences of impaired lysosomal acidification and the potential benefit of restoring 
acidification on autophagy and cellular function. 
To address this question we develop lysosome-localizing nanoparticles that acidify upon 
UV photo-activation. Specifically, the nanoparticles expand in size after UV-light 
activation (and are thus called expansile nanoparticles; i.e., eNPs) exposing negatively-
charged, carboxylic acid residues in the polymer that induce acidification in the 
lysosome. The eNPs show a dose-dependent uptake in INS1 and beta-cells within 1-2 
hours and localize to lysosomes as assessed by co-localization with LysoTracker staining. 
UV-activation of eNPs in INS1 cells exposed for 18 hours to palmitate show a significant 
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rescue of lysosomal acidity compared to palmitate treatment alone or palmitate co-treated 
with eNPs that were never UV-activated. Furthermore, palmitate-induced p62 and LC3-II 
accumulation significantly decrease following UV-activation of eNPs, indicating 
improvement of autophagic flux. Turnover of mitochondrial mass was also induced by 
eNPs, possibly promoting enhanced mitochondrial function under palmitate. Finally, UV-
activated eNPs were able to partially restore fatty acid-induced inhibition of glucose-
stimulated insulin secretion, suggesting that rescuing lysosomal acidity and autophagic 
flux with eNPs can improve beta-cell function. The capacity of eNPs to restore lysosomal 
acidity and autophagic flux supports an upstream role for impaired lysosomal dysfunction 
in the development of deregulated insulin secretion.  
Lysosomal acidification may prove to be a critical therapeutic target in systems other 
than the beta-cell exposed to lipotoxicity. A newly-developed acidic NP that will allow 
for constitutive acidification of the lysosome and the UV-inducible eNP are being tested 
in a hepatocyte model of lipotoxicity. Thus the positive results in beta-cells will be 
expanded upon to investigate whether altered lysosomal pH is indeed a critical 
therapeutic target in diseases where autophagic flux is inhibited. Acidifying NPs may 
hold specific therapeutic promise for treating non-alcoholic fatty liver disease (NAFLD) 
since previous studies show that NPs, regardless of material, surface conjugation, or 
functional performance will, upon systemic/intravenous administration, eventually 
accumulate in the liver201-204. Other recent studies have shown how poly(DL-lactic-co-
glycolide acid) NPs can increase lysosomal acidity and increase protein degradation in 
ARPE-19 cells showing lysosomal dysfunction or in Presenilin 1-KO cells (Alzheimer’s 
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disease-linked gene) 153, 205, 206. Compared to the PLGA NPs, the UV-inducible eNPs 
were able to significantly acidify lysosomes at a significantly lower concentration (25 
µg/mL eNPs vs. 1mg/mL of PLGA NPs), though as of yet the two different NP 
formulations have not been compared directly. Furthermore other studies lend support to 
the notion that restoring lysosomal pH to normal values by pharmacological approaches 
is sufficient to improve cellular outcomes 207. In summary, targeting lysosomal 
acidification with NPs provides key mechanistic insight into the role of lysosomal 
dysfunction in arresting autophagic flux and may have therapeutic potential for several 
diseases where autophagic flux is perturbed. 
Importantly, disruption of autophagy and mitochondrial dysfunction are inter-dependent 
processes which may be especially susceptible to aging and metabolic-related 
dysfunction. Though autophagy is the primary mechanism for degrading numerous 
substrates, including long-lived proteins and different organelles, turnover of 
mitochondria may represent the most critical function of autophagy in energy-demanding 
cells. There exists substantial evidence that inhibition of autophagy can lead to the 
accumulation of accumulation of dysfunctional mitochondria in different pathologies. For 
aging-related diseases such as diabetes, cardiovascular disease, and neurodegeneration 
the consequences of impaired autophagy on mitochondrial quality control has been 
extensively reviewed 48, 85, 148, 208, 209. Therefore proper quality control of mitochondria 
depend both on efficient segregation of damaged mitochondria by the coordinated 
processes of fusion, fission, and motility and adequate lysosome function for autophagic 
flux. Indeed under palmitate exposure we show that autophagy is inhibited along with 
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mitochondrial turnover (Appendix Three). In addition to turnover, mitochondria also rely 
on autophagy and lysosomes to recycle and provide iron for iron-sulfur cluster assembly 
for several components of the respiratory chain 210, and lipid catabolism via lipophagy 211. 
Disruption of autophagy and lysosome function inevitably leads to accumulation of 
damaged and dysfunctional mitochondria.  
Conversely, there is also strong evidence that autophagy is dependent upon sufficient 
mitochondrial function. Mainly, acidification of the lysosome requires activity of the 
lysosomal V-ATPase, which can represent a large ATP burden for the cell 212, 213. Models 
where primary mitochondrial dysfunction is induced leads to autophagic dysfunction 
likely due to the large ATP deficit 214, 215. Thus mitochondria are dependent on autophagy 
and vice versa, implicating mitochondria and autophagy as a critical axis in diseases of 
aging where post-mitotic cells must maintain a high bioenergetic burden. 
In summary, the thesis work elucidates how mitochondrial fusion, fission, and motility 
determine and are dependent upon autophagy to maintain mitochondrial function in 
pancreatic beta-cells exposed to a high nutrient environment (GLT). Studies using 
MitoTimer demonstrate that mitochondrial fusion and motility ensure efficient 
mitochondrial turnover by controlling the sorting and distribution of new and old protein 
in the mitochondrial network. In pancreatic beta-cells GLT alters mitochondrial dynamics 
and motility, mediated by nutrient-sensitive O-GlcNAcylation of Milton1, which 
determines bioenergetic adaptations to acute and chronic nutrient exposure. Thus 
mitochondrial dynamics and motility have competing funciton, to determine bioenergetic 
remodeling in response to nutrient changes and promoting long-term mitochondrial 
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turnover via autophagy-mediated removal. Importantly, autophagy-mediated removal is 
dependent upon adequate lysosomal acidification, as acidifying eNPs were able to restore 
lysosomal acidity, autophagic flux, and beta-cell function under GLT. Thus the adaptive 
mechanisms of mitochondrial dynamics, motility, and autophagy determine beta-cell 
response to fuel supply. 
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APPENDIX 
APPENDIX ONE: Published co-author papers  
PDFs of the papers are included with the thesis. 
Lovy A, Molina AJ, Cerqueira FM, Trudeau K, Shirihai OS: A faster, high resolution, 
mtPA-GFP-based mitochondrial fusion assay acquiring kinetic data of multiple cells in 
parallel using confocal microscopy, J Vis Exp 2012, e3991. 
 
My role in the project: In this online video publication, I assisted during the final 
development and testing of the macro-based imaging protocol. I also helped during the 
video demonstration of the protocol in addition to editing the final protocol text.  
 
 
Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, 
Seldin DC, Falk RH, MacRae CA, Liao R: Lysosomal dysfunction and impaired 
autophagy underlie the pathogenesis of amyloidogenic light chain-mediated 
cardiotoxicity, EMBO Mol Med 2014, 6:1493-1507  
My role in the project: In this paper I helped consult on experimental design related to 
all stages of the project except at the very beginning. This involved monthly 3-4 meetings 
over the course of 2 years in which results were discussed and further experiments 
planned. With regards to specific experiments, I helped design, conduct, and analyze the 
experiments assessing lysosomal acidity with Lysosensor dye (Figure 4A-B and D). 
Additionally I reviewed the final preparation of the manuscript as well as subsequent 
revisions. 
 
Forni MF, Peloggia J, Trudeau K, Shirihai O, Kowaltowski AJ: Murine Mesenchymal 
Stem Cell Commitment to Differentiation is Regulated by Mitochondrial Dynamics, Stem 
Cells 2015, doi: 10.1002/stem.2248. [Epub ahead of print] 
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My role in the project: In this paper I helped design, conduct, and analyze the 
experiments assessing mitochondrial fusion in the mouse mesenchymal stem cells 
induced towards different lineages (Figure 1K-O). Additionally, I consulted on results 
from other experiments and the role of mitochondrial dynamics changes in promoting 
changes to mitochondrial bioenergetics, turnover, etc. Additionally I reviewed the final 
preparation of the manuscript as well as the subsequent revision. 
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APPENDIX TWO: Current methodologies for assaying mitochondrial turnover in 
mammalian cells 
Interest in understanding mitochondrial turnover and how it is affected in various 
pathologies has increased dramatically in recent years; however the number of studies 
that quantify changes in the rates of mitochondrial turnover are limited. Due to the 
laborious nature of pulse-chase experiments that assess rates of turnover, other assays are 
often used to assess changes to mitochondrial mass or mitophagy. However, pulse-chase 
experiments still remain the only technique to quantify rates of mitochondrial turnover. 
Here we will briefly review current methodologies that provide readout for mitochondrial 
mass, mitophagy, and turnover in mammalian cells and tissues, with a focus on the 
limitations of each methodology. 
Assessing mitochondrial mass 
One assessment often used to infer changes to mitochondrial turnover is quantifying 
changes to mitochondrial mass; however quantification of mitochondrial mass can be 
highly inaccurate and its relationship to mitochondrial turnover is ill-defined. Quantifying 
mitochondrial areas in electron microscopy images or cellular imaging with 
fluorescently-labeled mitochondria are often used to assess the mass of the mitochondrial 
network 216. In addition, quantifying overall levels of various mitochondrial marker 
proteins, such as VDAC, OXPHOS, or matrix proteins 217, 218, or mitochondrial DNA 
itself 219, are used to infer mitochondrial mass. Staining with MitoTracker dye, 
specifically MitoTracker Green which should be membrane potential insensitive, and 
flow cytometry analysis can also be used to approximate changes to mitochondrial mass 
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220. These assessments come with obvious flaws. The most important being that changes 
to mitochondrial mass do not reflect changes in only mitochondrial turnover or 
mitophagy. Changes to other biological processes, including biogenesis and morphology 
changes, would greatly influence the readout of mitochondrial mass. Secondly, one must 
assume the system is at steady-state to infer changes to turnover or biogenesis. Lastly, the 
specific marker used to determine mitochondrial mass can show altered regulation even 
when mitochondrial mass may be unchanged. For instance, up- or down-regulation of 
specific mitochondrial proteins such as VDAC or OXPHOS subunits can occur in 
different conditions without significant overall changes to mitochondrial mass (identified 
by electron microscopy or imaging) 217. It can be noted that measurement of citrate 
synthase activity, a citric acid cycle enzyme, has been widely used as an estimate of 
mitochondria content in cells and tissues 221, 222. Importantly it has been reported that 
citrate synthase activity stays constant even when other aspects of mitochondrial function 
are disrupted. 
To this effect, assessing changes to specific mitochondrial marker proteins or mtDNA to 
represent mitochondrial mass should be combined with imaging of mitochondrial 
architecture, such as expression of a mitochondrial matrix-targeted fluorescent protein 
(DsRED) or staining with MitoTracker Green (labels all mitochondria) and imaging, or 
electron microscopy to identify mitochondria. In this way, visual identification of 
mitochondrial mass can be compared to changes in mitochondrial markers to more 
correctly assess changes to mitochondrial mass. However, even when studied thoroughly, 
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assessments of mitochondrial mass will never accurately reflect changes to mitochondrial 
turnover or mitophagy. 
Mitophagy-specific assays 
Several methodologies have been utilized in recent research to quantify mitophagy 
specifically. Here we will offer a brief description of each, including limitations of each 
assay. 
CCCP-induced mitochondrial depolarization with Parkin over-expression 
A number of studies have examined the Parkin-dependent mitophagy of depolarized 
mitochondria in different tissues, cells, and conditions. These experiments involve the 
over-expression of Parkin (an E3-ubiquitin ligase that is mutated in genetic forms of 
Parkinson’s disease) in cells, followed by pharmacological depolarization of the 
mitochondria via CCCP uncoupler treatment 54. Treatment with CCCP (10uM) for 1 hour 
induces rapid Parkin translocation to mitochondria. Prolonged CCCP treatment for 12-24 
hours can induce the complete elimination of mitochondria in HeLa and other cell lines 
54. Using this methodology, various treatments or genetic conditions can be tested for its 
effect on Parkin-dependent mitophagy 218, 223. These assays have several significant 
drawbacks. Parkin overexpression is required to see significant mitophagic substrates, 
and treatment with high concentrations (10uM) of CCCP uncoupler is a highly 
unphysiological condition for inducing mitophagy. However, for studying Parkin-
dependent mitophagy these assays can prove extremely valuable. 
Co-localization of mitochondria in autophagosomes 
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One relatively simple assay to measure mitophagy is the identification of 
autophagosomes co-localized to mitochondria 224, 225. Autophagosomes are usually 
identified as LC3-GFP or LC3 immuno-stained punctate structures. Concurrently, 
mitochondria will often be labelled via mito-DsRED or other fluorescent protein 
expression. Other mitochondrial labeling approaches such as immunostaining or dye-
staining could be used although it must be considered whether the mitochondria in the 
autophagosomes/lysosomes would contain the label; i.e. staining with a membrane-
potential dye would complicate identifying mitochondria in autophagosomes because 
they are usually depolarized once targeted for autophagy 4. Electron microscopy images 
can also be used to quantify the amount of mitochondria in autophagosomes/lysosomes 
226, although this is a more laborious process. 
A key consideration for this assay is that, under normal conditions, cells will not display 
many observable mitochondria undergoing mitophagy due to the rapid 
elimination/degradation of mitochondria after targeting to autophagosomes. It is 
recommended that autophagic degradation is arrested for 0.5-2 hours with lysosomal 
acidification inhibitors (bafilomycin or chloroquine) or lysosomal protease inhibitors 
(pepstatin A, E64D, and leupeptin) in order to identify mitochondria that have been 
targeted to autophagosomes during that time window. In this way an estimation of 
mitophagic rate can be determined and compared between different experimental groups. 
This methodology demands accurate and reliable identification of mitochondria co-
localized to autophagosomes. However, only limited pharmacological treatment to 
temporarily arrest autophagic degradation is needed, meaning this approach likely 
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measures physiological levels of mitophagy in cells. Lastly this approach can provide an 
estimation of flux through mitophagy, an important measurement that offers more insight 
than static quantifications of the number of mitochondria in autophagosomes at any one 
time point. 
Probing isolated mitochondria for autophagy markers 
As an alternative to imaging experiments to visualize mitochondria in autophagosomes, 
Western blot identification of autophagy markers in isolated mitochondrial extracts can 
yield similar assessments of mitophagic flux 225. Purification of isolated mitochondria 
must be performed to limit contaminating cellular compartments. Upon purification, 
mitochondria extracts from different experimental conditions can be assayed (via 
Western blot) for autophagic markers LC3-II and p62, as well as mitochondrial markers 
to demonstrate purity. As with imaging, samples can be compared with and without 
autophagic degradation inhibitors in order to estimate flux of mitophagy in the given 
conditions. However in this case it is not possible to approximate the actual number of 
mitophagic mitochondria in a given time as with imaging. Nonetheless the relative levels 
of mitophagic flux are still more informative than static levels of mitophagy in a given 
condition. Critically it has not been established whether localization of autophagosome 
and lysosome markers in mitochondrial lysates represent mitophagy or contamination of 
the mitochondrial fraction with autophagosomes and lysosomes during the isolation 
process.  
Novel mitochondrial fluorescent probes to assess mitophagy 
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Two fluorescent constructs have been developed that allow for direct identification and 
quantification of mitophagic events. These novel constructs are targeted to mitochondria 
and, upon lysosomal-delivery, the fluorescence readout changes due to the acidic 
environment of the lysosome. Thus this allows for direct and accurate identification of 
mitochondria that have been delivered to the lysosome. Since these constructs have been 
developed very recently, it is still unclear how easily these can be used to assess 
mitophagy.  
The first fluorescent construct, reported in 2011, a mitochondrial-targeted, coral-derived, 
acid-stable fluorescent protein called mt-mKeima 227. Specifically, mt-mKeima is 
targeted to the mitochondrial matrix. The mKeima shows a single emission, bimodal 
excitation fluorescence where the two excitation maxima correspond to the neutral (pH 7-
8, excitation 440nm) and ionized (pH 4-5, excitation 586nm) states of the protein. In 
addition, the mKeima is strongly resistant to lysosomal proteases, ensuring that the 
ionized state fluorescence will be detectable upon lysosomal localization. The resulting 
images show the majority of mt-mKeima throughout the mitochondrial network in the 
neutral state (excitation 440nm) with small, punctuate structures of the ionized mt-
mKeima (excitation 568nm). The construct mt-mKeima was used to show Parkin-
dependent delivery of mitochondria to the lysosome upon mitochondrial depolarization . 
Recently a mt-mKeima-expressing mouse was generated and was used to show changes 
to mitophagy in different tissues 228. Of note, it was shown that high fat diet decreased 
mitophagy in the liver. However since lysosomal acidity is perturbed in high fat diet 
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livers 189, 190, it remains to be resolved how this affects the interpretation of the pH-
dependent mt-mKeima.  
More recently, the mCherry-GFP-Fis1 construct has been used to screen for modulators 
of mitophagy 229. This construct contains the mCherry-GFP tandem fluorescent proteins 
fused to the outer mitochondrial membrane localization sequence of Fis1 (amino acids 
101-152). Upon mitochondrial localization, fluorescence of both mCherry and GFP labels 
the mitochondrial network yellow (overlap of red and green). After delivery to the 
lysosome, GFP fluorescence is quenched yet mCherry remains stable. Thus lysosome-
localized mitochondria appear as small, punctate, red-only structures.  
Both of these novel constructs identify the number of mitochondria undergoing 
mitophagy. The key application of these constructs is to assess mitophagic induction 
upon a given treatment, such as uncoupler CCCP 227 or iron chelator deferiprone 229. 
However, a key limitation of these fluorescent tools is that they do not allow direct 
quantification of mitophagic rates. These constructs are not amenable to the protocol for 
assessing mitophagic flux, which is to arrest autophagic degradation and observe the 
accumulation of mitophagy substrates per defined unit of time. If bafilomycin or 
chloroquine are used to neutralize lyosomal pH and inhibit autophagic degradation, the 
pH-dependent fluorescent “switch” which identifies mitochondria delivered to lysosomes 
can no longer occur. Thus there is no ability to see what mitophagic substrates 
accumulate and approximate the rate of flux through mitophagy. It may be possible that 
lysosomal protease inhibitors could substitute for bafilomycin or chloroquine to arrest 
autophagic degradation and allow assessment of mitophagic substrate accumulation with 
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the mt-mKeima or mCherry-GFP-Fis1 constructs. Studies with these constructs thus far 
have not attempted this approach, so it remains to be determined if and how accurately 
these novel fluorescent constructs could quantify rates of mitophagy. Nonetheless, 
fluorescent probes for mitophagy have great potential for further studies to evaluate 
alterations in mitophagy upon different treatments or under different pathological 
conditions. 
 
Measuring rates of mitochondrial turnover: pulse-chase approaches 
In order to measure mitochondrial turnover, an assay must quantify the rate of removal of 
some mitochondrial label over time. To this effect, only pulse-chase experiments using a 
measurable label can be used to assess rates of mitochondrial turnover. Careful 
consideration must be paid to the specific label that is being used, since this has direct 
implications for what is defined as “mitochondrial” turnover and the accuracy of the 
measurements. Past pulse-chase approaches have measured rates of turnover for 
mitochondrial proteins, lipids, and mitochondrial DNA with a variety of different labels. 
For this brief review of different pulse-chase approaches we will focus on the most 
frequently used strategies for metabolic labeling of mitochondria for turnover studies. For 
further details of each specific methodology, we will refer the reader to more appropriate 
articles/reviews. 
The majority of pulse-chase experiments have utilized radioisotope-labeled amino acids 
to metabolically label proteins and thus assess degradation rates after the “chase” period. 
In order to specifically quantify mitochondrial protein turnover, isolation and purification 
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of mitochondria is performed. Further sub-fractionation can measure turnover rates of 
different mitochondrial sub-compartments. Metabolic labeling has the inherent downfall 
of over-estimating protein half-lives due to label re-utilization. To minimize the label re-
utilization, NaH14CO3 has been used since the non-incorporated label is rapidly removed 
in cells. For a more complete and thorough review of metabolic labeling approaches to 
study mitochondrial turnover, we recommend the following review “Correction of 
radiolabel pulse-chase data by a mathematical model: application to mitochondrial 
turnover studies” 74. Metabolic labeling with radioisotope amino acids coupled with 
mitochondrial isolation allows for relatively straight-forward determination of rates of 
mitochondrial protein turnover. However, this assesses total mitochondrial protein 
turnover, which is the average of all proteins in mitochondria. Nonetheless, this technique 
is satisfactory to compare changes to rates of whole mitochondrial protein turnover in 
different conditions in cells or tissues. 
In order to determine changes to turnover rates of individual mitochondrial proteins, 
metabolic labeling with heavy-isotope (stable-isotope) amino acids followed by 
mitochondrial isolation and mass spectrometry analysis can be used. When the stable 
isotope is incorporated in a pulse-chase manner, the approach is referred to as dynamic 
SILAC (stable-isotope labeling of amino acids in culture). For a thorough review of this 
methodology, we refer the reader to this review 230. Alternatively, normal SILAC can be 
used to determine differences in protein abundance (but not turnover rates) between 
different conditions. Dynamic SILAC has the distinct advantage of measuring turnover 
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rates for hundreds of mitochondrial proteins in one sample. Due to the necessity of mass 
spectrometry analysis, the methodology is very labor and time intensive. 
Importantly, a recent study has demonstrated the applicability of heavy water labeling for 
assessing mitochondrial turnover 83. Use of heavy water as the isotopic label has several 
advantages over other metabolic labels including cost, labeling kinetics, safety, and 
universal labeling of all biomolecules (proteins, nucleic acids, carbohydrates, and lipids). 
This study by Kim et al. showed the extensive variability in mitochondrial protein 
turnover rates depending on tissue, mitochondrial sub-compartment, and functional 
group. In fact, protein turnover kinetics between the fastest and slowest proteins in liver 
differed by over 2 orders of magnitude in liver. Although labor-intensive, mass 
spectrometry analysis of individual mitochondrial protein turnover rates reveals 
important variability in protein kinetics within mitochondria. 
Summary 
In conclusion, these numerous methodologies can assess mitochondrial turnover in 
different ways. For each there are certain considerations to be aware of for both the 
experimental approach and interpretation of results. Since understanding mitochondrial 
turnover is increasingly a topic of research interest, it is imperative to properly integrate 
these different approaches to yield accurate findings related to mitochondrial turnover.   
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APPENDIX THREE: Palmitate increases mitochondrial mass by reducing 
mitochondrial turnover in INS1 cells 
Experiments were performed in collaboration with Dovi Shlomo, a masters student at 
Ben Gurion University in Israel. Detailed methods for these experiments can be found in 
the Methods section of Chapter 4.  
A) Mitochondrial mass was assessed by MitoTracker Green (MTG) staining and flow 
cytometry in INS1 cells. Treatment with bafilomycin (200nM) for 20 hours, which 
inhibits lysosomal acidification, increases mitochondrial mass. *=p<0.05 vs. Control. B) 
Mitohcondrial mass was assessed similarily in cells treated with control BSA media or 
400µM palmitate media (Palm:BSA) for 24 hours. Palmitate significantly increased 
mitochondrial mass. *=p<0.05 vs. BSA. C) To assess mitochondrial turnover, cells were 
stained with MTG for 0.5 hours (pulsed) followed by media washes (chase) and 
assessment of MTG intensity at 24 hours after staining. D) MTG fluorescence intensity at 
the indicated time points after pulse-chase staining. Reduction in MTG intensity after 24 
hours of “chase” indicates mitochondrial turnover. E) MTG fluorescence intensity after 
24 hours of pulse-staining and control (DMSO) treatment or bafilomycin (200nM). F) 
MTG fluorescence intensity after 24 hours of pulse-staining and control BSA treatment 
or 400µM palmitate (Palm:BSA). G) Images of INS1 cells expressing MitoTimer at time 
0 and after 25 hours of treatment with ontrol BSA or 400µM palmitate (Palm:BSA). H) 
Mean intensity of MitoTimer red and green fluorescence after 22 hours of Palm:BSA 
exposure. Values are normalized red and green MitoTimer intensity of the BSA 
condition. *=p<0.05 vs. BSA MitoTimer Red. I) Mean intensity of MitoTimer red and 
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green fluorescence after 22 hours of bafiomycin (200nM) treatment. Values are 
normalized red and green MitoTimer intensity of the control (DMSO) condition. 
*=p<0.05 vs. DMSO control MitoTimer Red. The data lend supporting evidence that palmitate exposure reduces mitochondrial turnover which leads to accumulation of mitochondrial mass in INS1 cells.  
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Teaching and Broader Community Outreach Experiences 
 
In-House Technical Coordinator for Celigo high-throughput imaging 
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present 
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